Liminal BioSciences (LMNL) 20-F 17 Mar 22 2021 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2021shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	LIMINAL BIOSCIENCES INC.
Entity Central Index Key	0001351172
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding	31,042,560
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Trading Symbol	LMNL
Title of 12(b) Security	Common Shares, no par value
Security Exchange Name	NASDAQ
Entity File Number	001-39131
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	440 Armand-Frappier Boulevard
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Laval, H7V 4B4
Entity Address, State or Province	QC
Entity Address, Postal Zip Code	H7V 4B4
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
ICFR Auditor Attestation Flag	false
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Oakville, Canada
Auditor Firm ID	271
Business Contact
Document Information [Line Items]
Contact Personnel Name	Bruce Pritchard
Entity Address, Address Line One	440 Armand-Frappier Boulevard
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Laval
Entity Address, State or Province	QC
Entity Address, Postal Zip Code	H7V 4B4
City Area Code	+1 450
Local Phone Number	781 0115

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 108,490	$ 45,075
Accounts receivable and others (note 7)	1,068	4,081
Inventories (note 8)		9,377
Prepaids	5,071	14,486
Total current assets	114,629	73,019
Other long-term assets (note 9)	362	1,353
Capital assets (note 10)	5,483	18,791
Right-of-use assets (note 11)	1,609	8,557
Intangible assets (note 12)	3,516	15,492
Deferred tax assets (note 26)	454	572
Total assets	126,053	117,784
Current liabilities
Accounts payable and accrued liabilities (note 13)	7,343	16,835
Current portion of lease liabilities (note 14)	7,194	6,946
Current portion of provisions (note 15)	3,957
Total current liabilities	18,494	23,781
Long-term portion of lease liabilities (note 14)	15,277	26,506
Provisions (note 15)	18,238
Warrant liability (note 16)	1,754	11,640
Long-term debt (note 17)	38,311	40,532
Other long-term liabilities (note 18)	98	313
Total liabilities	92,172	102,772
EQUITY
Share capital (note 19a)	979,849	977,261
Contributed surplus (note 19b)	44,109	39,877
Warrants (note 19c)	95,856	95,856
Accumulated other comprehensive loss	(3,010)	(3,030)
Accumulated other comprehensive income of disposal group held for sale		184
Deficit	(1,074,167)	(1,087,049)
Equity attributable to owners of the parent	42,637	23,099
Non-controlling interests (note 20)	(8,756)	(8,087)
Total equity	33,881	15,012
Total liabilities and equity	$ 126,053	$ 117,784

Consolidated Statements of Oper

Consolidated Statements of Operations - CAD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues (note 22)	$ 643	$ 724	$ 745
Expenses
Research and development expenses	18,347	14,234	15,873
Administration expenses	31,928	32,619	37,661
Gain on foreign exchange	(1,397)	(35)	(756)
Finance costs (note 23a)	6,330	2,899	6,867
Loss (gain) on extinguishments of liabilities (notes 17)	(75)	(79)	92,374
Change in fair value of financial instruments measured at fair value through profit or loss (note 16)	(9,886)	(850)	(1,140)
Impairment losses (note 25)	341	1,087	763
Loss from continuing operations before income taxes	(44,945)	(49,230)	(150,897)
Current income tax		(144)	(336)
Deferred income tax	118	(65)	111
Income tax expense (recovery) from continuing operations	118	(209)	(225)
Net loss from continuing operations	(45,063)	(49,021)	(150,672)
Discontinued operations
Gain on sale of subsidiaries, net of income taxes $nil (note 6)	140,403	3,380	26,346
Loss from discontinued operations, net of income taxes (note 6)	(83,127)	(73,116)	(82,427)
Total income (loss) from discontinued operations	57,276	(69,736)	(56,081)
Net income (loss)	12,213	(118,757)	(206,753)
Net income (loss) attributable to:
Non-controlling interests - continuing operations (note 20)	(669)	(832)	(1,044)
Owners of the parent
- Continuing operations	(44,394)	(48,189)	(149,628)
- Discontinued operations	57,276	(69,736)	(56,081)
Total Net loss attributable to owners of the parent from continuing and discontinued operations	12,882	(117,925)	(205,709)
Net income (loss)	$ 12,213	$ (118,757)	$ (206,753)
Income (loss) per share attributable to the owners of the parent basic and diluted:
From continuing operations	$ (1.47)	$ (1.97)	$ (9.32)
From discontinued operations	1.90	(2.85)	(3.49)
Total income (loss) per share	$ 0.43	$ (4.83)	$ (12.81)
Weighted average number of outstanding shares (in thousands) (note 27)	30,164	24,438	16,062

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Gain on sale of subsidiaries, income taxes	$ 0	$ 0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Comprehensive Income [Abstract]
Net income (loss)	$ 12,213	$ (118,757)	$ (206,753)
Items that may be subsequently reclassified to profit and loss:
Exchange differences on translation of foreign operations from continuing operations	20	104	180
Exchange differences on translation of foreign operations from discontinued operations	(140)	149	(578)
Reclassification of exchange differences on translation of foreign operations sold to consolidated statement of operations (note 6)	(44)		(1,449)
Total other comprehensive (loss) income	(164)	253	(1,847)
Total comprehensive income (loss)	12,049	(118,504)	(208,600)
Total comprehensive income (loss) attributable to:
Non-controlling interests	(669)	(832)	(1,044)
Owners of the parent- Continuing operations	(44,374)	(48,085)	(149,448)
Owners of the parent- Discontinued operations	57,092	(69,587)	(58,108)
Total comprehensive income (loss)	$ 12,049	$ (118,504)	$ (208,600)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - CAD ($) $ in Thousands	Total	Share Capital	Contributed Surplus	Warrants	Foreign Currency Translation Reserve	Deficit	Total Equity (Deficiency) Attributable to Owners of the Parent	Non-controlling Interests
Beginning balance at Dec. 31, 2018	$ (63,146)	$ 583,117	$ 21,923	$ 95,296	$ (1,252)	$ (755,688)	$ (56,604)	$ (6,542)
Net income (loss)	(206,753)					(205,709)	(205,709)	(1,044)
Foreign currency translation reserve	(398)				(398)		(398)
Reclassification of exchange differences on translation of foreign operations to consolidated statement of operations (note 6)	(1,449)				(1,449)		(1,449)
Issuance of shares (note 19a)	349,834	349,834					349,834
Share-based payments expense (note 19b)	22,030		22,030				22,030
Share-based compensation paid in cash (note 19b)	(421)		(421)				(421)
Issuance of warrants (note 19c)	560			560			560
Share and warrant issuance cost	(5,323)					(5,323)	(5,323)
Effect of changes in the ownership of a subsidiary and funding arrangements on non-controlling interests (note 20)						(331)	(331)	331
Ending balance at Dec. 31, 2019	94,934	932,951	43,532	95,856	(3,099)	(967,051)	102,189	(7,255)
Net income (loss)	(118,757)					(117,925)	(117,925)	(832)
Foreign currency translation reserve	253				253		253
Issuance of shares (note 19a)	31,755	31,755					31,755
Share-based payments expense (note 19b)	6,234		6,234				6,234
Exercise of stock options (note 19b)	82	167	(85)				82
Share-based compensation paid in cash (note 19b)	(40)		(40)				(40)
Shares issued pursuant to restricted share unit plan (note 19b)		9,764	(9,764)
Share issuance cost	(2,073)					(2,073)	(2,073)
Issuance of warrants (note 19c)	2,623			2,623			2,623
Exercise of warrants (note 19c)	1	2,624		(2,623)			1
Ending balance at Dec. 31, 2020	15,012	977,261	39,877	95,856	(2,846)	(1,087,049)	23,099	(8,087)
Net income (loss)	12,213					12,882	12,882	(669)
Foreign currency translation reserve	(120)				(120)		(120)
Reclassification of exchange differences on translation of foreign operations to consolidated statement of operations (note 6)	(44)				(44)		(44)
Share-based payments expense (note 19b)	4,252		4,252				4,252
Share-based compensation paid in cash (note 19b)	(20)		(20)				(20)
Shares issued upon conversion of debt (note 17)	2,588	2,588					2,588
Ending balance at Dec. 31, 2021	$ 33,881	$ 979,849	$ 44,109	$ 95,856	$ (3,010)	$ (1,074,167)	$ 42,637	$ (8,756)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows used in operating activities
Net loss from continuing operations during the year	$ (45,063)	$ (49,021)	$ (150,672)
Net income (loss) from discontinued operations during the year	57,276	(69,736)	(56,081)
Adjustments to reconcile net loss to cash flows used in operating activities:
Finance costs and foreign exchange	4,317	8,307	12,809
Loss (gain) from disposition of capital and intangible assets	(6)	(15)	196
Non-cash issuance of warrants (note 16)		2,228
Gain on sale of subsidiaries (note 6)	(140,403)	(3,380)	26,346
Change in fair value of financial instruments measured at fair value through profit or loss (note 16)	(9,886)	(850)	(1,140)
Impairment losses (notes 6, 25)	1,752	20,859	12,366
Deferred income taxes (note 26)	118		87
Gain (loss) on extinguishments of liabilities (note 17)	(75)	(79)	92,374
Provision expense (note 15)	22,367
Share-based payments expense (note 19b)	4,232	6,194	21,609
Depreciation of capital assets (note 10)	1,368	2,779	3,734
Depreciation of right-of-use assets (note 11)	1,013	4,578	4,913
Amortization of intangible assets (note 12)	1,963	1,090	1,259
Cash flows from (used in) operations before changes in working capital	(101,027)	(77,046)	(84,892)
Change in non-cash working capital items	1,424	1,129	(14,498)
Cash flows used in operating activities	(99,603)	(75,917)	(99,390)
Cash flows from (used in) financing activities
Proceeds from share issuances (with or without warrants) (note 19a)		39,960	118,785
Proceeds from long-term debt (with or without warrants) (notes 17)		31,533	19,859
Repayment of principal on long-term debt (note 17)		(165)	(988)
Repayment of interest on long-term debt (note 17)	(3,945)	(1,879)	(3,540)
Exercise of options (note 19b)		82
Proceeds from exercise of pre-funded warrants (note 19c)		1
Payments of principal on lease liabilities (note 14)	(3,241)	(7,069)	(7,563)
Payment of interest on lease liabilities (note 14)	(1,080)	(2,098)	(1,767)
Debt, share and warrants issuance costs	(158)	(2,960)	(6,867)
Cash flows from (used in) financing activities	(8,424)	57,405	117,919
Cash flows from (used in) investing activities
Additions to capital assets	(293)	(966)	(2,741)
Additions to intangible assets	(170)	(1,080)	(1,703)
Proceeds from sale of discontinued operations business (note 6)	173,357	4,555	43,958
Transaction costs paid relating to the sale of discontinued operations business	(2,492)	(787)	(4,228)
Proceeds from disposal of capital assets	52	133
Release of restricted cash	165		65
Interest received	73	450	745
Cash flows from (used in) investing activities	170,692	2,305	36,096
Net change in cash and cash equivalents during the year	62,665	(16,207)	54,625
Net effect of currency exchange rate on cash and cash equivalents	750	(3)	(729)
Cash and cash equivalents, beginning of year	45,075	61,285	7,389
Cash and cash equivalents, end of year	108,490	45,075	61,285
Comprising of:
Cash	108,490	45,075	41,761
Cash equivalents			19,524
Total cash and cash equivalents	$ 108,490	$ 45,075	$ 61,285

Nature of operations and going

Nature of operations and going concern	12 Months Ended
	Dec. 31, 2021
Disclosure Of Nature Of Operations And Going Concern [Abstract]
Nature of operations and going concern	1. N ature of operations and going concern Liminal BioSciences Inc. or Liminal, or the Company, is incorporated under the Canada Business Corporations Act and is a publicly traded clinical stage biopharmaceutical company (Nasdaq symbol: LMNL) focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform and data driven approach. Our lead small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose, or MAD, clinical trial and we anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support our development plan. In addition, the Company is currently developing a selective G‑protein-coupled receptor 84, or GPR84 antagonist candidate and an oral, selective OXER1 antagonist candidate. The GPR84 and OXER1 antagonist programs are currently at the preclinical stage. The Company previously operated a segment devoted to the development of plasma-derived therapeutics, leveraging Liminal’s experience in bioseparation technologies used to isolate and purify biopharmaceuticals from human plasma and received approval, from the U.S. Food and Drug Administration or FDA in June 2021 for its plasma-derived product Ryplazim ® (plasminogen) or Ryplazim ® , a highly purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The Company has completed the divestment of this segment in October 2021. These activities are also presented as discontinued operations in the audited annual consolidated financial statements for the years ended December 31, 2021 and 2020 (note 6). The Company’s registered office is located at 231 Dundas Street East, Belleville, Ontario, K8N 1E2 and its principal executive office is located at 440, Boul. Armand-Frappier, suite 300, Laval, Québec, Canada, H7V 4B4. Liminal has active business operations in Canada and the United Kingdom. Structured Alpha LP or SALP has been Liminal’s majority and controlling shareholder since the debt restructuring on April 23, 2019 (note 17) and is considered Liminal’s parent entity for accounting purposes. Thomvest Asset Management Ltd., or Thomvest, is the general partner of SALP and the ultimate controlling parent, for accounting purposes, of Liminal is The 2003 TIL Settlement. The consolidated financial statements for the year ended December 31, 2021 have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting standards Board, or IASB, on a going concern basis, which presumes the Company will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. During the year ended December 31, 2021, the Company incurred a net loss from continuing operations of $ 45.1 million ($ 49.0 million for the year ended December 31, 2020) and had negative operating cash flows, including continuing and discontinued operations, of $ 99.6 million ($ 75.9 million for the year ended December 31, 2020). At December 31, 2021, the Company had an accumulated deficit of $ 1,074.2 million ($ 1,087.0 million at December 31, 2020) and a working capital of $ 96.1 million ($ 49.2 million at December 31, 2020). The December 31, 2021 working capital position reflects the proceeds the Company received as a result of the various transactions it concluded as part of the divestment of the plasma-derived therapeutics segment (note 6). In February 2022, the Company used $ 39.1 million of the proceeds from the divestment to repay the full amount of its long-term debt (note 33). Considering Liminal’s main activities continue to be related to the preclinical and clinical stage, the Company’s cash runway is dependent on the research programs currently underway, the pace of their progression and the results they render, as well as those planned to be undertaken in the short term. As such, there is always a degree of uncertainty in regards to the outcome or cost of those programs. The cash runway is also dependent on decisions the Company makes in terms of managing its capital, including raising capital through the issuance of debt and equity or repaying financial obligations before their maturity, and the Company's ability to conclude such financing transactions at an acceptable cost. As such, there is uncertainty whether the Company’s current financial position will be sufficient to fund its operations for at least the next 12 months and it is likely that additional sources of funding will be required during this time. Additional external financing may include public or private equity offerings, debt financings, strategic collaborations, alliances and licensing arrangements, grant funding or other sources. Despite the Company’s efforts to obtain the necessary funding and improve profitability of its operations, there can be no assurance of its success in doing so, especially with respect to its access to further funding on acceptable terms, if at all. These circumstances indicate the existence of a material uncertainty that may cast substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s preclinical, clinical and regulatory efforts, which are critical to the realization of its business plan. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Material accounting policies

Material accounting policies	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Material accounting policies	2. Material accounting policies Statement of compliance These audited annual consolidated financial statements for the year ended December 31, 2021, or consolidated financial statements, have been prepared in accordance with IFRS as issued by the IASB and were approved by the Board of Directors on March 17, 2 022. Functional and presentation currency The consolidated financial statements are presented in Canadian dollars, ($ or CAD) which is also the Company’s functional currency. The use of other currencies will be specified. Basis of consolidation The consolidated financial statements include the accounts of Liminal BioSciences Inc., and those of its subsidiaries. The Company’s subsidiaries at December 31, 2021, 2020 and 2019 are as follows: Name of subsidiary Segment activity Place of incorporation and Proportion of ownership interest held 2021 2020 2019 Fairhaven Pharmaceuticals Inc. Small molecule therapeutics Quebec, Canada 100 % 100 % nil Liminal R&D BioSciences Inc. Small molecule therapeutics Quebec, Canada 100 % 100 % 100 % Liminal BioSciences Holdings Limited Small molecule therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Liminal BioSciences Limited Small molecule therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Prometic Pharma SMT B.V Small molecule therapeutics Amsterdam, Netherlands 100 % 100 % N/A Prometic Bioproduction Inc. Plasma-derived therapeutics Quebec, Canada nil * 100 % 100 % Prometic Plasma Resources Inc. Plasma-derived therapeutics Winnipeg, Canada nil * 100 % 100 % Telesta Therapeutics Inc. Plasma-derived therapeutics Quebec, Canada 100 % 100 % 100 % NantPro Biosciences, LLC Plasma-derived therapeutics Delaware, U.S. 73 % 73 % 73 % Prometic Biotherapeutics Inc. Plasma-derived therapeutics Delaware, U.S. nil * 100 % 100 % Prometic Plasma Resources USA Inc. Plasma-derived therapeutics Delaware, U.S. nil * 100 % 100 % Prometic Biotherapeutics Ltd Plasma-derived therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Prometic Biotherapeutics B.V. Plasma-derived therapeutics Amsterdam, Netherlands 100 % 100 % N/A Pathogen Removal and Diagnostic Corporate Delaware, U.S. 77 % 77 % 77 % * Entity sold in 2021 as part of our divestment of the plasma-derived therapeutics segment. The Company consolidates investees when, based on the evaluation of the substance of the relationship with the Company, it concludes that it controls the investees. The financial statements of the subsidiaries are prepared for the same reporting period as the parent Company, using consistent accounting policies. All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation. When a subsidiary is not wholly-owned the Company recognizes the non-controlling interests’ share of the net assets and results of operations in the subsidiary. Financial instruments Recognition and derecognition Financial instruments are recognized in the consolidated statement of financial position when the Company becomes a party to the contractual obligations of the instrument. On initial recognition, financial instruments are recognized at their fair value plus, in the case of financial instruments not at fair value through profit or loss (“FVPL”), transaction costs that are directly attributable to the acquisition or issue of financial instruments. Financial assets are subsequently derecognized when payment is received in cash or other financial assets or if the debtor is discharged of its liability. A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing liability is replaced by another from the same creditor on substantially different terms, or the terms of the liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated statement of operations. Classification Subsequent to initial recognition, financial instruments are measured according to the category to which they are classified. Financial instruments are measured at amortized cost unless they are classified as fair value through other comprehensive income, or FVOCI, classified as FVPL or designated as FVPL, in which case they are subsequently measured at fair value. The classification of financial asset debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Assets that are held to collect contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. Equity instruments that are held for trading (including all equity derivative instruments) are classified as FVPL. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL (such as instruments held for trading or derivatives) or the Company has opted to measure them at FVPL. The Company classifies cash, trade receivables, other receivables, restricted cash, and long-term deposits as financial assets measured at amortized cost and trade payables, wages and benefits payable, royalty payment obligations and long-term debt as financial liabilities measured at amortized cost. The Company classifies the warrant liability as a financial liability at FVPL for which the variation in fair value is recorded in consolidated statement of operations. Inventories Inventories of raw materials and finished goods are valued at the lower of cost and net realizable value. Cost is determined on a first in, first out basis. The cost of manufactured inventories comprises all costs that are directly attributable to the manufacturing process, such as raw materials, direct labour and manufacturing overhead based on normal operating capacity. Net realizable value is the estimated selling price in the ordinary course of business and the estimated selling costs except for raw materials for which it is determined using replacement cost. Capital assets Capital assets are recorded at cost less any government assistance, accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as described below. Capital asset Period Buildings and improvements 20 years Leasehold improvements The lower of the lease term and the useful life Production and laboratory equipment 5 - 20 years Furniture 5 - 10 years Computer equipment 3 - 5 years Government assistance Government assistance programs, including investment tax credits on research and development expenses and salary and rent subsidies are reflected as reductions to the cost of the assets or to the expenses to which they relate and are recognized when there is reasonable assurance that the assistance will be received and all attached conditions are complied with. Right-of-use assets The Company recognizes a right-of-use, or ROU, asset at the commencement date of a lease which is when the date at which the underlying asset is available for use. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use asset is depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Intangible assets Intangible assets are carried at cost less accumulated amortization. Amortization commences when the intangible asset is available for use and is calculated over the estimated useful lives of the intangible assets acquired using the straight-line method. The maximum period used for each category of intangible asset are presented in the table below. Intangible asset Period Licenses and other rights 30 years Donor lists 10 years Patents 20 years Software 5 years Impairment of long-lived assets At the end of each reporting period, the Company reviews the carrying amounts of its capital, ROU and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If impairment indicators exist, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. For intangible assets not yet available for use, an impairment test is performed annually at November 30, until amortization commences, whether or not there are impairment indicators. The recoverable amount is the higher of the fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. An impairment loss is recognized when the carrying amount of an asset or a cash-generating unit, or CGU, exceeds its recoverable amount by the amount of this excess. An impairment loss is recognized immediately in profit or loss in the period during which the loss is incurred. An impairment loss can be subsequently reversed, if certain conditions are met and the amount of the reversal will not exceed the carrying amount that would have been determined had an impairment loss not been recognized for the asset or CGU in prior periods. A reversal of an impairment loss is recognized immediately in profit or loss. Lease liabilities At the commencement date of a lease, the Company recognizes a lease liability measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of a lease liability is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of a lease liability is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment whether the underlying asset will be purchased. The Company applies the short-term lease recognition exemption to leases of 12 months or less, as well as the lease of low-value assets recognition exemption. Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term. The Company has elected, for the class of assets related to the lease of building space, not to separate non-lease components from lease components, and instead account for each lease component and any associated non-lease components as a single lease component. Provisions If changes in circumstances render a contract to be onerous, meaning the unavoidable cost of meeting the contract exceeds the econom ic benefits expected under it, the Company recognizes the present value of the obligations as a provision. Before a separate provision for an onerous contract is established, an entity recognizes any impairment loss that has occurred on assets dedicated to that contract. The amount recognized as a provision is the best estimate of the cash disbursements required to settle the present obligation at the end of a reporting period and as such, a provision will change if the estimate changes. The discount rate used is the pre-tax rate that reflects the market assessment of the time value of money and the risks specific to the liability. Revenue recognition Sale of goods Revenue from sale of goods is recognized when the terms of a contract with a customer have been satisfied. This occurs when: • The control over the product has been transferred to the customer; and • The product is received by the customer or transfer of title to the customer occurs upon shipment. Following delivery, the customer bears the risks of obsolescence and loss in relation to the goods. Revenue is recognized based on the price specified in the contract, net of estimated sales discounts and returns. Revenue from the sale of goods is presented as part of the results from discontinued operations. Royalty revenue Royalty revenues are recognized once the sale of products to which the royalties gives rise occurs. Rental revenue The Company accounts for the lease or sub-lease with its tenant as an operating lease when the Company has not transferred substantially all of the risks and benefits of ownership of its property or leased property. Revenue recognition under an operating lease commences when the tenant has a right to use the leased asset, and the total amount of contractual rent to be received from the operating lease is recognized on a straight-line basis over the term of the lease. Rental revenue also includes recoveries of operating expenses and property taxes. Research and development expenses Expenditure on research activities is recognized as an expense in the period during which it is incurred. An internally generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated: • the technical feasibility of completing the intangible asset so that it will be available for use or sale; • the intention to complete the intangible asset and use or sell it; • the ability to use or sell the intangible asset; • how the intangible asset will generate probable future economic benefits; • the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and • the ability to measure reliably the expenditures attributable to the intangible asset during its development. To date, the Company has not capitalized any development costs. Foreign currency translation Transactions and balances Transactions in foreign currencies are initially recorded by the Company and its entities at their respective functional currency rates prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange at the reporting date. All differences are taken to the consolidated statement of operations. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates when the initial transactions took place. Group companies The assets and liabilities of foreign operations are translated into Canadian dollars at the rate of exchange prevailing at the reporting date and their statements of operations are translated at exchange rates prevailing at the dates of the transactions. The exchange differences arising on the translation are recognized in other comprehensive loss. On disposal of a foreign operation, the component of other comprehensive loss relating to that particular foreign operation is reclassified from the consolidated statement of comprehensive loss to the consolidated statement of operations as part of the gain or loss on the disposal of the foreign operation. Share-based payments The fair value of stock options granted by the Company is determined at the grant date using the Black-Scholes option pricing model and is expensed over the vesting period of the options. Grants with graded vesting are considered to be multiple awards for fair value measurement. An estimate of the number of awards that are expected to be forfeited is also made at the time of grant and revised periodically if actual forfeitures differ from those estimates. The Company also made use of a restricted share unit plan as part of its long-term incentive plan up until the end of 2020. The fair value of Restricted Share Units, or RSU, is determined using the market value of the Company’s shares on the grant date. The expense associated with RSU awards that vest over time are recognized over the vesting period. When the vesting of RSU is dependent on meeting performance targets as well as a service requirement, the Company will estimate the outcome of the performance targets to determine the expense to recognize over the vesting period, and revise those estimates until the final outcome is determined. An estimate of the number of awards that are expected to be forfeited is also made at the time of grant and revised periodically if actual forfeitures differ from those estimates. The Company’s policy is to issue new shares upon the exercise of stock options and the release of RSU for which conditions have been met. Assets held for sale and discontinued operations The Company classifies non-current assets and disposal groups as held for sale at the end of a given reporting period if their carrying amounts will be recovered principally through a sale rather than through continuing use. Such non-current assets and disposal groups classified as held for sale are measured at the lower of their carrying amount and their fair value less cost to sell. Costs to sell are the incremental costs directly attributable to the sale, excluding finance costs and income tax expense. Such assets are only presented as held for sale when the sale is highly probable and the assets or disposal group are available for immediate sale in their present condition. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the sale will be withdrawn. Management must be committed to the sale, which should be expected to qualify for recognition as a completed sale within one year from the date of classification. Capital assets included as part of the assets held for sale are not depreciated once classified as held for sale. Assets and liabilities classified as held for sale are presented separately as current items in the consolidated statement of financial position. The results of discontinued operations are presented net of tax in the consolidated statement of operations. Incremental cost related to the disposition and income taxes are allocated to discontinued operations. The discontinued operations also include the gain or loss on the disposal, which will also include the reclassification of historical exchange differences on translation of foreign operations sold. The results of discontinued operations exclude the allocation of the corporate finance costs and general corporate overhead in the form of management fees if the costs will continue to be incurred by Liminal following the disposition. The prior period results from discontinued operations are reclassified and presented in the consolidated statements of operations. Share and warrant issue expenses The Company records share and warrant issue expenses as an increase to the deficit.

Significant accounting judgemen

Significant accounting judgements and estimation uncertainty	12 Months Ended
	Dec. 31, 2021
Disclosure Of Changes In Accounting Estimates [Abstract]
Significant accounting judgements and estimation uncertainty	3. Significant accounting judgements and estimation uncertainty The preparation of these consolidated financial statements requires the use of judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. The uncertainty that is often inherent in estimates and assumptions could result in material adjustments to assets or liabilities affected in future periods. The significant judgments made and estimates used in the preparation of these consolidated financial statements are explained below. Significant judgments Going concern - In assessing whether the going concern assumption is appropriate and whether there are material uncertainties that may cast significant doubt about the Company’s ability to continue as a going concern, management must estimate future cash flows for a period of at least twelve months following the end of the reporting period by considering relevant available information about the future. Management has considered a wide range of factors relating to expected cash inflows such as whether the Company will earn other significant revenues, what will be the next steps in its research and development programs and the related expenditures as well as the financing strategy it would like to pursue and the potential sources of debt and equity financing available to it in case further financing is desired. Management has also estimated expected cash outflows such as operating and capital expenditures and debt repayment schedules. These cash flow estimates are subject to uncertainty. Functional currency – The functional currency of foreign subsidiaries is reviewed on an ongoing basis to assess if changes in the underlying transactions, events and conditions have resulted in a change. This assessment is also performed for new subsidiaries. When assessing the functional currency of a foreign subsidiary, management’s judgment is applied in order to determine, amongst other things, the primary economic environment in which an entity operates, the currency in which the activities are funded and the degree of autonomy of the foreign subsidiary from the reporting entity in its operations and financially. Judgment is also applied in determining whether the inter-company loans denominated in foreign currencies form part of the parent Company’s net investment in the foreign subsidiary. Considering such loans as part of the net investment in the foreign subsidiary results in foreign currency translation gains or losses from the translation of these loans being recorded in other comprehensive loss instead of the consolidated statement of operations. During the year ended December 31, 2020, the functional currency of the Pathogen Removal and Diagnostic Technologies Inc., or PRDT, subsidiary changed from GBP to USD. Share-based compensation - On March 23, 2020, the board of directors of the Company approved a plan to seek shareholder approval to modify the exercise price of certain stock options as disclosed in note 19b. In order to determine when the expense related to this modification is recognized in the consolidated statement of operations, management evaluated the timing of notification to option holders, the timing and method of determining the exercise price and the service period. Management further considered whether the holders of the stock options had sufficient understanding of the terms and conditions of the potentially revised awards, the degree of certainty of the approval for the repricing and whether the service period for earning the rights to the awards had commenced. Management concluded that the definition of the grant date was not met but that the service period had commenced and therefore a preliminary calculation of the incremental fair value of the repricing of the awards was performed using assumptions as of March 31, 2020. On May 26, 2020, the conditions for a grant date were met and the options exercise price was revised to $ 15.21 and a final calculation to determine the incremental fair value of the repriced options was performed. Estimates and assumptions COVID-19 – The negative impact of the COVID-19 pandemic on the financial statements for years ended December 31, 2021 and 2020 has been limited. During a portion of those two years, however, the Company was eligible for salary and rent subsidy programs from the Government of Canada under which it submitted claims (note 22). As of the date of these consolidated financial statements, there are no subsidy programs to which the Company is eligible. Consistent within the global biopharmaceutical sector, some clinical programs may have been and may be impacted by the shift of resources within hospitals and contract research organizations, or CRO, to COVID-19 and related matters, resulting in potential delays to recruitment or site initiation on our clinical and preclinical programs, and potentially causing an adjustment of certain development timelines and activities. The partial disruption caused by COVID-19 may continue to impact the Company’s operations, workforce and overall business by delaying the progress of our research and development programs, regulatory submissions and reviews, and business and corporate development activities. There is uncertainty as to the duration of the COVID-19 pandemic and related government restrictions, including travel bans, the impact on our workforce, the availability of healthy subjects and patients for the conduct of clinical trials and its impact on the global economy. The effects of the COVID-19 pandemic continue to be fluid. Fair value of financial instruments – The individual fair values attributed to the different components of a financing transaction, are determined using valuation techniques. Management uses judgment to select the methods used to determine certain inputs/assumptions used in the models and the models used to perform the fair value calculations in order to determine, 1) the values attributed to each component of a transaction at the time of their issuance, 2) the fair value measurements for certain instruments that require subsequent measurement at fair value on a recurring basis and 3) the fair value of financial instruments subsequently carried at amortized cost. When the determination of the fair value of a new loan is required, discounted cash flow techniques which includes inputs that are not based on observable market data and inputs that are derived from observable market data are used. When determining the appropriate discount rates to use, Management seeks comparable interest rates, where available. If unavailable, it uses those considered appropriate for the risk profile of a Company in the industry. In determining the fair value of the warrants issued in November 2020 (note 16), which are presented as a warrant liability in the consolidated statement of financial position and considered to be a level 3 measurement, the Company made assumptions on unobservable inputs used in the valuation model that have an important impact on the resulting fair value computed. Notably, the Company estimated the timing and the amounts of equity financings it expects to complete before the expiry of those warrants. The fair value computed could be higher if the actual equity financing needs of the Company are higher than those expected. The Company also estimated the future volatility of the common shares of Liminal for the contractual life of the warrants. To do so, the Company used the historical volatility of its own shares and of comparable companies in the same industry as a starting basis for this estimate and also considered whether there are factors that would indicate that the historical volatility is not indicative of the future. In addition, the Company applied an illiquidity discount rate on the resulting Black-Scholes pricing model to reflect that the November 2020 warrants are not publicly traded instruments and therefore the ability to sell them is limited. In establishing the illiquidity discount rate, the Company considered the remaining life of the warrants and the volatility assumption for the underlying shares. Had the Company selected a higher volatility rate and/or a lower illiquidity discount rate, the fair value of the warrant liability would have been higher. The fair value estimates could be significantly different because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. Uncertainty over income tax treatments - R&D tax credits for the current and prior periods are measured at the amount the Company expects to recover, based on its best estimate and judgment, of the amounts it expects to receive from the tax authorities as at the reporting date, either in the form of income tax refunds or refundable grants. However, there are uncertainties as to the interpretation of the tax legislation and regulations, in particular regarding what constitutes eligible R&D activities and expenditures, as well as the amount and timing of recovery of these tax credits. In order to determine whether the expenses it incurs are eligible for R&D tax credits, the Company must use judgment in determining whether its complex R&D activities qualify for available tax credits, which makes the recovery of tax credits uncertain. As a result, there may be a significant difference between the estimated timing and amount recognized in the consolidated financial statements in respect of tax credits receivable and the actual amount of tax credits received as a result of the tax administrations' review of matters that were subject to interpretation. These uncertainties, relating to entities the Company has sold may still affect Liminal as certain indemnification obligations may be called upon, subject to contractual limitations, when these entities may be subjected to the tax administrations reviews for taxation periods prior to the sale. The amounts recognized in the consolidated financial statements are based on the best estimates of the Company and in its best possible judgment, as noted above. Assessing the recoverable amount of long-lived assets - The Company evaluates the recoverable value of long-lived assets when indicators of impairment arise or as part of the annual impairment test, if they are intangible assets not yet available for use. The recoverable value is the higher of the value in use and the fair value less costs of disposal, or FVLCD. Long-lived assets include capital assets, ROU assets and intangible assets such as patents and licenses and other rights. Some of these rights are considered not available for use until regulatory approval to commercialize the product candidate is obtained. When calculating the net recoverable amounts for the impairments on continuing operations (note 24) and discontinued operations (note 6), management made estimates and assumptions regarding the outcome of certain future events, future cash flows and their timing. When determining the FVLCD for its Ryplazim ® CGU (note 6), significant estimates made included amongst others, the outcome of the exercise it had undertaken in evaluating the potential alternatives for the Ryplazim ® CGU, including the probability of completing a sale or closing those activities; the operating cash outflows to support those operations until one of the alternative strategies was executed; the outcome of the FDA review of the Company’s Biological License Application, or BLA for its Ryplazim ® product candidate and the timing of completion of the review; if the Company would be able to benefit from the monetization of a Priority Review Voucher, if received, and what would be the amount received upon its monetization; and whether some assets, liabilities and commitments could potentially be excluded from the activities sold and for those commitments that could be retained, the possibility of reducing those commitments and what would be their settlement amount. A 10 % change in the probability weighted terminal value would have impacted the impairment recorded on the Ryplazim ® CGU by $ 3,638 . When calculating the FVLCD of an asset or a group of assets for which selling price information for comparable assets are not readily available, management also must make assumptions regarding the value it may recuperate from its sale. Share-based compensation - To determine the fair value of stock options on a given date, the Company must determine the assumptions that will be used as inputs to the Black-Scholes option pricing model, including the assumption regarding the future volatility of the common shares of Liminal for the expected life of the stock options. The Company uses the historical volatility as a starting basis for the estimate and also considers whether there are factors that would indicate that the past volatility is not indicative of the future volatility. In making this assessment, management considers changes in the Company's activities and other factors such as a significant share consolidation. As the volatility is an assumption that has a significant impact on the calculated value of a stock option, the impact of this estimate can significantly impact the share-based payment expense over the vesting period of an award. Valuation of deferred income tax assets – To determine the extent to which deferred income tax assets can be recognized, management estimates the amount of probable future taxable profits that will be available against which deductible temporary differences and unused tax losses can be utilized. Management exercises judgment to determine the extent to which realization of future taxable benefits is probable, considering the history of taxable profits, budgets and forecasts and availability of tax strategies. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require it to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities, and the Company is unable to estimate the potential impact on its future business or its financial results as of the date of this filing. These estimates may change as new events occur and additional information is obtained and changes in those estimates are recognized in the consolidated financial statements as soon as they become known.

Change in standards, interpreta

Change in standards, interpretations and accounting policies	12 Months Ended
	Dec. 31, 2021
Disclosure Of Initial Application Of Standards Or Interpretations [Abstract]
Change in standards, interpretations and accounting policies	4. Change in standards, interpretations and accounting policies a) Adoption of new accounting standards The accounting policies used in these annual consolidated financial statements are consistent with those applied by the Company in its December 31, 2020 and 2019 audited annual consolidated financial statements except for the amendments to certain accounting standards which are relevant to the Company and were adopted by the Company since January 1, 2020 as described below. Amendments to IFRS 3, Business Combinations or IFRS 3 The amendments to IFRS 3 clarifies the definition of a business and includes an optional concentration test to determine whether an acquired set of activities and assets is a business. These amendments were adopted on January 1, 2020 and are applied prospectively to acquisitions made on or after this date. Amendment to IFRS 16 , Leases or IFRS 16 for COVID-19-Related Rent Concessions - IFRS 16 has been revised to incorporate an amendment issued by the IASB in May 2020. The amendment permits lessees not to assess whether particular COVID-19-related rent concessions are lease modifications and, instead, account for those rent concessions as if they were not lease modifications. In addition, the amendment to IFRS 16 provides specific disclosure requirements regarding COVID-19-related rent concessions. The amendment was adopted as of January 1, 2021 and had no impact on the financial statements for the year ended December 31, 2021 since the Company has not benefited from COVID-19 related rent concessions. Amendment to IAS 1, Presentation of Financial statements or IAS 1 - IAS 1 has been revised to require the disclosure of material accounting policies rather than significant accounting policies and provides guidance to apply materiality judgments to accounting policy disclosure. The Company early adopted these amendments, and consequential amendments to other standards, for its annual audited financial statements for the year ended December 31, 2021 resulting in a reduction of its accounting policy disclosure in note 2 - Material accounting policies. b) New Standards and interpretations not yet adopted The IFRS accounting standards, amendments, and interpretations that the Company reasonably expects may have a material impact on the disclosures, the financial position or results of operations of the Company when applied at a future date are as follows: Amendments to IAS 37, Provisions, Contingent Liabilities and Contingent Assets (IAS 37) - IAS 37 has been revised to specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments are effective for annual reporting periods beginning on or after January 1, 2022. The cumulative effect of initially applying the amendment, if any, will be recorded as an adjustment to the opening retained earnings and comparative periods will not be restated. Earlier application is permitted. The Company has determined that the adoption of this modification as of January 1, 2022 will not have an impact on the provision presently recorded at December 31, 2021. Amendment to IFRS 9 Financial Instruments ( IFRS 9) - IFRS 9 has been revised to clarify the fees an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and is to be applied to financial liabilities that are modified after the date of adoption. Earlier application is permitted. Amendments to I AS 8, Accounting policies , Changes in Accounting Estimates and Errors (IAS 8) and IAS 1, Presentation of Financial Statements (IAS 1) - The amendments to IAS 8 introduce a definition of accounting estimates and provide clarifications to distinguish accounting policies from accounting estimates. In addition, IAS 1 has been revised to clarify how to classify debt and other liabilities as current or non-current. The amendments help to determine whether, in the statement of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments also include clarifying the classification requirements for debt an entity might settle by converting it into equity. The amendments are applicable retrospectively and is effective for annual reporting periods beginning on or after January 1, 2023 with earlier application permitted. Amendments to IAS 12, Income taxes (IAS 12) - The amendments to IAS 12 clarify the accounting for deferred tax assets or liabilities arising from a single transaction such as leases, namely that the scope of the recognition exemption no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 with earlier application permitted. The Company is evaluating the impact of the amendments to IAS 8, IAS 1 and IAS 12 on its consolidated financial statements.

Acquisition of Fairhaven Pharma

Acquisition of Fairhaven Pharmaceuticals Inc	12 Months Ended
	Dec. 31, 2021
Disclosure Of Business Combinations [Abstract]
Acquisition of Fairhaven Pharmaceuticals Inc	5. Acquisition of Fairhaven Pharmaceuticals Inc. Pursuant to a share purchase agreement, or SPA, dated July 17, 2020 , the Company acquired 100 % of the issued and outstanding common shares of Fairhaven Pharmaceuticals Inc., or Fairhaven, a company with a preclinical research program of small molecule antagonists. As consideration for the acquisition, the Company issued 202,308 common shares. Upon achievement of certain pre-determined research and development milestones prior to July 17, 2025, the Company may be obligated to make additional payments in the form of common shares totalling up to $ 4,374 . The number of shares to be issued, if any, upon completion of a milestone, will be calculated using the five -trading day volume weighted average trading price, or VWAP of the Company’s common shares on Nasdaq prior to the achievement of such milestone events. As Fairhaven did not meet the definition of a business under IFRS 3, the acquisition has been accounted for as an asset acquisition, the total cost of the net assets acquired being the fair value of the consideration paid. The shares issued were recorded at a fair value of $ 3,441 , based on the closing price of Liminal’s common shares at the date of the transaction. The transaction costs of $ 308 incurred by the Company were capitalized and allocated to the net assets acquired. Any future milestone payments would be recognized if and when the triggering event occurs. The consideration paid and the allocation thereof to the net assets acquired were as follows: Cost of acquisition Fair value of common shares issued $ 3,441 Cash payment 50 Total consideration paid $ 3,491 Transaction fees 308 Total cost of acquisition $ 3,799 Net assets acquired Current assets $ 217 Licenses and other rights (note 12) 3,796 Current liabilities ( 214 ) Total net assets acquired $ 3,799

Discontinued operations

Discontinued operations	12 Months Ended
	Dec. 31, 2021
Discontinued Operations [Abstract]
Discontinued operations	6. Discontinued operations The Company has entered into several share purchase agreement(s), or SPA(s), in 2019 and in 2021 for the sale of businesses that were no longer part of its core strategy. 2019 and 2020 On November 25, 2019, the Company sold two subsidiaries in its bioseparations segment, Prometic Bioseparations Ltd and Prometic Manufacturing Inc., to Gamma Biosciences GP LLC, representing the majority of its bioseparations operations and all of the bioseparations revenues. As of December 31, 2019, the Company had received $ 50,752 in cash and recorded an amount receivable of $ 1,175 . This amount was received in the beginning of 2020 and then later during the year, an additional amount of $ 3,380 in proceeds was recorded and received upon resolution of a taxation matter. In the event the operations sold achieve certain yearly performance criteria during the four years following the transaction, additional cash payments will be received; for the two first years following the sale, the performance criteria were not met. As of the date of these consolidated financial statements, the aggregate cash consideration that could still be earned until the end of 2023 is $ 13,724 (£ 8,000,000 ). At the time of the sale and since then the fair value of the contingent consideration available has been evaluated as $ nil as its receipt is dependent on future target achievement that is out of the Company’s influence and is primarily dependent on the growth of the operations sold. 2021 The Company entered into two SPAs with Kedrion S.p.A., or Kedrion, during the quarter ended June 30, 2021: the first for the sale of Prometic Plasma Resources Inc. and Prometic Plasma Resources USA Inc., operating the plasma collection centers, and the second for the sale of its Ryplazim ® business operated through its subsidiaries Prometic Bioproduction Inc., or PBP, and the Company’s plasma-derived therapeutics manufacturing facility and PBT, the holder of the biologicals license application or BLA and intellectual property rights for Ryplazim ® . Additionally, the Company’s subsidiary PBT entered into an agreement, during the quarter ended September 30, 2021, with another party for the sale of the Priority Review Voucher, or PRV, it received on June 4, 2021, in conjunction with FDA approval of its BLA. These disposals cover the majority of Liminal’s plasma-derived therapeutics segment. The sale of the plasma collection centers was closed on May 21, 2021. Concurrently with the closing of this transaction, the Company entered into an option agreement, or Option, which granted Kedrion the right to acquire the Ryplazim ® business by June 15, 2021 which was subsequently extended to June 22, 2021. The SPA for the Ryplazim ® business was signed on June 22, 2021, with the sale of PBP subsequently closing on July 9, 2021. Between the original expiry date of the Option and the sale of PBP, the Company received additional proceeds compensating the Company for the extension of the Option and the operating costs of PBP until that date. On August 6, 2021, PBT entered into a definitive agreement for the sale of the PRV with another party for proceeds of USD 105 million. The sale of the PRV closed on September 28, 2021 with PBT receiving $ 130,966 (net of selling costs of $ 1,891 ). The sale of PBT to Kedrion closed on October 15, 2021. As part of the SPAs signed with Kedrion, the Company could be required to indemnify the buyer if certain events occur following the closing of each sale transactions, the whole subject to contractual limitations on such indemnifications. Estimates of potential payments and actual payments, if any, will be recorded against the gain on sale of subsidiaries. Gain on sale of subsidiaries The details of the gain on sale of subsidiaries during the years ended December 31, 2021, 2020 and 2019 is provided in the table below: Year ended December 31 2021 2020 2019 Sale of bioseparation business Proceeds received $ — $ 3,380 $ 51,927 Less: Carrying amount of net assets sold — — 22,015 Transaction costs — — 5,015 Reclassification of foreign currency translation reserve from other — — ( 1,449 ) Gain on sale of bioseparation business $ — $ 3,380 $ 26,346 Sale of plasma collection centers Proceeds received $ 13,570 $ — $ — Less: Carrying amount of net assets sold 10,849 — — Transaction costs 204 — — Reclassification of foreign currency translation reserve from other ( 44 ) — — Gain on sale of plasma collection centers $ 2,561 $ — $ — Sale of Ryplazim business Proceeds received $ 159,787 $ — $ — Less: Carrying amount of net assets sold 19,541 — — Indemnification adjustments 116 Transaction costs 2,288 — — Gain on sale of Ryplazim business $ 137,842 $ — $ — Gain on sale of subsidiaries, net of income taxes $ nil $ 140,403 $ 3,380 $ 26,346 The carrying amounts of the assets and liabilities of the entities sold during the year ending December 31, 2021, as part of the sale of the plasma collection centers and the Ryplazim ® business, on the dates control of the entities were transferred to the purchaser, are as follows: Bioseparation business Plasma collection centers Ryplazim business Cash $ 6,794 $ — $ — Accounts receivable 1,148 137 1,879 Inventories 8,313 8,441 4,640 Prepaids 236 21 399 Other long-term assets 48 54 50 Capital assets 8,483 2,376 9,304 Right-of-use assets 3,300 2,000 3,795 Intangible assets 370 1,092 7,277 Deferred tax assets 12 — — Total assets $ 28,704 $ 14,121 $ 27,344 Accounts payable and accrued liabilities 2,163 639 2,887 Deferred revenue 370 — — Current portion of lease liabilities 809 665 986 Long-term portion of deferred revenues 87 — — Long-term portion of lease liabilities 3,260 1,968 3,930 Total liabilities $ 6,689 $ 3,272 $ 7,803 Net assets sold $ 22,015 $ 10,849 $ 19,541 Results and cash flows from discontinued operations During the quarter ended March 31, 2021, the Company had determined that the plasma collection centers met the criteria to be presented as discontinued operations and therefore the results of operations and other comprehensive loss of that disposal group have been presented as discontinued operations since that quarter. Following the signing of the SPA for the Ryplazim ® business during the quarter ended June 30, 2021, the results of PBP and PBT have also been presented as discontinued operations since that quarter and as well as the results of Prometic Biotherapeutics Ltd, a subsidiary that was also part of the plasma-derived therapeutics segment but was not sold and which operations will cease. The results of the former bioseparation entities have been presented as discontinued operations since the disposal on November 25, 2019. The revenues and costs relating to all the above entities were reclassified and presented retrospectively in the consolidated statements of operations, statement of comprehensive loss for the years ended December 31, 2021, 2020 and 2019 and notes to the consolidated financial statements as discontinued operations. When presenting the result of discontinued operations, certain adjustments are made to past cost allocations if those costs are expected to be retained by the continuing operations. As such, the results from discontinued operations will not equal the historical losses from the plasma-derived therapeutic segment. Effective with the period ended June 30, 2021, Liminal is no longer presenting segmented information as the Company’s continuing operations all pertain to the small molecule segment. The net loss from discontinued operations for the years ended December 31, 2021, 2020 and 2019 are presented below: Year ended December 31 2021 2020 2019 Revenues $ 949 $ 2,593 $ 27,233 Expenses Cost of sales and other production expenses 1,465 1,868 14,012 Research and development expenses 1) 2) 76,733 42,757 65,840 Administration expenses 2,360 5,933 11,009 Gain on foreign exchange ( 136 ) ( 633 ) ( 759 ) Impairment losses 3) 1,411 19,772 11,603 Gain on extinguishment of liabilities — ( 79 ) — Finance costs 2,242 6,083 7,926 Loss from discontinued operations, $ ( 83,126 ) $ ( 73,108 ) $ ( 82,398 ) Current income tax (note 26) 1 8 53 Deferred income tax (note 26) — — ( 24 ) Net loss from discontinued operations $ ( 83,127 ) $ ( 73,116 ) $ ( 82,427 ) 1) The expense relating to an agreement with a contract development and manufacturing organization, or CDMO, which is considered an onerous contract (note 15) is included in research and development expenses for the year ended December 31, 2021. 2) On September 29, 2021 prior to the closing of the sale of PBT, PBT paid PBP, which ownership had already passed to Kedrion, $ 39,457 representing 30 % of the net proceeds it received from the sale of the PRV, as compensation for past research and development services. A second payment made by PBT to PBP of $ 6,357 in prepayment for future R&D services on the same date was recognized as R&D expense since this amount would not be recoverable upon the sale of PBT. 3) During the year 2019, the Company, evaluated its intellectual property and the related market opportunities in the context of the Company’s financial situation and has made further decisions about the areas the Company will or will not pursue. One of these decisions affecting our plasma-derived therapeutic segment was to no longer pursue further indications relating to the human-plasma protein plasminogen. As such, the Company decided it would retain sufficient staff to complete and resubmit a BLA, for congenital plasminogen deficiency and to build ongoing manufacturing supply, but then it would cease all R&D activities in the plasma-derived therapeutics segment not relating to Ryplazim ® . Because of this, the Company’s long-term production forecasts for plasminogen were reduced and it was decided that one of its planned manufacturing facilities and a technical transfer facility would no longer be required. The Company also decided to close its R&D facility in Rockville, MD by the end of 2020. Consequently, the capital and intangible assets in the Plasma-derived therapeutics segment that were no longer to be used as originally planned were reviewed for impairment and written-down to their net recoverable value determined as the FVLCD using a market approach. The Company assessed the resale value of the property, plant and equipment, the licenses and patents, in their present condition, less cost of disposal and consequently, recorded an impairment of $ 7,070 and $ 4,535 on capital assets and intangible assets, respectively for the year ended December 31, 2019. At September 30, 2021, the carrying amount of the net assets of PBT, presented as assets of disposal group held for sale, exceeded the amount of the proceeds to be received upon the closing of the sale transaction that occurred on October 15, 2021. As assets held for sale must be carried at the lowest of their carrying amount or their fair value less cost to sell, an impairment of $ 1,389 was recorded on the intangible assets during the quarter ended September 30, 2021 (note 12). At the beginning of 2021, the Company announced it had undertaken to evaluate potential alternatives aimed at minimizing the plasma-derived therapeutics segment cash burn which may result in divestment in whole or part of this business, or other courses of action including but not limited to the closure of the Ryplazim ® related operations, in order to focus our resources on the small molecules segment. As the capital, intangible and ROU assets in the Ryplazim ® CGU were no longer to be used as originally planned, management proceeded to review them for impairment and writing them down to their net recoverable value determined as the FVLCD using a market approach. The Ryplazim ® CGU includes the assets involved in production, R&D and commercialization activities relating to the Ryplazim ® product candidate that has yet to receive regulatory approval for commercialization. The Ryplazim ® CGU evaluated excluded the assets pertaining to the plasma collection activities since these can generate distinct cash inflows and could potentially be divested separately from the Ryplazim ® assets. The plasma collection assets were not considered impaired. The FVLCD was calculated using a discounted cash flow model for one year and a terminal value of $ 58.1 million using a post-tax discount rate of 7.75 %. The fair value computed by management is considered as a level 3 computation in the fair value hierarchy under IFRS 13, Fair value measurement . As part of this valuation exercise, management needed to make several key assumptions which affected the cash inflows and outflows considered in the model. The significant estimates used in determining the FVLCD are disclosed in note 3. As a result of this exercise, the Company recorded impairment of $ 665 on capital assets (note 10), $ 18,553 on ROU assets (note 11) and $ 480 on intangible assets (note 12), respectively, representing an aggregate impairment of $ 19,698 on these plasma-derived therapeutic assets for the year ended December 31, 2020. Also during the year, the Company recorded other impairments on ROU assets amounting to $ 74 . The consolidated statements of cash flows for the years ended December 31, 2021 and 2020 were not restated to present the cash flows from the discontinued operations separately as the Company selected to provide this information in the present note. The cash flows from the discontinued operations and the gain on sale of subsidiaries for the years ended December 31, 2021 and 2020 are presented in the following table: Year ended December 31 2021 2020 2019 Cash flows from (used in) in operating activities 1) $ ( 43,089 ) $ 8,015 $ 19,493 Cash flows used in financing activities ( 3,470 ) ( 7,943 ) ( 8,446 ) Cash flows from (used in) investing activities 171,225 ( 729 ) 36,275 Net effect of currency exchange rate on cash ( 30 ) 76 ( 3 ) Cash flows generated during the year $ 124,636 $ ( 581 ) $ 47,319 Total cash flows generated from $ 124,636 $ ( 581 ) $ 47,319 1) When compiling the cash flows from discontinued operations which include only certain entities from the Liminal group of companies, intra-group cash transfers between entities in the discontinued operations group and those part of continuing activities, for example the funding provided by Liminal to the discontinued operations, have been classified as part of the operating activities cash flows.

Accounts receivable and Others

Accounts receivable and Others	12 Months Ended
	Dec. 31, 2021
Trade And Other Receivables [Abstract]
Accounts receivable and others	7. Accounts receivable and others December 31, December 31, 2021 2020 Trade receivables $ 229 $ 943 Tax credits and government grants — 1,808 Sales taxes receivable 280 431 Restricted cash — 178 Other receivables 559 721 $ 1,068 $ 4,081

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Classes Of Inventories [Abstract]
Inventories	8. Inventories December 31, December 31, 2021 2020 Raw materials $ — $ 9,138 Finished goods — 239 $ — $ 9,377 Inventories sold in the amount of $ 376 , $ 1,102 and $ 12,441 were recognized in cost of sales and other production expenses from discontinued operations during the years ended December 31, 2021, 2020 and 2019, respectively. Inventory write-downs affecting the results from discontinued operations were $ nil , $ nil and $ 642 during the years ended December 31, 2021, 2020 and 2019, respectively.

Other long-term assets

Other long-term assets	12 Months Ended
	Dec. 31, 2021
Other Non Current Assets [Abstract]
Other long-term assets	9. Other long-term assets December 31, December 31, 2021 2020 Long-term deposits $ 30 $ 137 Tax credits receivable 332 1,216 $ 362 $ 1,353

Capital assets

Capital assets	12 Months Ended
	Dec. 31, 2021
Disclosure Of Property Plant And Equipment [Abstract]
Capital assets	10. Capital assets Production Furniture and Land and Leasehold and laboratory computer Buildings improvements equipment equipment Total Cost Balance at January 1, 2020 $ 4,567 $ 8,558 $ 32,417 $ 3,223 $ 48,765 Additions — 214 295 550 1,059 Disposals — ( 1,380 ) ( 2,791 ) ( 404 ) ( 4,575 ) Effect of foreign exchange differences — ( 43 ) ( 17 ) ( 4 ) ( 64 ) Balance at December 31, 2020 $ 4,567 $ 7,349 $ 29,904 $ 3,365 $ 45,185 Additions — — 99 13 112 Disposals — ( 399 ) ( 1,516 ) ( 306 ) ( 2,221 ) Sold - discontinued operations (note 6) — ( 6,324 ) ( 21,525 ) ( 2,256 ) ( 30,105 ) Effect of foreign exchange differences — ( 107 ) ( 45 ) ( 9 ) ( 161 ) Balance at December 31, 2021 $ 4,567 $ 519 $ 6,917 $ 807 $ 12,810 Accumulated depreciation Balance at January 1, 2020 $ 609 $ 3,429 $ 20,796 $ 2,460 $ 27,294 Depreciation expense 195 710 1,450 424 2,779 Disposals — ( 1,380 ) ( 2,527 ) ( 404 ) ( 4,311 ) Impairments (note 25) — 167 498 — 665 Effect of foreign exchange differences — ( 25 ) ( 9 ) 1 ( 33 ) Balance at December 31, 2020 $ 804 $ 2,901 $ 20,208 $ 2,481 $ 26,394 Depreciation expense 195 268 662 243 1,368 Impairments (note 6) — — 22 — 22 Disposals — ( 400 ) ( 1,301 ) ( 306 ) ( 2,007 ) Sold - discontinued operations (note 6) — ( 2,400 ) ( 14,281 ) ( 1,744 ) ( 18,425 ) Effect of foreign exchange differences — ( 12 ) ( 7 ) ( 6 ) ( 25 ) Balance at December 31, 2021 $ 999 $ 357 $ 5,303 $ 668 $ 7,327 Carrying amounts At December 31, 2021 $ 3,568 $ 162 $ 1,614 $ 139 $ 5,483 At December 31, 2020 3,763 4,448 9,696 884 18,791 Impairment losses of $ 22 , $ 665 and $ 7,070 were recorded on capital assets that were part of the discontinued operations (note 6) during the years ended December 31, 2021, 2020 and 2019, respectively. The depreciation expense for the year ended December 31, 2019 was $ 3,734 .

Right-of-use assets

Right-of-use assets	12 Months Ended
	Dec. 31, 2021
Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]
Right-of-use assets	11. Right-of-use assets Production and laboratory Buildings equipment Other Total Balance at January 1, 2020 $ 32,246 $ 912 $ 96 $ 33,254 Additions 378 151 15 544 Lease modifications and other remeasurements ( 1,998 ) — — ( 1,998 ) Depreciation expense ( 3,956 ) ( 561 ) ( 61 ) ( 4,578 ) Impairments (note 6) ( 18,553 ) ( 70 ) ( 4 ) ( 18,627 ) Effect of foreign exchange differences ( 31 ) ( 6 ) ( 1 ) ( 38 ) Net book value at December 31, 2020 $ 8,086 $ 426 $ 45 $ 8,557 Lease modifications and other remeasurements 3 ( 53 ) ( 2 ) ( 52 ) Sold - discontinued operations (note 6) ( 5,497 ) ( 272 ) ( 26 ) ( 5,795 ) Depreciation expense ( 906 ) ( 95 ) ( 12 ) ( 1,013 ) Effect of foreign exchange differences ( 77 ) ( 6 ) ( 5 ) ( 88 ) Net book value at December 31, 2021 $ 1,609 $ — $ — $ 1,609 The depreciation expense for the year ended December 31, 2019 was $ 4,913 .

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2021
Disclosure Of Intangible Assets [Abstract]
Intangible assets	Licenses and Patents Software Total Cost Balance at January 1, 2020 $ 158,268 $ 6,309 $ 3,648 $ 168,225 Additions (note 5) 3,796 668 29 4,493 Disposals — ( 179 ) ( 362 ) ( 541 ) Effect of foreign exchange differences — ( 15 ) ( 9 ) ( 24 ) Balance at December 31, 2020 $ 162,064 $ 6,783 $ 3,306 $ 172,153 Additions — 114 ( 1 ) 113 Disposals ( 1,300 ) ( 61 ) ( 33 ) ( 1,394 ) Sold - discontinued operations (note 6) ( 15,006 ) ( 1,403 ) ( 2,963 ) ( 19,372 ) Effect of foreign exchange differences 1 ( 2 ) ( 19 ) ( 20 ) Balance at December 31, 2021 $ 145,759 $ 5,431 $ 290 $ 151,480 Accumulated amortization Balance at January 1, 2020 $ 149,870 $ 3,039 $ 1,470 $ 154,379 Amortization expense 242 289 559 1,090 Disposals — ( 23 ) ( 333 ) ( 356 ) Impairments (notes 6, 25) 480 1,072 15 1,567 Effect of foreign exchange differences — ( 12 ) ( 7 ) ( 19 ) Balance at December 31, 2020 $ 150,592 $ 4,365 $ 1,704 $ 156,661 Amortization expense 316 1,248 399 1,963 Disposals ( 1,298 ) ( 51 ) ( 34 ) ( 1,383 ) Sold - discontinued operations (note 6) ( 8,698 ) ( 533 ) ( 1,772 ) ( 11,003 ) Impairments (notes 6, 25) 1,389 341 — 1,730 Effect of foreign exchange differences 16 ( 13 ) ( 7 ) ( 4 ) Balance at December 31, 2021 $ 142,317 $ 5,357 $ 290 $ 147,964 Carrying amounts At December 31, 2021 $ 3,442 $ 74 $ — $ 3,516 At December 31, 2020 11,472 2,418 1,602 15,492 Impairment losses of $ 341 , $ 1,087 and $ 763 were recorded on certain licenses and patents pertaining to continuing operations (note 6) during the years ended December 31, 2021, 2020 and 2019, respectively, while impairment losses of $ 1,389 , $ 480 and $ 4,533 were recorded on intangible assets pertaining to discontinued operations during the years ended December 31, 2021, 2020 and 2019, respectively. The amortization expense for the year ended December 31, 2019 was $ 1,259 .

Accounts payable and accrued li

Accounts payable and accrued liabilities	12 Months Ended
	Dec. 31, 2021
Trade And Other Current Payables [Abstract]
Accounts payable and accrued liabilities	13. Accounts payable and accrued liabilities December 31, December 31, Trade payables $ 5,762 $ 9,153 Wages and benefits payable 1,297 3,083 Refundable tax credits 113 — Current portion of royalty payment obligations 25 3,248 Current portion of other employee benefit 146 1,351 $ 7,343 $ 16,835

Lease liabilities

Lease liabilities	12 Months Ended
	Dec. 31, 2021
Lease Liabilities [Abstract]
Lease liabilities	14. Lease liabilities The transactions affecting the lease liabilities during the years ended December 31, 2021 and 2020 were as follows: 2021 2020 Balance at January 1 $ 33,452 $ 38,237 Additions — 544 Interest expense 3,754 6,030 Payments ( 4,321 ) ( 9,167 ) Derecognized - discontinued ( 7,549 ) — Lease modification and other remeasurements ( 2,588 ) ( 1,934 ) Effect of foreign exchange differences ( 277 ) ( 258 ) Balance at December 31 $ 22,471 $ 33,452 Less current portion of lease liabilities ( 7,194 ) ( 6,946 ) Long-term portion of lease liabilities $ 15,277 $ 26,506 Interest expense on lease liabilities is included as part of finance costs in the consolidated statement of operations. Interest on the lease liabilities was $ 7,068 for the year ended December 31, 2019. On August 12, 2021, the Company gave a notice of early termination of a master services agreement entered into with a CDMO with whom it has a contract pertaining to its former plasma-derived therapeutics business, using the available 5-year early cancellation notification period set forth under the CDMO contract which resulted in a decrease in the term of the contract by 3.8 years. A portion of the commitments under this CDMO contract are accounted for as a lease liability while the non-lease commitment is being accounted for as an onerous contract provision since June 2021 (note 15). The financial impact of revising the lease term to reflect the effect of exercising the termination option was a decrease in lease liabilities of $ 2,529 and the gain on this transaction was recorded as part of the net loss from discontinued operations for the year ended December 31, 2021.

Provisions

Provisions	12 Months Ended
	Dec. 31, 2021
Restructuring provision [abstract]
Provisions	15. Provisions Initial recognition of provisions at June 30, 2021 $ 21,928 Increase to provisions during the period 439 Effect of foreign exchange difference ( 262 ) Interest expense 90 Balance at December 31, 2021 $ 22,195 Less current portion of provisions ( 3,957 ) Long-term portion of provisions $ 18,238 The Company has a long-term contract with a CDMO for which it has no use following its decision to exit the plasma-derived therapeutics business (note 14). As such, the Company recorded in June 2021, an initial provision for onerous contract for the non-lease portion of the contract calculated as the discounted value of the estimated purchase commitment set forth under the contract using the available 5-year early cancellation notification period. In August 2021, the Company sent the CDMO an early termination notice and the provision was adjusted to reflect the revised maturity date of the contract. The payments under the lease and non-lease portions are variable since there is a CAD/USD foreign exchange variation component that affects each portion, however the total purchase commitment under the lease remains the same at $ 9,000 per year. As such, the effects the foreign exchange differences have on the computation of the carrying value of the provision from period to period essentially offset by the opposite variation of the foreign exchange differences on the lease portion, or the lease liability, of this same contract (note 14). The Company is investigating different avenues to potentially reduce the impact of this contract on its future cash outflows. Changes in the provision expense are included as part of the net loss from discontinued operations. The gain or losses on foreign exchange and the interest expense recorded on this CDMO contract are included in the results from continuing operations.

Warrant liability

Warrant liability	12 Months Ended
	Dec. 31, 2021
Warrant Liability [Abstract]
Warrant Liability	16. Warrant liability 2019 As consideration for the modification of the terms of the loan agreements between Liminal and SALP on November 14, 2018, the Company had a commitment to issue warrants, or Warrants #9, to SALP on or before March 20, 2019 . The exact number of warrants to be issued was based on the number of warrants necessary to increase the ownership of SALP to 19.99 % on a fully diluted basis at the date of issuance. On February 22, 2019, the Company further amended the fourth loan agreement with SALP with the addition of two tranches, one of US$ 10 million and another one of US$ 5 million, that were drawn on February 22, 2019 and March 22, 2019 , respectively. As consideration for the modification to the fourth loan agreement, the Company amended the terms applicable at the time of issuance of Warrants #9 to reduce the originally agreed exercise price from $ 1,000.00 to $ 156.36 per preferred share and to issue the Warrants #9 concurrently with this modification. Accordingly, the Company issued 19,402 warrants on February 22, 2019. Each warrant entitled the holder to acquire one preferred share at a price of $ 156.36 per preferred share expiring on February 22, 2027 . The Warrants #9 did not meet the definition of an equity instrument since the underlying preferred shares qualify as a liability instrument, and therefore they were accounted for as a financial instrument carried at fair value through profit or loss and were presented in the consolidated statement of financial position as a warrant liability. The change in fair value of the warrant liability between December 31, 2018, when it was valued at $ 157 and prior to its modification on February 22, 2019, in the amount of $ 218 was recorded in the consolidated statement of operations. The Company recorded the increase in fair value of the warrants of $ 1,137 resulting from the reduction of the exercise price of Warrants #9 on February 22, 2019 against the two additional tranches of the credit facility, treating the increase as financing fees. The change in fair value of the warrant liability between February 22, 2019, after the modification, and March 31, 2019 was an increase of $ 11 and a decrease in fair value of $ 1,369 (a gain) between March 31, 2019 to April 23, 2019. Both variations were recorded in the consolidated statements of operations. The estimated fair value of these warrants at April 23, 2019 was $ 153 . As part of the debt restructuring agreement entered into on April 23, 2019 (note 17), all the outstanding warrants belonging to SALP, including the Warrants #9, were cancelled and replaced by 168,735 warrants having an exercise price of $ 15.21 (note 19c). The cancellation and the issuance of new warrants was treated as a modification. Following this modification, the Warrants #9 no longer meet the definition of a liability instrument and the Company reclassified the fair value of the Warrants #9 as of April 23, 2019 of $ 153 from warrant liability to warrants classified as equity. 2020 and 2021 As part of the consideration for the private placement completed on November 3, 2020 (note 19a) where SALP and another investor participated equally, and a subsequent amendment to this private placement agreement made on November 25, 2020, the Company issued a total of 7,894,734 warrants that expire on November 3, 2025 . Both of these issuances combined are referred to as the November 2020 warrants. Each warrant can be exercised to acquire one common share at an exercise price initially set at USD 5.50 and that can be reduced if equity financings are completed at a lower price before its expiry. The November 2020 warrants do not meet the definition of an equity instrument since the exercise price is denominated in USD which is different than the functional currency of Liminal which is the CAD. Consequently, they are accounted for as a financial instrument, presented as a warrant liability in the consolidated statement of financial position and carried at fair value through profit or loss. The fair value of the warrants issued on November 3, 2020 and November 25, 2020 were $ 10,263 and $ 2,227 , respectively. The portion of the total issuance cost pertaining to the private placement allocated to the issuance of the November 3, 2020 warrants of $ 709 and the fair value of the additional warrants issued on November 25, 2020 were recorded in the consolidated statement of operation transactions in financing costs and administration, selling and marketing expenses respectively. The fair value of the warrant liability of the November 2020 warrants was $ 11,640 at December 31, 2020. The gain of $ 850 resulting from the change in fair value of the warrants since their issuance was recognized in the statement of operations for the year ended December 31, 2020. The fair value of the November 2020 warrants was $ 1,754 at December 31, 2021 and the gain of $ 9,886 , resulting from the change in fair value of the November 2020 warrants during the year ended December 31, 2021 was recognized in the consolidated statement of operations. The fair value for the November 2020 warrants held by SALP was $ 877 and $ 5,820 at December 31, 2021 and 2020. The fair value of the November 2020 warrants on the various dates discussed above was calculated using a Black-Scholes option pricing model in a Monte Carlo simulation in order to evaluate the downward adjustment mechanism to the exercise price. The assumptions used at the different valuation dates are provided in the table below: December 31, December 31, 2021 2020 Underlying common share fair value (in USD) $ 1.09 $ 4.20 Remaining life until expiry 3.8 4.8 Volatility 56.0 % 49.0 % Risk-free interest rate 1.13 % 0.34 % Expected dividend rate — — Fair value of a warrant calculated using a $ 0.08 $ 1.41 Fair value of exercise price adjustment mechanism $ 0.16 $ 0.22 Illiquidity discount 28.0 % 29.0 % Fair value of a warrant (in USD) $ 0.18 $ 1.16 Fair value of a warrant (in CAD) $ 0.22 $ 1.47

Long-term debt

Long-term debt	12 Months Ended
	Dec. 31, 2021
Disclosure Of Detailed Information About Borrowings [Abstract]
Long-term debt	17. Long-term debt 2021 2020 Balance at January 1 $ 40,532 $ 8,834 Stated and accreted interest 4,388 2,209 Drawdown on non-revolving line of credit — 29,123 Issuance of secured convertible debentures — 2,410 Conversion of secured convertible debt into shares ( 2,664 ) — Repayment of principal — ( 165 ) Repayment of stated interest ( 3,945 ) ( 1,879 ) Balance at December 31 $ 38,311 $ 40,532 At December 31, 2021 and 2020, the carrying amount of the debt comprised the following loans: December 31, December 31, 2021 2020 First term loan having a principal of $ 10,000 maturing April 23, 2024 bearing stated interest of 10 % per annum 15.05 %) 1) $ 9,188 $ 8,910 Second term loan having a principal of $ 29,123 maturing on April 23, 2024 bearing stated interest of 10 % per annum 10.47 %) 1) 29,123 29,123 Secured convertible debentures having an aggregate principal 2,410 maturing on March 31, 2022 bearing stated 8 % per annum (effective interest rate of 8.24 %) 2) — 2,499 $ 38,311 $ 40,532 Less current portion of long-term debt — — Long-term portion of long-term debt $ 38,311 $ 40,532 1) The first and second term loans issued under the consolidated loan agreement with SALP are secured by all the assets of the Company and require that certain covenants be respected including maintaining an adjusted working capital ratio. In February 2022, these loans were repaid in full (note 33). 2) The secured convertible debentures were secured by all the assets of Fairhaven. The Company’s security interest granted in connection with its consolidated loan agreement with SALP, its parent, was subordinated to the security interest on the Fairhaven assets granted in favor of the holder of the secured convertible debentures. 2019 On April 23, 2019, the Company entered into a debt restructuring agreement with the long-term debt holder whereby the entirety of the principal on the Credit Facility plus a portion of the interest due, the entirety of the First and Second Original Issue Discount (“OID”) loans and the majority of the Third OID loan would be repaid by Liminal by the issuance of common shares, at a conversion price, rounded to the nearest two decimals, of $ 15.21 per common share. Consequently, the US$ 95 million of principal plus interest due on the Credit Facility was reduced to $ 663 and the aggregate face value of the three OID loans was reduced by $ 99,552 to $ 10,000 with the remaining balance of the Third OID loan modified into an interest-bearing loan at a stated interest of 10 % payable quarterly. This resulted in the reduction of the long-term debt recorded on the consolidated statement of financial position by $ 141,536 . The Company issued 15,050,312 common shares on that date which were recorded in share capital at a value of $ 228,915 . The difference between the carrying amount of the debt converted into common shares and the increase in the value of the share capital is recognized as a loss on extinguishment of a loan of $ 87,379 . The balance of interest due on the credit facility of $ 663 was paid in cash. The deferred financing fees pertaining to the extinguished loans of $ 653 was expensed. The 15,050,312 common shares issued as part of the debt restructuring contained trading restrictions and accordingly, the Company determined that their quoted price did not fairly represent the value of the shares issued. As such, the issued shares were recorded at fair value using a market approach under a level 2 fair value measurement of $ 15.21 per share, resulting in a value of the shares issued of $ 228,915 . The fair value was based on a share issuance for cash on the same date with a non-related party. Pursuant to the debt restructuring, the Company cancelled the warrants previously held by SALP and replaced them with 168,735 new warrants having an exercise price rounded to the nearest two decimals of $ 15.21 per common share, expiring on April 23, 2027 (note 19c). The incremental fair value of the replacement warrants of $ 408 was recognized in warrants equity and as part of the loss on the debt extinguishment together with the legal fees incurred to finalize all the related legal agreements. The modification in terms of the remaining balance of the Third OID loan of $ 10,000 was accounted for as an extinguishment of the long-term debt and the re-issuance of a new interest-bearing loan, the first term loan. The difference between the carrying amount of the loan extinguished of $ 4,667 and the $ 8,521 recognized as the fair value of the new loan with the parent was recorded as a loss on debt extinguishment of $ 3,854 . The fair value of the modified loan was determined using a discounted cash flow model with a market interest rate of 15.1 %. As a result of this transaction and the extinguishments of liabilities that occurred earlier in the beginning of 2019 following payments made to suppliers by the issuance of equity (note 19a), the consolidated statement of operations for the year ended December 31, 2019, includes a loss on extinguishment of liabilities of $ 92,374 detailed as follows: Loss on extinguishment of liabilities due to April 23, 2019 loan modification Comprising the following elements: Debt to equity conversion $ 87,379 Expensing of financing fees on loan extinguishment 653 Extinguishment of previous loan ( 4,667 ) Recognition of modified loan 8,521 Expensing of increase in the fair value of the warrants (note 19c) 408 Loss on extinguishment of liabilities due to April 23, 2019 loan modification $ 92,294 Loss on extinguishment of liabilities to suppliers (note 19a) 80 Loss on extinguishments of liabilities $ 92,374 During the year ended December 31, 2019, the aggregate stated and accreted interest on the long-term debt was $ 7,874 . 2020 Concurrently with the Fairhaven acquisition that closed on July 17, 2020 , the Company issued secured convertible debentures, or SCD, to certain former Fairhaven shareholders, for an aggregate principal amount of $ 2,410 and bearing an interest rate of 8 % per annum, compounded quarterly. The SCD are due on the earlier of i) March 31, 2022 , the maturity date, unless converted into common shares of the Company prior to the maturity date or ii) upon a change of control event. At any time prior to the maturity date, the SCD holders have the right to convert the SCD into common shares of the Company. Liminal has the right to convert the SCD into common shares under certain pre-determined events. The five -trading day VWAP of Liminal’s common shares immediately preceding the date of any conversion will be used to determine the number of common shares of the Company that will be issued. The SCD were recorded as financial liabilities. The conversion features were determined to have no value. At any time prior to the maturity date and until the amendment discussed below, the holders had a collective right to purchase additional SCD issued by the Company for an aggregate principal amount of up to $ 5,740 with substantially the same terms and conditions as set out in the original SCD. If the pre-determined events allowing the Company to trigger the conversion of the SCD occur prior to the maturity date, the Company has the right to require the holders of the SCD to purchase additional SCD for an aggregate principal amount of up to $ 5,740 , which would then be converted into common shares. On November 11, 2019, the consolidated loan agreement with SALP was amended to provide for a non-revolving line of credit bearing the same terms and conditions as the first term loan. On September 14, 2020 , the Company drew down $ 29,123 on the non-revolving line of credit representing the entire balance available, which resulted in the issuance of the second term loan. The second term loan bears an annual interest rate of 10 % compounded monthly , is payable quarterly and matures on April 23, 2024 . 2021 On October 20, 2021, the Company exercised its right to convert the entirety of its SCD, having a balance of $ 2,664 on the conversion date into 1,098,577 common shares of Liminal, using a conversion price of $ 2.42 (USD 1.96 ) calculated as the volume weighted average trading price of the shares in the five trading days immediately preceding the conversion. Liminal’s conversion right became exercisable upon the occurrence of an event which resulted in the Company having a cash balance over $ 75,000 . The difference between the carrying value of the SCD and the fair value of the common shares issued and recorded in share capital of $ 2,589 , calculated using the closing trading price on the conversion date, was $ 75 and was recorded as a gain on extinguishment of a liability. The Company and the parties to the share purchase agreement dated July 17, 2020 entered into an amendment to this agreement in November 2021 to terminate 1) the collective rights of certain sellers to purchase additional SCD issued by the Company for an aggregate principal amount of up to $ 5,740 with substantially the same terms and conditions as set out in the original SCD and 2) the Company’s right, if the pre-determined events allowing the Company to trigger the conversion of the SCD occur prior to the maturity date, to require certain sellers to purchase additional SCD for an aggregate principal amount of up to $ 5,740 , which would then be converted into common shares. At December 31, 2021, the Company was in compliance with all of its covenants under its long-term debt agreement. Subsequent to December 31, 2021, the consolidated loan agreement with SALP was terminated and the first and second term loans were repaid (note 33).

Other long-term liabilities

Other long-term liabilities	12 Months Ended
	Dec. 31, 2021
Miscellaneous Noncurrent Liabilities [Abstract]
Other long-term liabilities	18. Other long-term liabilities December 31, December 31, 2021 2020 Royalty payment obligations (a) $ 123 $ 3,355 Other employee benefit liabilities 146 1,557 $ 269 $ 4,912 Less: Current portion of royalty payment obligations (note 13) ( 25 ) ( 3,248 ) Current portion of other employee benefit liabilities (note 13) ( 146 ) ( 1,351 ) $ 98 $ 313 a) Royalty payment obligations i) Royalty payment obligations to SALP During 2018, the Company signed a royalty stream agreement with SALP at the same time as certain conditions pertaining to the second advance of the credit facility were modified. The financial commitments that remain under this agreement at December 31, 2021 and 2020 include 1) a minimum royalty payment of USD 5,000,000 per quarter until approximately 2034 and a liability of $ 123 was recognized in the consolidated statement of financial position at December 31, 2021 ($ 132 at December 31, 2020), and 2) a net sales royalty commitment (note 30) for which no liabilities have yet to be recorded in the consolidated financial statements. On February 15, 2022, the royalty stream agreement was terminated (note 33). ii) Royalty payment obligation for reacquired rights As part of the consideration given by the Company in 2016 for the reacquisition of the rights to 50 % of the worldwide profits pertaining to the sale of plasminogen for the treatment of plasminogen congenital deficiency which were previously granted to a licensee under a license agreement, the Company agreed to make royalty payments on the sales of plasminogen for congenital deficiency, using a rate of 5 % up to a total of USD 2.5 million, the unpaid balance becoming due at December 31, 2020. At December 2020, the Company recognized a royalty payment obligation of $ 3,223 (USD 2.5 million) in the consolidated statement of financial position. The balance was paid in 2021.

Share capital and other equity

Share capital and other equity instruments	12 Months Ended
	Dec. 31, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Share capital and other equity instruments	19. Share capital and other equity instruments a) Share capital Authorized and without par value Common shares: unlimited number authorized, participating, carrying one vote per share, entitled to dividends. Preferred shares: unlimited number authorized, issuable in one or more series. - Series A preferred shares: unlimited number authorized, no par value, non-voting, ranking in priority to the common shares, entitled to the same dividends as the common shares, non-transferable, redeemable at the redemption amount offered for the common shares upon a change in control event. Changes in the issued and outstanding common shares during the year ended December 31, 2021 and 2020 were as follows: 2021 2020 Number Amount Number Amount Balance - beginning of year 29,943,839 $ 977,261 23,313,164 $ 932,951 Issued to acquire assets — — 299,141 4,681 Exercise of stock options (note 19b) — — 5,391 167 Exercise of pre-funded warrants (note 19c) — — 557,894 2,624 Shares issued pursuant to a restricted share 144 — 10,355 9,764 Shares issued for cash — — 5,757,894 27,074 Shares issued upon conversion of debt 1,098,577 2,588 — — Balance - end of year 31,042,560 $ 979,849 29,943,839 $ 977,261 2021 On October 20, 2021, the Company exercised its right to convert, the entirety of its secured convertible debt (note 17) into 1,098,577 of its common shares. 2020 On January 29, 2020, the Company issued 96,833 common shares as a consideration for the final payment for a license acquired in January 2018. This transaction was accounted for as an extinguishment of the license acquisition payment obligation and the difference between the carrying value of the liability of $ 1,319 and the amount recorded for the shares issued of $ 1,240 , which were valued at the market price of the shares on their date of issuance, was recorded as a gain on extinguishment of liabilities of $ 79 during the year ended December 31, 2020. On July 17, 2020 the Company issued 202,308 common shares in payment for the acquisition of Fairhaven, which has been accounted for as an asset acquisition (note 5). The common shares issued were valued at the market price of the shares, on their date of issuance for an aggregate value of $ 3,441 . On November 3, 2020, the Company completed a private placement for a total gross proceed of $ 39,960 in exchange for the issuance of 5,757,894 common shares, 557,894 prefunded warrants (note 19c) and 6,315,788 warrants (note 16, 19c). SALP’s participation in the private placement was for gross proceeds of $ 19,980 . The total gross proceeds were allocated to the warrant liability based on its fair value of $ 10,263 on that date with the residual value being allocated between the common shares and the pre‑funded warrants. The value attributed to the common share was $ 27,074 . The total transaction costs of $ 2,755 were allocated to the three instruments issued based on their relative fair values. The amount allocated to the common shares and the pre-funded warrants, of $ 2,048 , was recognized in the deficit. On December 30, 2020, the 557,894 pre-funded warrants were exercised resulting in the issuance of 557,894 common shares and the receipt of $ 1 in cash. An amount of $ 2,623 was reclassified from warrants to common shares. 2019 On February 25 and 27, 2019, the Company issued a total of 1,472 common shares in payment for amounts due to certain suppliers. This transaction was accounted for as an extinguishment of liabilities and the difference between the carrying value of the accounts payable of $ 465 and the amount recorded for the shares issued of $ 545 , which were valued at the market price of the shares on their date of issuance, was recorded as a loss on extinguishment of liabilities of $ 80 (note 17). As part of the settlement agreement concluded in April 2019 with the former CEO of the Company, common shares held in escrow as security for a share purchase loan of $ 400 to the former CEO were released and the loan extinguished in exchange for the receipt of a payment of $ 137 , representing the fair value of the shares at the time of the settlement. In May 2019, the Company announced a Rights Offering to the holders of its common shares at the close of business on May 21, 2019 to subscribe for up to 20 additional common shares, for each share they held, for a subscription price rounded to the nearest two decimals of $ 15.21 per common share. The Right Offering was subject to a proration to ensure that no more than $ 75,000 was raised. In June 2019, the Company issued 2,592,628 common shares for gross proceeds of $ 39,434 as part of the Right Offerings less transactions costs of $ 271 recorded in deficit, for total net proceeds of $ 39,163 . b) Contributed surplus (Share-based payments) Stock options The Company has established a stock option plan for its directors, officers, employees and service providers. The plan provides that the aggregate number of shares reserved for issuance at any time under the plan may not exceed 3,749,714 common shares and the maximum number of common shares, which may be reserved for issuance to any individual, may not exceed 5 % of the outstanding common shares. The stock options issued under the plan may be exercised over a period not exceeding ten years from the date they were granted. Most of the stock options outstanding have a contractual life of 10 years . The vesting period of the stock options varies from immediate vesting to vesting over a period not exceeding six years , most of them vesting over four years . Participants meeting certain service and age requirements may see the vesting of certain awards accelerate upon retirement. The vesting conditions are established by the Board of Directors on the grant date. The exercise price is based on the weighted average share price for the five business days prior to the grant. For stock options having a CAD exercise price, the changes in the number of stock options outstanding during the years ended December 31, 2021 and 2020 were as follows: 2021 2020 2019 Weighted Weighted Weighted average average average exercise price exercise price exercise price Number ($) Number ($) Number ($) Balance - beginning of year 2,485,555 $ 18.70 2,209,864 $ 38.72 21,625 $ 1,464.49 Granted — — 436,570 14.06 2,218,810 33.13 Forfeited ( 1,321,651 ) 14.34 ( 153,982 ) 19.33 ( 16,774 ) 159.61 Exercised — — ( 5,391 ) 15.21 — — Cancelled — — — — ( 11,713 ) 1,237.94 Expired ( 136,126 ) 40.70 ( 1,506 ) 2,462.46 ( 2,084 ) 1,176.20 Repriced - options before repricing — — ( 1,929,685 ) 35.14 — — Repriced - options after repricing — — 1,929,685 15.21 — — Balance - end of year 1,027,778 $ 21.39 2,485,555 $ 18.70 2,209,864 $ 38.72 For options having a USD exercise price, the changes in the number of stock options outstanding during the years ended December 31, 2021 and 2020 were as follows: 2021 2020 Weighted Weighted average average exercise price exercise price Number (USD) Number (USD) Balance - beginning of year 305,000 $ 4.70 — $ — Granted 492,000 2.80 305,000 4.70 Forfeited ( 38,000 ) 4.10 — — Expired ( 10,000 ) 4.27 — — Balance - end of year 749,000 $ 3.49 305,000 $ 4.70 2021 In January 2021, 40,000 stock options having an exercise price of USD 5.34 , of which 20,000 stock options vested immediately and the remaining stock options vest over a period up to one year , were issued to a member of the Board of Directors. In June 2021, 50,000 stock options having an exercise price of USD 4.09 , of which 25,000 stock options vested immediately and the remaining stock options vest over a period up to one year , were issued to a member of the Board of Directors. In July 2021, 50,000 stock options having an exercise price of USD 3.93 , of which 12,500 stock options vested on October 1, 2021 and the remaining stock options vest over a period up to one year , were issued to members of the Board of Directors. In October 2021, 352,000 stock options, having an exercise price of USD 2.17 and vesting over a period of up to four years , were issued to employees. 2020 In March 2020, Liminal’s board of directors approved a plan to reduce the exercise price of the stock options issued in June 2019, held by active employees and directors at the time of the repricing. On May 26, 2020, a revised exercise price, pending approval, of $ 15.21 was determined, changing the exercise price to the higher of (i) $ 15.21 and (ii) the five trading-day VWAP of Liminal common shares on the repricing date. On June 8, 2020, the repricing of 1,929,685 of the outstanding stock options having exercise prices of $ 27.00 and $ 36.00 to the revised exercise price was approved at the Company’s annual shareholder meeting. Although the stock options were not repriced until May 26 2020, management concluded that the service period for employees and directors to earn the modified awards had commenced from the date the Company informed the holders of these stock options of the repricing proposal and the expense resulting from the repricing plan should be recognized starting from that date. Using the revised exercise price of $ 15.21 , the Company calculated the final incremental fair value of the repricing on the grant date of May 26, 2020 to be $ 3,000 . This incremental fair-value will be amortized from the services commencement date of March 25 over the remaining vesting period of the repriced options. The incremental grant date fair value of the repriced options was estimated based on the Black-Scholes option-pricing model calculated before and after the effect of the repricing. The following Black-Scholes assumption were used: Expected dividend rate — Expected volatility of share price 93.2 % Risk-free interest rate 0.4 % Expected life in years 6.3 Weighted average grant date incremental fair value $ 1.55 In June 2020, 436,570 stock options, having an exercise price of $ 14.06 and vesting over a period of up to four years , were issued to employees and directors. In October 2020, 20,000 stock options, having an exercise price of US$ 10.80 and vesting over a period of three years were issued to a new director. In December 2020, 285,000 stock options having an exercise price of US$ 4.27 , of which 95,000 stock options vested immediately and the remaining stock options vest over a period up to three years , were issued to key management. During the year ended December 31, 2020, 5,391 stock options were exercised resulting in cash proceeds of $ 82 and a transfer from contributed surplus to share capital of $ 85 . The weighted average share price on the date of exercise of the stock options during the year ended December 31, 2020 was $ 18.47 . 2019 On January 24, 2019, 1,622 stock options were granted at an exercise price of $ 300.00 and vesting on December 31, 2019. On June 4, 2019, 1,794,224 stock options were granted to management at a strike price of $ 36.00 of which 248,825 stock options vested immediately and the remaining vest over a period up to six years . On June 19, 2019, 251,714 stock options were issued at a strike price of $ 27.00 of which 60,717 stock options vested immediately and the remaining vest over a period up to four years . On September 3, 2019, 71,250 stock options were issued at a strike price of $ 11.99 and on December 3, 2019, 100,000 stock options were issued at a strike price of $ 7.86 , both of these grants having a vesting period of up to four years . The weighted average grant date fair value of the stock options issued in 2019 was $ 12.74 . In June and August 2019, the Company cancelled the options that were issued prior to June 2019, as the exercise price of these options were so above the market price at the time, that it was highly unlikely that they would ever be exercised. In compensation for their agreement to the cancellation, key management and employees, received the new options granted to them in June 2019 discussed above. Consequently, 11,084 stock options with a weighted average exercise price of $ 1,256.73 were cancelled. There was no exercise of stock options in 2019. The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options at the date of grant. The weighted average inputs into the model and the resulting grant date fair values during the years ended December 31, 2021, 2020 and 2019 were as follows: 2021 2020 2019 Expected dividend rate — — — Expected volatility of share price 115.0 % 100.5 % 45.0 % Risk-free interest rate 1.21 % 0.5 % 1.4 % Expected life in years 6.7 6.7 7.2 Weighted average grant date fair value $ 2.85 $ 8.66 $ 12.74 At December 31, 2021, stock options issued and outstanding denominated in CAD and USD by range of exercise price are as follows: Weighted Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in CAD outstanding (in years) ($) exercisable ($) $ 7.86 -$ 11.99 30,000 7.7 $ 11.99 16,875 $ 11.99 $ 14.06 141,650 8.4 14.06 78,112 14.06 $ 15.21 800,778 7.4 15.21 522,862 15.21 $ 27.00 -$ 2,220.00 55,350 7.3 134.61 54,985 130.88 1,027,778 7.6 $ 21.39 672,834 $ 24.45 Weighted Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in USD outstanding (in years) (USD) exercisable (USD) $ 2.17 349,000 9.8 $ 2.17 — $ — $ 3.93 -$ 5.34 380,000 9.1 4.31 192,500 4.34 $ 10.80 20,000 8.8 10.80 6,666 10.80 749,000 9.4 $ 3.49 199,166 $ 4.55 A share-based payment compensation expense of $ 4,252 was recorded for the stock options for the year ended December 31, 2021 ($ 6,169 and $ 12,212 for the year ended December 31, 2020 and 2019 respectively). Restricted share units The Company has established an equity-settled RSU plan for executive officers of the Company, as part of its incentive program designed to align the interests of its executives with those of its shareholders, and in accordance with its long-term incentive plan. The vesting conditions are established by the Board of Directors on the grant date. Participants meeting certain service and age requirements may see the vesting of certain awards accelerate upon retirement. Each vested RSU gives the right to receive a common share. There have been no RSU grants since 2018 and all the RSU that were earned have since been settled. Changes in the number of RSU outstanding during the years ended December 31, 2021, 2020 and 2019 were as follows: 2021 2020 2019 Balance - beginning of year 4,216 17,565 18,299 Granted — — 12,564 Forfeited ( 48 ) ( 46 ) ( 409 ) Released ( 144 ) ( 10,355 ) — Paid in cash ( 4,024 ) ( 2,948 ) ( 8,396 ) Cancelled — — ( 4,493 ) Balance - end of year — 4,216 17,565 2021 There was $ nil share-based payment compensation expense recorded in regards to the RSU during the year ended December 31, 2021. During the year ended December 31, 2021, 4,024 RSU were paid in cash resulting in a reduction to contributed surplus of $ 20 . 2020 During the year ended December 31, 2020, 2,948 RSU were paid in cash resulting in a reduction to contributed surplus of $ 40 . As at December 31, 2020, all 4,216 outstanding RSU were vested. A share-based payment compensation expense of $ 65 was recorded during the year ended December 31, 2020. 2019 On January 31, 2019, the Company granted 12,564 RSU at a grant price of $ 300.00 and a one-year vesting period. On May 30, 2019, the Company decided to vest the 12,564 RSU and the employees were given the choice to receive the then current value of the shares in cash or to receive the shares at a later date. As a result, 8,396 RSU were released and paid in cash resulting in a reduction to contributed surplus of $ 421 . On May 7, 2019 the 12,886 performance based RSU pertaining to the “2017-2019” cycle and the “2018-2020” cycle were modified by removing the performance conditions and converting them into time-vesting RSU. The quantity modified into time-vesting units was equivalent to the 100 % achievement range whereby in the past, the outcome of the performance conditions could go from zero to 150 %. Historically, the Company has always reported the quantity of RSU outstanding as the maximum number of shares that could be issued under the plan. This change resulted in the cancellation of 4,305 units. At December 31, 2019, 13,262 vested RSU and 4,303 unvested RSU were outstanding. Share-based payments compensation expense of $ 9,818 was recorded during the year ended December 31, 2019. Share-based payments expense The total share-based payments compensation expense, comprising the above-mentioned expenses for stock options and RSU, has been included in the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019 as indicated in the following table: 2021 2020 2019 Administration expenses $ 3,760 $ 3,248 $ 14,315 Research and development expenses 936 2,430 2,836 Loss from discontinued operations ( 444 ) 556 4,879 $ 4,252 $ 6,234 $ 22,030 c) Warrants The following table presents the number of warrants outstanding with an exercise price in CAD during the years ended December 31, 2021 and 2020: 2021 2020 Weighted Weighted average average exercise price exercise price Number ($) Number ($) Balance of warrants - end of year 172,735 $ 84.33 172,735 $ 84.33 The following table presents the changes in the number of warrants outstanding with an exercise price in USD during the years ended December 31, 2021 and 2020: 2021 2020 Weighted Weighted average average exercise price exercise price Number (USD) Number (USD) Balance of warrants - beginning of year 7,894,734 $ 5.50 — $ — Issued for cash — — 6,873,682 5.05 Issued for no consideration — — 1,578,946 5.50 Exercised — — ( 557,894 ) — Balance of warrants - end of year 7,894,734 $ 5.50 7,894,734 $ 5.50 The 7,894,734 warrants shown in the table above, are those accounted for as a warrant liability (note 16) and are included in this note in order that all the outstanding warrants are presented in aggregate in the tables above. 2020 As a consideration to the private placement on November 3, 2020 (note 19a), the Company issued 6,315,788 warrants and 557,894 pre-funded warrants. The gross proceeds allocated to the pre-funded warrants was $ 2,623 . The pre-funded warrants exercise price was US$ 0.001 and a term of five years . On November 25, 2020, the Company issued 1,578,946 additional warrants with the same terms and conditions as described above, following an amendment to the private placement agreement, for a total of 7,894,734 warrants (note 16). On December 30, 2020, the pre-funded warrants were fully exercised and 557,894 common shares were issued (note 19a). The warrants outstanding as at December 31, 2021, their exercise price in CAD or in USD, expiry rate and the overall weighted average exercise price in both currency are as follows: Number Expiry Exercise 4,000 January 2023 $ 3,000.00 168,735 April 2027 15.21 Warrants outstanding with an exercise price in CAD 172,735 $ 84.33 Number Expiry Exercise Warrants outstanding with an exercise price in USD 7,894,734 November 2025 $ 5.50 On February 15, 2022, the 168,735 warrants having an exercise price of $ 15.21 were cancelled (note 33).

Non-controlling interests

Non-controlling interests	12 Months Ended
	Dec. 31, 2021
Non Controlling Interests [Abstract]
Non-controlling interests	20. Non-controlling interests The Company held less than 100 % interest in the following two entities during the last three fiscal years. The Company's interest in these subsidiaries at December 31, 2021 and 2020 was as follows: Name of subsidiary Segment activity Place of incorporation and operation Proportion of ownership interest held by group Pathogen Removal and Diagnostic Corporate Delaware, U.S. 77 % NantPro Biosciences, LLC Plasma-derived therapeutics Delaware, U.S. 73 % NantPro Biosciences, LLC or Nantpro, wound up its activities in 2019. There have been no operating costs since 2020. The carrying value of NantPro’s assets and liabilities was $nil at December 31, 2021 and 2020 and consequently, the share of the NCI in the NantPro statement of financial position is $nil at December 31, 2021 and 2020. The summarized statements of financial position for Pathogen Removal and Diagnostic Technologies Inc, or PRDT, and the summarized statements of operations for PRDT are provided below. This information is based on amounts before inter-company eliminations. Summarized statements of financial position for PRDT: December 31, December 31, 2021 2020 Receivables (current) $ 227 $ 233 Capital and intangible assets (long-term) 74 113 Trade and other payables (current) ( 987 ) ( 877 ) Intercompany loan ( 17,329 ) ( 16,846 ) Total equity (negative equity) $ ( 18,015 ) $ ( 17,377 ) Attributable to non-controlling interests $ ( 8,756 ) $ ( 8,087 ) The share of the NCI in PRDT’s statement of financial position represents an asset on the Company’s consolidated statement of financial position. Summarized statement of operations of PRDT: Year ended December 31 2021 2020 2019 Royalty revenues $ 565 $ 572 $ 585 Royalty expenses ( 88 ) ( 128 ) ( 132 ) Research and development expenses ( 244 ) ( 196 ) ( 215 ) Administration expenses ( 946 ) ( 1,506 ) ( 896 ) Impairment loss — — ( 129 ) Net loss and comprehensive loss $ ( 713 ) $ ( 1,258 ) $ ( 787 ) Attributable to non-controlling interests $ ( 669 ) $ ( 832 ) $ ( 713 )

Capital management

Capital management	12 Months Ended
	Dec. 31, 2021
Disclosure Of Capital Management [Abstract]
Capital management	21. Capital management The Company defines its capital as shareholders’ equity including warrants presented as a liability and financial instruments of a long-term nature (including the current portion) less cash. December 31, December 31, 2021 2020 Warrant liability $ 1,754 $ 11,640 Lease liabilities 22,471 33,452 Provisions 22,195 — Long-term debt 38,311 40,532 Total equity 33,881 15,012 Cash ( 108,490 ) ( 45,075 ) Total capital $ 10,122 $ 55,561 The Company manages its capital resources to fund the growth and development of its business and to ensure it has sufficient liquidities to support the working capital required to maintain its ability to continue as a going concern and to pay long-term obligations upon maturity. The Company monitors its ability to meet its financial obligations and evaluates funding requirements by forecasting cash requirements. Financial covenants of existing debt agreements, including capital requirements (note 17) are reviewed by management on an ongoing basis to monitor compliance. At the present time, the Company favors financing by issuing equity instruments in order to minimize future financial obligations, however it considers all sources of financing reasonably available, including but not limited to the issuance of equity instruments, debt and the sale of assets. The Company considers the cost of capital, the terms and conditions and the dilutive effect on shareholders when considering the different forms financings that it may prevail upon.

Revenues from continuing operat

Revenues from continuing operations	12 Months Ended
	Dec. 31, 2021
Revenue [Abstract]
Revenues from continuing operations	22. Revenues from continuing operations 2021 2020 2019 Royalty revenues $ 565 $ 572 $ 575 Rental revenue 78 152 170 $ 643 $ 724 $ 745 All the rental revenues are generated from subleasing right-of-use assets.

Supplemental information

Supplemental information	12 Months Ended
	Dec. 31, 2021
Disclosure Of Supplemental Information Regarding Consolidated Statements Of Operations [Abstract]
Supplemental information	23. Supplemental information a) Supplemental information regarding the consolidated statements of operations i) Government assistance For the years ended December 31, 2021 and 2020, the Company recognized, government grants in connection with the Canada Emergency Wage Subsidy program and the Canada Emergency Rent Subsidy program, two subsidies program created by the Government of Canada in 2020 in response to the COVID-19 pandemic that the Company benefits from. Following the sale of its plasma-derived business in the middle of the second quarter of 2021, the Company was no longer eligible to these programs. The Company also recognized research and development tax credits during the years ended December 31, 2021 and 2020. These grants were recorded as a reduction of salary expenses and other related charges and are recognized as follows in the consolidated statement of operations: Year ended December 31 2021 2020 2019 Government grants recognized in research Salary subsidy $ 372 $ 1,017 $ — Rent subsidy 140 108 — Research and development tax credits 124 426 572 $ 636 $ 1,551 $ 572 Government grants recognized in Salary subsidy $ 325 $ 1,457 $ — Rent subsidy 86 63 — $ 411 $ 1,520 $ — Government grants recognized in loss from Salary subsidy $ 2,502 $ 4,758 $ — Rent subsidy 682 426 — Research and development tax credits 116 1,332 — $ 3,300 $ 6,516 $ — ii) Finance costs Year ended December 31 2021 2020 2019 Interest accretion on long-term debt $ 4,388 $ 2,209 $ 7,874 Amortization of fees for credit facility — — 10 Financing fees on warrant liability — 709 — Interest expense on provisions 90 — — Other interest expense, transaction and bank fees 413 485 594 Interest expense on lease liabilities 3,754 6,030 7,068 Interest income ( 73 ) ( 451 ) ( 753 ) $ 8,572 $ 8,982 $ 14,793 The table above includes financing costs from continuing and discontinued operations. Financing costs from discontinued operations for the years ended December 31, 2021, 2020 and 2019 were $ 2,242 , $ 6,083 and $ 7,926 , respectively, and mainly represented interest expense on lease liabilities (note 6 ). iii) Employee compensation expense Year ended December 31 2021 2020 2019 Wages and salaries $ 19,731 $ 32,410 $ 48,846 Employer's benefits 3,201 5,443 8,263 Share-based payments expense 4,252 6,234 22,030 $ 27,184 $ 44,087 $ 79,139 The table above includes employee compensation expense from continuing and discontinued operations. Employee compensation expenses from discontinued operations for the year ended December 31, 2021, 2020 and 2019 were $ 9,958 , $ 23,146 and $ 40,536 , respectively. b) Information by geographic area i) Capital, intangible and right-of-use assets by geographic area 2021 2020 Canada $ 10,041 $ 28,231 United Kingdom 567 2,092 United States — 12,517 $ 10,608 $ 42,840 ii) Revenues by location from continuing operations 2021 2020 2019 Canada 78 152 170 United Kingdom 565 572 575 $ 643 $ 724 $ 745 Revenues are attributed to countries based on the location of the third party.

Pension Plan

Pension Plan	12 Months Ended
	Dec. 31, 2021
Disclosure Of Defined Benefit Plans [Abstract]
Pension Plan	2 4. Pension Plan The Company maintains a defined contribution pension plan for its permanent employees. The Company matches the contributions made by employees who elect to participate in the plan up to a maximum percentage of their annual salary. The Company’s contributions recognized as an expense, for continuing and discontinued operations in aggregate, for the year ended December 31, 2021 amounted to $ 598 ($ 1,055 and $ 1,495 for the years ended December 31, 2020 and 2019, respectively).

Impairment losses

Impairment losses	12 Months Ended
	Dec. 31, 2021
Disclosure Of Impairment Loss And Reversal Of Impairment Loss [Abstract]
Impairment losses	25. Impairment losses 2021 During the quarter ended June 30, 2021, the Company decided it would not be moving fezagepras into a Phase 2 clinical study in Idiopathic Pulmonary Fibrosis or IPF, and a phase 1a/2b study in hypertriglyceridemia following its analysis of the interim PK results from the ongoing fezagepras phase 1 MAD clinical trial. As a result of these decisions which were considered impairment indicators, the Company recorded an impairment on the carrying value of the intangible assets for the related patents of $ 341 reducing their value to their estimate recoverable value of $ nil . Other fezagepras patents were unaffected by the above decisions. 2020 At the end of 2020, in reviewing its portfolio of compounds in the small molecule therapeutics segment, the Company identified impairment indicators for certain patents. One of the patent families impaired concerned a molecule that had entered into a phase 1 clinical trial in 2019 that was subsequently discontinued after the review of the pharmacokinetic data for the first three cohorts obtained. Following additional pre-clinical studies conducted in 2020 to further the Company’s understanding of the mechanism of action, or MOA, lead to findings that the MOA included engaging a receptor which has been known in other products which engage the same receptor to occasionally cause undesirable side effects. Subsequently, management decided that the preclinical and clinical development activities associated with demonstrating that such molecule did not induce such side effects would be both time-consuming and costly and therefore the future development has been suspended. Another patent family impaired concerned another molecule that is licensed for development with a third party, whose research and development work we believe to be delayed from the agreed upon timelines and is unlikely to perform significant development in the near future. Further, the development of another compound was deprioritized, as the Company wishes to prioritize development of its lead compound fezagepras, as well as GPR84 and OXER1 drug candidates, which led to the impairment of the related patents. These small molecules patents were written down to their net recoverable amount of $ nil , as both the FVLCD and the value in use were determined to be insignificant, resulting in an impairment of $ 1,072 for the year ended December 31, 2020 (note 12). During the year, the Company also recorded software impairments amounting to $ 15 (note 12). 2019 In reviewing its portfolio of compounds in the small molecule therapeutics segment, the Company identified compounds that where not within the areas of fibrosis on which it intends to focus and evaluated the net recoverable value of those related patents as $ nil , determined as the fair value less cost of disposal using a market approach. An impairment on intangible assets of $ 634 was recognized for the year ended December 31, 2019. As a result of the bioseparations business sale, some intellectual property including patents retained by the company are no longer expected to be developed. The company evaluated the net recoverable value of those patents is $ nil , using a FVLCD using a market approach. An impairment on intangible assets of $ 127 was recognized for the year ended December 31, 2019.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2021
Major Components Of Tax Expense Income [Abstract]
Income taxes	26. Income taxes The income tax expense (recovery) reported in the consolidated statement of operations for the years ended December 31, 2021, 2020 and 2019 are as follows: 2021 2020 2019 Current income tax expense (recovery) $ — $ ( 144 ) $ ( 336 ) Deferred income tax expense (recovery) 118 ( 65 ) 111 Income tax expense (recovery) from continuing operations 118 ( 209 ) ( 225 ) Current income tax expense (recovery) 1 8 53 Deferred income tax expense (recovery) — — ( 24 ) Total income tax expense (recovery) $ 119 $ ( 201 ) $ ( 196 ) The following table provides a reconciliation of the income tax expense (recovery) calculated at the combined statutory income tax rate to the income tax expense (recovery) for both continuing and discontinued operations, recognized in the consolidated statements of operations. 2021 2020 2019 Net loss before tax from continuing operations $ ( 44,945 ) $ ( 49,230 ) $ ( 150,897 ) Net income before tax from discontinued operations 57,277 ( 69,728 ) ( 56,052 ) Combined Canadian statutory income tax rate 26.5 % 26.5 % 26.6 % Income tax expense (recovery) at combined income tax rate 3,268 ( 31,524 ) ( 55,048 ) Increase (decrease) in income taxes resulting from: Unrecorded potential tax benefit arising from 1,658 33,238 31,962 Effect of tax rate differences in foreign subsidiaries 9,756 1,101 4,989 Non-deductible or taxable items ( 6,149 ) ( 157 ) ( 696 ) Change in tax rate ( 5,354 ) ( 1,455 ) 1,609 Non-deductible loss (taxable gain) on debt renegotiation — — 24,572 Research and development tax credit ( 3,012 ) ( 494 ) ( 740 ) Non-taxable gain on disposition of subsidiary (note 6) — ( 896 ) ( 6,903 ) Other ( 48 ) ( 14 ) 59 Income tax expense (recovery) $ 119 $ ( 201 ) $ ( 196 ) The following table presents the deferred tax assets (recoveries) related to R&D expenditures at December 31, 2021 and 2020. 2021 2020 Balance - beginning of year $ ( 572 ) $ ( 507 ) Credited to profit and loss 118 ( 65 ) Balance - end of year $ ( 454 ) $ ( 572 ) Available temporary differences not recognized at December 31, 2021 and 2020 are as follows: 2021 2020 Tax losses (non-capital) $ 371,146 $ 569,542 Tax losses (capital) 185,085 305 Unused research and development expenses 25,170 84,556 Undeducted financing expenses 16,914 27,053 Interest expenses carried forward 22,616 32,475 Trade and other payable 22,592 1,640 Capital assets 4,575 3,392 Intangible assets 2,578 68,329 Start-up expense 1,908 5,358 Unrealized loss on exchange rate — 5,430 Lease obligations 21,583 15,494 Other 51 1,071 $ 674,218 $ 814,645 At December 31, 2021, the Company has non-capital losses of $ 439,706 of which $ 371,146 are available to reduce future taxable income for which the benefits have not been recognized. These non-capital losses expire at various dates from 2022 to 2041 except for the non-capital losses in the United Kingdom and US losses that arose after 2017 which do not expire. Capital losses arising in Canada can only be utilized to shelter future capital gains. At December 31, 2021, the Corporation also has federal unused research and development expenses of $ 33,283 (provincial $ 17,552 ), of which $ 31,570 are available to reduce future taxable income for which the benefits have not been recognized. These expenses can be carried forward indefinitely. At December 31, 2021, the Corporation also has unused federal tax credits available to reduce future income tax in the amount of $ 8,980 expiring between 2024 and 2041 . Those credits have not been recorded and no deferred income tax assets have been recognized in respect to those tax credits. The unused non-capital losses expire as indicated in the table below: Canada Foreign At December 31, 2021 Federal Provincial Countries Losses carried forward expiring in: 2027 $ 3,510 $ 3,495 $ — 2028 — — $ — 2029 — — — 2030 — — — 2031 — — — 2032 1,001 995 — 2033 4,610 4,606 — 2034 7,760 9,807 — 2035 12,565 12,563 — 2036 14,468 22,678 — 2037 7,393 7,394 — 2038 7,003 6,595 — 2039 26,441 26,305 — 2040 37,884 37,751 — 2041 39,933 39,904 — $ 162,568 $ 172,093 $ — Not expiring - UK — — 270,144 Not expiring - US (post 2017) 1) — — 2,821 $ 162,568 $ 172,093 $ 272,965 1) US tax rules impose restrictions that will impact how $ 114,107 of losses are available to shelter income in future taxation years. As a result, approximately $ 111,286 of losses will no longer be available to the company and are not presented in the available tax loss table presented above.

Basic and diluted earnings per

Basic and diluted earnings per share	12 Months Ended
	Dec. 31, 2021
Basic And Diluted Earnings Per Share [Abstract]
Basic and diluted earnings per share	27. Basic and diluted earnings per share The Company presents basic and diluted earnings per share, or EPS, data for its common shares. Basic EPS is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. For the years ended December 31, 2021, 2020 and 2019, all warrants, stock options and RSU were anti-dilutive since the Company reported net losses from continuing operations. The secured convertible debentures issued in 2020 and subsequently converted into common shares in 2021 were also anti-dilutive during the period they were outstanding. The numbers for the average basic and diluted shares outstanding presented in the consolidated statements of operations for the year ended December 31, 2019 have been adjusted in order to reflect the effect of the bonus element of the Rights Offering that occurred in June 2019 (note 19a).

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related party transactions	28. Related party transactions Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Company and other related parties are disclosed below and in other notes according to the nature of the transactions. These transactions have been recorded at the exchange amount, meaning the amount agreed to between the parties. At December 31, 2021 and 2020, a former CEO had a balance of $ 283 and $ 170 , respectively, owing to the Company under a tax equalization program, the amounts to be repaid once a refund is received from the taxation authority for each of the two years covered by the program. All material transactions with SALP are disclosed in notes 16, 17, 18a, 19a, 19c, and 33 where the particular transactions are disclosed, and otherwise in this note. During the year ended December 31, 2021, the Company recorded an interest expense and paid interest on the loan with its parent, SALP, of $ 4,222 and of $ 3,945 , respectively ($ 2,121 and $ 1,879 , respectively, for the year ended December 31, 2020). During the year ended December 31, 2021, the Company also recorded and paid legal expenses of $ 326 and of $ 181 respectively ($ nil for the year ended December 30, 2020), incurred by SALP that it is required to reimburse pursuant to the subscription agreement signed with SALP on April 14, 2019. On October 1, 2021, the Company entered into a forbearance agreement with SALP and Thomvest to forbear the reimbursement of such legal fees incurred between October 1, 2021 and June 30, 2022, until the latter date. In February 2022, the Company repaid its loan with SALP (note 33).

Compensation of key management

Compensation of key management personnel	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Of Key Management Personnel [Abstract]
Compensation of key management personnel	29. Compensation of key management personnel The Company’s key management personnel comprise the external directors, officers and executives which included 16 individuals in 2021, 20 individuals in 2020 and 28 individuals in 2019. The remuneration of the key management personnel during the years ended December 31, 2021 and 2020 was as follows: 2021 2020 2019 Current employee benefits 1) $ 5,466 $ 6,153 $ 10,083 Pension costs 78 115 267 Share-based payments 4,351 4,917 16,842 Termination benefits 406 319 2,919 $ 10,301 $ 11,504 $ 30,111 1) Current employee benefits include salaries, bonuses, other employee benefits other than those listed in the table and director fees paid in cash.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2021
Disclosure Of Commitments [Abstract]
Commitments	30. Commitments In the normal course of business, the Company enters into license agreements for the market launching or commercialization of products. Under a royalty stream agreement entered into January 2022, the Company has made a minimum upfront payment of $ 400 which can be used to reduce future royalty payments calculated as a low-single digit percentage of net sales on products and a low-single digit percentage of license revenues in regard to certain small molecule product candidates targeted by the agreement. A licensing agreement requires a royalty calculated as a low-single digit percentage of net sales on products for a certain small molecule drug candidate. Under licensing agreements pertaining to the Company's former bioseparations business, the Company must pay royalties ranging from a low-single digit to a mid-double digit percentage on the royalty revenues it earns from a sub-licensing agreement. At December 31, 2021, SALP had the right to receive, under a royalty stream agreement, minimum royalty payments (note 18) and a 2 % royalty on future revenues relating to patents of a specified small molecule product candidate and analogues. The obligations under this royalty agreement were secured by all the assets of the Company until the expiry of the last patent covered by this agreement. In the case where royalties based on revenues became payable, the minimum royalty previously paid would be deducted from future remittances. In February 2022, the royalty stream agreement was terminated (note 33).

Legal proceedings

Legal proceedings	12 Months Ended
	Dec. 31, 2021
Legal proceedings provision [abstract]
Legal proceedings	31. Legal proceedings The Company is, in the course of its business, subject to lawsuits and other claims. On April 15, 2019, the Company announced its intention to enter into a series of related arrangements to restructure its outstanding indebtedness, reduce its interest and certain other payment obligations, and raise sufficient cash to build a robust balance-sheet for the next phase of its development (collectively, the “Refinancing Transactions”). On March 2, 2021, Liminal was served with an action instituted by multiple individual shareholder plaintiffs (the “Plaintiffs”) against Liminal, SALP, Thomvest, Consonance Capital Management LP (“Consonance”), as well as the directors (the “Directors”) that were on the Company’s Board on March 31, 2019 or on April 15, 2019 and certain officers of the Company (the “D&Os”, together with Liminal, SALP, Thomvest and Consonance, the “Defendants”). Such action was publicly disclosed on March 24, 2021. On November 2, 2021, Liminal received service of an amended proceeding. The Plaintiffs’s request in damages has gone from almost $ 700 million initially to almost $ 950 million in damages, approximately $ 905 million of which is based on the loss of future value of the Company’s shares. The Company believes that the Plaintiffs’ claims are completely without merit and intends to vigorously defend itself. Defense and settlement costs associated with such lawsuits and claims can be substantial, even when these lawsuits and claims have no merit. Due to the inherent uncertainty of the litigation process, the resolution of any particular legal proceeding could have an adverse effect on the Company’s operating results or financial performance. No provisions have been recorded in the interim financial statements in regards to these claims.

Financial instruments and finan

Financial instruments and financial risk management	12 Months Ended
	Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]
Financial instruments and financial risk management	32. Financial instruments and financial risk management a) Fair value As at December 31, 2021, the fair value of financial liabilities for which fair value disclosure is required include the royalty payment obligation, the license acquisition payment obligations and the long-term debt. The fair value of those liabilities approximate the carrying amount of such instruments, except for the long-term debt at December 31, 2021, where the fair value of the debt was estimated at $ 39,132 while the carrying amount was $ 38,311 (at December 31, 2020 the fair value was estimated at $ 41,922 while the carrying amount was $ 40,532 ). The fair value of the long-term debt at December 31, 2021 was calculated using a discounted cash flow model and the market interest rates specific to the term of the debt instruments of 10.47 % (2020 - 10 %). Fair value hierarchy Financial instruments recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels: Level 1 – valuation based on quoted prices observed in active markets for identical assets or liabilities. Level 2 – valuation techniques based on inputs that are quoted prices of similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; inputs other than quoted prices used in a valuation model that are observable for that instrument; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 – valuation techniques with significant unobservable market inputs. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value. Cash and restricted cash are considered to be level 1 fair value measurements. The long-term deposits, royalty payment obligation, license acquisition payment obligations, provisions and long-term debt are level 2 measurements. The warrant liability is considered to be a level 3 measurements. Further discussion regarding assumptions used in determining its fair value are discussed in notes 3 and 16. b) Financial risk management The Company has exposure to credit risk, liquidity risk and market risk. The Company’s Board of Directors has the overall responsibility for the oversight of these risks and reviews the Company’s policies on an ongoing basis to ensure that these risks are appropriately managed. Credit risk: Credit risk is the risk of financial loss to the Company if a customer, partner or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s cash and receivables. The carrying amount of the financial assets represents the maximum credit exposure. The Company's exposure to credit risk is generally limited since it has limited revenues and thus limited accounts receivable. Liminal mitigates credit risk through a credit risk assessment, when credit is granted and subsequently at each reporting period. Following the sale of its bioseparations business and its plasma-derived business, the Company no longer has product sales and as such the Company’s exposure to customer credit risk is limited. Liquidity risk: Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages its liquidity risk by continuously monitoring forecasts and actual cash flows. The Company’s current liquidity situation is discussed in note 1. The following table presents the contractual maturities of the financial liabilities as of December 31, 2021: Contractual Cash flows Carrying amount Less than 2-3 4 - 5 More than Total Accounts payable and accrued 1) $ 7,343 $ 7,343 $ — $ — $ — $ 7,343 Long-term portion of royalty 98 — 51 51 197 299 Lease liabilities 22,471 7,369 10,629 8,285 — 26,283 Provisions 22,195 3,961 9,094 9,544 — 22,599 Long-term debt 2) 38,311 3,945 44,297 — — 48,242 $ 90,418 $ 22,618 $ 64,071 $ 17,880 $ 197 $ 104,766 1) Short-term portions of the royalty payment obligations and of other employee benefit liabilities are included in the account payable and accrued liabilities. 2) The Company has fully repaid its long-term debt in February 2022 (note 33). Market risk: Market risk is the risk that changes in market prices, such as interest rates and foreign exchange rates, will affect the Company’s income or the value of its financial instruments. i) Interest risk The Company’s interest-bearing financial liabilities have fixed rates and as such, there is limited exposure to changes in interest payments as a result of interest rate risk. In February 2022, the Company fully repaid its interest bearing long-term debt (note 33). ii) Foreign exchange risk: The Company is exposed to the financial risk related to the fluctuation of foreign exchange rates. The Company has had operations and suppliers in the U.S. and the U.K. during the past years and therefore a portion of its expenses incurred are in USD and in GBP. The majority of the Company’s revenues from the sale of products in 2021 and 2020, that are part of its discontinued operations were in USD which served to mitigate a portion of the U.S. foreign exchange risk relating to the expenditures. In 2021, the proceeds received from the divestment of its discontinued operations (note 6) were in USD resulting in an increased exposure to the USD which is partially mitigated by expenditures denominated in USD from its continuing operations. Financial instruments that have exposed the Company to foreign exchange risk have been cash, receivables, trade and other payables, lease liabilities, license payment obligations. The Company manages foreign exchange risk by holding foreign currencies it received to support forecasted cash outflows in foreign currencies. As at December 31, 2021 and 2020, the Company’s net exposure to currency risk through financial assets and financial liabilities denominated respectively in USD and GBP was as follows: 2021 2020 Amount Equivalent in Amount Equivalent in Exposure in USD in USD full CAD in USD full CAD Cash 78,045,915 99,094,899 17,281,338 22,018,153 Accounts receivable 185,954 236,106 886,211 1,129,121 Other long-term assets — — 45,428 57,880 Accounts payable and accrued liabilities ( 951,284 ) ( 1,207,845 ) ( 6,023,877 ) ( 7,675,022 ) Lease liabilities — — ( 10,918,525 ) ( 13,911,293 ) Other long-term liabilities ( 77,075 ) ( 97,862 ) ( 162,000 ) ( 206,404 ) Long-term derivatives ( 1,381,603 ) ( 1,754,221 ) — — Net exposure 75,821,907 96,271,077 1,108,575 1,412,435 2021 2020 Amount Equivalent in Amount Equivalent in Exposure in GBP in GBP full CAD in GBP full CAD Cash 2,832,439 4,859,049 4,619,225 8,032,832 Accounts receivable 134,605 230,914 230,588 400,993 Accounts payable and accrued liabilities ( 1,026,984 ) ( 1,761,791 ) ( 983,697 ) ( 1,710,649 ) Lease liabilities ( 203,186 ) ( 348,566 ) ( 271,623 ) ( 472,352 ) Net exposure 1,736,873 2,979,606 3,594,493 6,250,824 Based on the above net exposures as at December 31, 2021, and assuming that all other variables remain constant, a 10 % depreciation or appreciation of the CAD against the USD would result in a decrease or an increase of the consolidated total comprehensive loss of approximately $ 9,627 while a 10 % depreciation or appreciation of the CAD against the GBP would result in a decrease or an increase of the consolidated total comprehensive loss of approximately $ 298 . If we exclude cash denominated in USD from our net exposure at December 31, 2021, a 10 % depreciation or appreciation of the CAD against the USD would result in a decrease or an increase of the consolidated net loss of approximately $ 282 . The Company has not hedged its exposure to currency fluctuations.

Subsequent event

Subsequent event	12 Months Ended
	Dec. 31, 2021
Disclosure Of Nonadjusting Events After Reporting Period [Abstract]
Subsequent event	33. Subsequent event On February 15, 2022, the Company repaid the entirety of the first and second term loans, for an aggregate amount of $ 39,123 (note 17), thus terminating the consolidated loan agreement with SALP and releasing of the security interests granted by the Company over its assets pursuant to the loan agreement and related documents. The repayment also terminated the royalty stream agreement with SALP resulting in the derecognition of the royalty payment obligation to SALP (note 18a) and the 168,735 warrants held by SALP, having an exercise price of $ 15.21 per common share (note 19c), were cancelled. The Company is presently evaluating the accounting for these transactions.

Material accounting policies (P

Material accounting policies (Policies)	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Statement of compliance	Statement of compliance These audited annual consolidated financial statements for the year ended December 31, 2021, or consolidated financial statements, have been prepared in accordance with IFRS as issued by the IASB and were approved by the Board of Directors on March 17, 2 022.
Functional and presentation currency	Functional and presentation currency The consolidated financial statements are presented in Canadian dollars, ($ or CAD) which is also the Company’s functional currency. The use of other currencies will be specified.
Basis of consolidation	Basis of consolidation The consolidated financial statements include the accounts of Liminal BioSciences Inc., and those of its subsidiaries. The Company’s subsidiaries at December 31, 2021, 2020 and 2019 are as follows: Name of subsidiary Segment activity Place of incorporation and Proportion of ownership interest held 2021 2020 2019 Fairhaven Pharmaceuticals Inc. Small molecule therapeutics Quebec, Canada 100 % 100 % nil Liminal R&D BioSciences Inc. Small molecule therapeutics Quebec, Canada 100 % 100 % 100 % Liminal BioSciences Holdings Limited Small molecule therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Liminal BioSciences Limited Small molecule therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Prometic Pharma SMT B.V Small molecule therapeutics Amsterdam, Netherlands 100 % 100 % N/A Prometic Bioproduction Inc. Plasma-derived therapeutics Quebec, Canada nil * 100 % 100 % Prometic Plasma Resources Inc. Plasma-derived therapeutics Winnipeg, Canada nil * 100 % 100 % Telesta Therapeutics Inc. Plasma-derived therapeutics Quebec, Canada 100 % 100 % 100 % NantPro Biosciences, LLC Plasma-derived therapeutics Delaware, U.S. 73 % 73 % 73 % Prometic Biotherapeutics Inc. Plasma-derived therapeutics Delaware, U.S. nil * 100 % 100 % Prometic Plasma Resources USA Inc. Plasma-derived therapeutics Delaware, U.S. nil * 100 % 100 % Prometic Biotherapeutics Ltd Plasma-derived therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Prometic Biotherapeutics B.V. Plasma-derived therapeutics Amsterdam, Netherlands 100 % 100 % N/A Pathogen Removal and Diagnostic Corporate Delaware, U.S. 77 % 77 % 77 % * Entity sold in 2021 as part of our divestment of the plasma-derived therapeutics segment. The Company consolidates investees when, based on the evaluation of the substance of the relationship with the Company, it concludes that it controls the investees. The financial statements of the subsidiaries are prepared for the same reporting period as the parent Company, using consistent accounting policies. All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation. When a subsidiary is not wholly-owned the Company recognizes the non-controlling interests’ share of the net assets and results of operations in the subsidiary.
Financial instruments	Financial instruments Recognition and derecognition Financial instruments are recognized in the consolidated statement of financial position when the Company becomes a party to the contractual obligations of the instrument. On initial recognition, financial instruments are recognized at their fair value plus, in the case of financial instruments not at fair value through profit or loss (“FVPL”), transaction costs that are directly attributable to the acquisition or issue of financial instruments. Financial assets are subsequently derecognized when payment is received in cash or other financial assets or if the debtor is discharged of its liability. A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing liability is replaced by another from the same creditor on substantially different terms, or the terms of the liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated statement of operations. Classification Subsequent to initial recognition, financial instruments are measured according to the category to which they are classified. Financial instruments are measured at amortized cost unless they are classified as fair value through other comprehensive income, or FVOCI, classified as FVPL or designated as FVPL, in which case they are subsequently measured at fair value. The classification of financial asset debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Assets that are held to collect contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. Equity instruments that are held for trading (including all equity derivative instruments) are classified as FVPL. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL (such as instruments held for trading or derivatives) or the Company has opted to measure them at FVPL. The Company classifies cash, trade receivables, other receivables, restricted cash, and long-term deposits as financial assets measured at amortized cost and trade payables, wages and benefits payable, royalty payment obligations and long-term debt as financial liabilities measured at amortized cost. The Company classifies the warrant liability as a financial liability at FVPL for which the variation in fair value is recorded in consolidated statement of operations.
Inventories	Inventories Inventories of raw materials and finished goods are valued at the lower of cost and net realizable value. Cost is determined on a first in, first out basis. The cost of manufactured inventories comprises all costs that are directly attributable to the manufacturing process, such as raw materials, direct labour and manufacturing overhead based on normal operating capacity. Net realizable value is the estimated selling price in the ordinary course of business and the estimated selling costs except for raw materials for which it is determined using replacement cost.
Capital assets	Capital assets Capital assets are recorded at cost less any government assistance, accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as described below. Capital asset Period Buildings and improvements 20 years Leasehold improvements The lower of the lease term and the useful life Production and laboratory equipment 5 - 20 years Furniture 5 - 10 years Computer equipment 3 - 5 years
Government assistance	Government assistance Government assistance programs, including investment tax credits on research and development expenses and salary and rent subsidies are reflected as reductions to the cost of the assets or to the expenses to which they relate and are recognized when there is reasonable assurance that the assistance will be received and all attached conditions are complied with.
Right-of-use assets	Right-of-use assets The Company recognizes a right-of-use, or ROU, asset at the commencement date of a lease which is when the date at which the underlying asset is available for use. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use asset is depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term.
Intangible assets	Intangible assets Intangible assets are carried at cost less accumulated amortization. Amortization commences when the intangible asset is available for use and is calculated over the estimated useful lives of the intangible assets acquired using the straight-line method. The maximum period used for each category of intangible asset are presented in the table below. Intangible asset Period Licenses and other rights 30 years Donor lists 10 years Patents 20 years Software 5 years
Impairment of long-lived assets	Impairment of long-lived assets At the end of each reporting period, the Company reviews the carrying amounts of its capital, ROU and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If impairment indicators exist, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. For intangible assets not yet available for use, an impairment test is performed annually at November 30, until amortization commences, whether or not there are impairment indicators. The recoverable amount is the higher of the fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. An impairment loss is recognized when the carrying amount of an asset or a cash-generating unit, or CGU, exceeds its recoverable amount by the amount of this excess. An impairment loss is recognized immediately in profit or loss in the period during which the loss is incurred. An impairment loss can be subsequently reversed, if certain conditions are met and the amount of the reversal will not exceed the carrying amount that would have been determined had an impairment loss not been recognized for the asset or CGU in prior periods. A reversal of an impairment loss is recognized immediately in profit or loss.
Lease liabilities	Lease liabilities At the commencement date of a lease, the Company recognizes a lease liability measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of a lease liability is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of a lease liability is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment whether the underlying asset will be purchased. The Company applies the short-term lease recognition exemption to leases of 12 months or less, as well as the lease of low-value assets recognition exemption. Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term. The Company has elected, for the class of assets related to the lease of building space, not to separate non-lease components from lease components, and instead account for each lease component and any associated non-lease components as a single lease component.
Provisions	Provisions If changes in circumstances render a contract to be onerous, meaning the unavoidable cost of meeting the contract exceeds the econom ic benefits expected under it, the Company recognizes the present value of the obligations as a provision. Before a separate provision for an onerous contract is established, an entity recognizes any impairment loss that has occurred on assets dedicated to that contract. The amount recognized as a provision is the best estimate of the cash disbursements required to settle the present obligation at the end of a reporting period and as such, a provision will change if the estimate changes. The discount rate used is the pre-tax rate that reflects the market assessment of the time value of money and the risks specific to the liability.
Revenue recognition	Revenue recognition Sale of goods Revenue from sale of goods is recognized when the terms of a contract with a customer have been satisfied. This occurs when: • The control over the product has been transferred to the customer; and • The product is received by the customer or transfer of title to the customer occurs upon shipment. Following delivery, the customer bears the risks of obsolescence and loss in relation to the goods. Revenue is recognized based on the price specified in the contract, net of estimated sales discounts and returns. Revenue from the sale of goods is presented as part of the results from discontinued operations. Royalty revenue Royalty revenues are recognized once the sale of products to which the royalties gives rise occurs. Rental revenue The Company accounts for the lease or sub-lease with its tenant as an operating lease when the Company has not transferred substantially all of the risks and benefits of ownership of its property or leased property. Revenue recognition under an operating lease commences when the tenant has a right to use the leased asset, and the total amount of contractual rent to be received from the operating lease is recognized on a straight-line basis over the term of the lease. Rental revenue also includes recoveries of operating expenses and property taxes.
Research and development expenses	Research and development expenses Expenditure on research activities is recognized as an expense in the period during which it is incurred. An internally generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated: • the technical feasibility of completing the intangible asset so that it will be available for use or sale; • the intention to complete the intangible asset and use or sell it; • the ability to use or sell the intangible asset; • how the intangible asset will generate probable future economic benefits; • the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and • the ability to measure reliably the expenditures attributable to the intangible asset during its development. To date, the Company has not capitalized any development costs.
Foreign currency translation	Foreign currency translation Transactions and balances Transactions in foreign currencies are initially recorded by the Company and its entities at their respective functional currency rates prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange at the reporting date. All differences are taken to the consolidated statement of operations. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates when the initial transactions took place. Group companies The assets and liabilities of foreign operations are translated into Canadian dollars at the rate of exchange prevailing at the reporting date and their statements of operations are translated at exchange rates prevailing at the dates of the transactions. The exchange differences arising on the translation are recognized in other comprehensive loss. On disposal of a foreign operation, the component of other comprehensive loss relating to that particular foreign operation is reclassified from the consolidated statement of comprehensive loss to the consolidated statement of operations as part of the gain or loss on the disposal of the foreign operation.
Share-based payments	Share-based payments The fair value of stock options granted by the Company is determined at the grant date using the Black-Scholes option pricing model and is expensed over the vesting period of the options. Grants with graded vesting are considered to be multiple awards for fair value measurement. An estimate of the number of awards that are expected to be forfeited is also made at the time of grant and revised periodically if actual forfeitures differ from those estimates. The Company also made use of a restricted share unit plan as part of its long-term incentive plan up until the end of 2020. The fair value of Restricted Share Units, or RSU, is determined using the market value of the Company’s shares on the grant date. The expense associated with RSU awards that vest over time are recognized over the vesting period. When the vesting of RSU is dependent on meeting performance targets as well as a service requirement, the Company will estimate the outcome of the performance targets to determine the expense to recognize over the vesting period, and revise those estimates until the final outcome is determined. An estimate of the number of awards that are expected to be forfeited is also made at the time of grant and revised periodically if actual forfeitures differ from those estimates. The Company’s policy is to issue new shares upon the exercise of stock options and the release of RSU for which conditions have been met.
Assets held for sale and discontinued operations	Assets held for sale and discontinued operations The Company classifies non-current assets and disposal groups as held for sale at the end of a given reporting period if their carrying amounts will be recovered principally through a sale rather than through continuing use. Such non-current assets and disposal groups classified as held for sale are measured at the lower of their carrying amount and their fair value less cost to sell. Costs to sell are the incremental costs directly attributable to the sale, excluding finance costs and income tax expense. Such assets are only presented as held for sale when the sale is highly probable and the assets or disposal group are available for immediate sale in their present condition. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the sale will be withdrawn. Management must be committed to the sale, which should be expected to qualify for recognition as a completed sale within one year from the date of classification. Capital assets included as part of the assets held for sale are not depreciated once classified as held for sale. Assets and liabilities classified as held for sale are presented separately as current items in the consolidated statement of financial position. The results of discontinued operations are presented net of tax in the consolidated statement of operations. Incremental cost related to the disposition and income taxes are allocated to discontinued operations. The discontinued operations also include the gain or loss on the disposal, which will also include the reclassification of historical exchange differences on translation of foreign operations sold. The results of discontinued operations exclude the allocation of the corporate finance costs and general corporate overhead in the form of management fees if the costs will continue to be incurred by Liminal following the disposition. The prior period results from discontinued operations are reclassified and presented in the consolidated statements of operations.
Share and warrant issue expenses	Share and warrant issue expenses The Company records share and warrant issue expenses as an increase to the deficit.
Adoption of new accounting standards	a) Adoption of new accounting standards The accounting policies used in these annual consolidated financial statements are consistent with those applied by the Company in its December 31, 2020 and 2019 audited annual consolidated financial statements except for the amendments to certain accounting standards which are relevant to the Company and were adopted by the Company since January 1, 2020 as described below. Amendments to IFRS 3, Business Combinations or IFRS 3 The amendments to IFRS 3 clarifies the definition of a business and includes an optional concentration test to determine whether an acquired set of activities and assets is a business. These amendments were adopted on January 1, 2020 and are applied prospectively to acquisitions made on or after this date. Amendment to IFRS 16 , Leases or IFRS 16 for COVID-19-Related Rent Concessions - IFRS 16 has been revised to incorporate an amendment issued by the IASB in May 2020. The amendment permits lessees not to assess whether particular COVID-19-related rent concessions are lease modifications and, instead, account for those rent concessions as if they were not lease modifications. In addition, the amendment to IFRS 16 provides specific disclosure requirements regarding COVID-19-related rent concessions. The amendment was adopted as of January 1, 2021 and had no impact on the financial statements for the year ended December 31, 2021 since the Company has not benefited from COVID-19 related rent concessions. Amendment to IAS 1, Presentation of Financial statements or IAS 1 - IAS 1 has been revised to require the disclosure of material accounting policies rather than significant accounting policies and provides guidance to apply materiality judgments to accounting policy disclosure. The Company early adopted these amendments, and consequential amendments to other standards, for its annual audited financial statements for the year ended December 31, 2021 resulting in a reduction of its accounting policy disclosure in note 2 - Material accounting policies.
New Standards and interpretations not yet adopted	b) New Standards and interpretations not yet adopted The IFRS accounting standards, amendments, and interpretations that the Company reasonably expects may have a material impact on the disclosures, the financial position or results of operations of the Company when applied at a future date are as follows: Amendments to IAS 37, Provisions, Contingent Liabilities and Contingent Assets (IAS 37) - IAS 37 has been revised to specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments are effective for annual reporting periods beginning on or after January 1, 2022. The cumulative effect of initially applying the amendment, if any, will be recorded as an adjustment to the opening retained earnings and comparative periods will not be restated. Earlier application is permitted. The Company has determined that the adoption of this modification as of January 1, 2022 will not have an impact on the provision presently recorded at December 31, 2021. Amendment to IFRS 9 Financial Instruments ( IFRS 9) - IFRS 9 has been revised to clarify the fees an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and is to be applied to financial liabilities that are modified after the date of adoption. Earlier application is permitted. Amendments to I AS 8, Accounting policies , Changes in Accounting Estimates and Errors (IAS 8) and IAS 1, Presentation of Financial Statements (IAS 1) - The amendments to IAS 8 introduce a definition of accounting estimates and provide clarifications to distinguish accounting policies from accounting estimates. In addition, IAS 1 has been revised to clarify how to classify debt and other liabilities as current or non-current. The amendments help to determine whether, in the statement of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments also include clarifying the classification requirements for debt an entity might settle by converting it into equity. The amendments are applicable retrospectively and is effective for annual reporting periods beginning on or after January 1, 2023 with earlier application permitted. Amendments to IAS 12, Income taxes (IAS 12) - The amendments to IAS 12 clarify the accounting for deferred tax assets or liabilities arising from a single transaction such as leases, namely that the scope of the recognition exemption no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 with earlier application permitted. The Company is evaluating the impact of the amendments to IAS 8, IAS 1 and IAS 12 on its consolidated financial statements.

Material Accounting Policies (T

Material Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Summary of Company's Subsidiaries	The consolidated financial statements include the accounts of Liminal BioSciences Inc., and those of its subsidiaries. The Company’s subsidiaries at December 31, 2021, 2020 and 2019 are as follows: Name of subsidiary Segment activity Place of incorporation and Proportion of ownership interest held 2021 2020 2019 Fairhaven Pharmaceuticals Inc. Small molecule therapeutics Quebec, Canada 100 % 100 % nil Liminal R&D BioSciences Inc. Small molecule therapeutics Quebec, Canada 100 % 100 % 100 % Liminal BioSciences Holdings Limited Small molecule therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Liminal BioSciences Limited Small molecule therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Prometic Pharma SMT B.V Small molecule therapeutics Amsterdam, Netherlands 100 % 100 % N/A Prometic Bioproduction Inc. Plasma-derived therapeutics Quebec, Canada nil * 100 % 100 % Prometic Plasma Resources Inc. Plasma-derived therapeutics Winnipeg, Canada nil * 100 % 100 % Telesta Therapeutics Inc. Plasma-derived therapeutics Quebec, Canada 100 % 100 % 100 % NantPro Biosciences, LLC Plasma-derived therapeutics Delaware, U.S. 73 % 73 % 73 % Prometic Biotherapeutics Inc. Plasma-derived therapeutics Delaware, U.S. nil * 100 % 100 % Prometic Plasma Resources USA Inc. Plasma-derived therapeutics Delaware, U.S. nil * 100 % 100 % Prometic Biotherapeutics Ltd Plasma-derived therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Prometic Biotherapeutics B.V. Plasma-derived therapeutics Amsterdam, Netherlands 100 % 100 % N/A Pathogen Removal and Diagnostic Corporate Delaware, U.S. 77 % 77 % 77 % The Company held less than 100 % interest in the following two entities during the last three fiscal years. The Company's interest in these subsidiaries at December 31, 2021 and 2020 was as follows: Name of subsidiary Segment activity Place of incorporation and operation Proportion of ownership interest held by group Pathogen Removal and Diagnostic Corporate Delaware, U.S. 77 % NantPro Biosciences, LLC Plasma-derived therapeutics Delaware, U.S. 73 %
Summary of Estimated Useful Lives of the Capital Assets	Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as described below. Capital asset Period Buildings and improvements 20 years Leasehold improvements The lower of the lease term and the useful life Production and laboratory equipment 5 - 20 years Furniture 5 - 10 years Computer equipment 3 - 5 years
Summary of Estimated Useful Lives of the Intangible Asset	Intangible asset Period Licenses and other rights 30 years Donor lists 10 years Patents 20 years Software 5 years

Acquisition of Fairhaven Phar_2

Acquisition of Fairhaven Pharmaceuticals Inc (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Business Combinations [Abstract]
Summary of Consideration Paid and Allocation to Net Assets Acquired	The consideration paid and the allocation thereof to the net assets acquired were as follows: Cost of acquisition Fair value of common shares issued $ 3,441 Cash payment 50 Total consideration paid $ 3,491 Transaction fees 308 Total cost of acquisition $ 3,799 Net assets acquired Current assets $ 217 Licenses and other rights (note 12) 3,796 Current liabilities ( 214 ) Total net assets acquired $ 3,799

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations [Abstract]
Summary of Gain on the Sale of Subsidiaries	The details of the gain on sale of subsidiaries during the years ended December 31, 2021, 2020 and 2019 is provided in the table below: Year ended December 31 2021 2020 2019 Sale of bioseparation business Proceeds received $ — $ 3,380 $ 51,927 Less: Carrying amount of net assets sold — — 22,015 Transaction costs — — 5,015 Reclassification of foreign currency translation reserve from other — — ( 1,449 ) Gain on sale of bioseparation business $ — $ 3,380 $ 26,346 Sale of plasma collection centers Proceeds received $ 13,570 $ — $ — Less: Carrying amount of net assets sold 10,849 — — Transaction costs 204 — — Reclassification of foreign currency translation reserve from other ( 44 ) — — Gain on sale of plasma collection centers $ 2,561 $ — $ — Sale of Ryplazim business Proceeds received $ 159,787 $ — $ — Less: Carrying amount of net assets sold 19,541 — — Indemnification adjustments 116 Transaction costs 2,288 — — Gain on sale of Ryplazim business $ 137,842 $ — $ — Gain on sale of subsidiaries, net of income taxes $ nil $ 140,403 $ 3,380 $ 26,346
Summary of Carrying Amounts of Assets and Liabilities Sold	The carrying amounts of the assets and liabilities of the entities sold during the year ending December 31, 2021, as part of the sale of the plasma collection centers and the Ryplazim ® business, on the dates control of the entities were transferred to the purchaser, are as follows: Bioseparation business Plasma collection centers Ryplazim business Cash $ 6,794 $ — $ — Accounts receivable 1,148 137 1,879 Inventories 8,313 8,441 4,640 Prepaids 236 21 399 Other long-term assets 48 54 50 Capital assets 8,483 2,376 9,304 Right-of-use assets 3,300 2,000 3,795 Intangible assets 370 1,092 7,277 Deferred tax assets 12 — — Total assets $ 28,704 $ 14,121 $ 27,344 Accounts payable and accrued liabilities 2,163 639 2,887 Deferred revenue 370 — — Current portion of lease liabilities 809 665 986 Long-term portion of deferred revenues 87 — — Long-term portion of lease liabilities 3,260 1,968 3,930 Total liabilities $ 6,689 $ 3,272 $ 7,803 Net assets sold $ 22,015 $ 10,849 $ 19,541
Summary of Results and Cash Flows from Discontinued Operations	The net loss from discontinued operations for the years ended December 31, 2021, 2020 and 2019 are presented below: Year ended December 31 2021 2020 2019 Revenues $ 949 $ 2,593 $ 27,233 Expenses Cost of sales and other production expenses 1,465 1,868 14,012 Research and development expenses 1) 2) 76,733 42,757 65,840 Administration expenses 2,360 5,933 11,009 Gain on foreign exchange ( 136 ) ( 633 ) ( 759 ) Impairment losses 3) 1,411 19,772 11,603 Gain on extinguishment of liabilities — ( 79 ) — Finance costs 2,242 6,083 7,926 Loss from discontinued operations, $ ( 83,126 ) $ ( 73,108 ) $ ( 82,398 ) Current income tax (note 26) 1 8 53 Deferred income tax (note 26) — — ( 24 ) Net loss from discontinued operations $ ( 83,127 ) $ ( 73,116 ) $ ( 82,427 ) 1) The expense relating to an agreement with a contract development and manufacturing organization, or CDMO, which is considered an onerous contract (note 15) is included in research and development expenses for the year ended December 31, 2021. 2) On September 29, 2021 prior to the closing of the sale of PBT, PBT paid PBP, which ownership had already passed to Kedrion, $ 39,457 representing 30 % of the net proceeds it received from the sale of the PRV, as compensation for past research and development services. A second payment made by PBT to PBP of $ 6,357 in prepayment for future R&D services on the same date was recognized as R&D expense since this amount would not be recoverable upon the sale of PBT. 3) During the year 2019, the Company, evaluated its intellectual property and the related market opportunities in the context of the Company’s financial situation and has made further decisions about the areas the Company will or will not pursue. The cash flows from the discontinued operations and the gain on sale of subsidiaries for the years ended December 31, 2021 and 2020 are presented in the following table: Year ended December 31 2021 2020 2019 Cash flows from (used in) in operating activities 1) $ ( 43,089 ) $ 8,015 $ 19,493 Cash flows used in financing activities ( 3,470 ) ( 7,943 ) ( 8,446 ) Cash flows from (used in) investing activities 171,225 ( 729 ) 36,275 Net effect of currency exchange rate on cash ( 30 ) 76 ( 3 ) Cash flows generated during the year $ 124,636 $ ( 581 ) $ 47,319 Total cash flows generated from $ 124,636 $ ( 581 ) $ 47,319 1) When compiling the cash flows from discontinued operations which include only certain entities from the Liminal group of companies, intra-group cash transfers between entities in the discontinued operations group and those part of continuing activities, for example the funding provided by Liminal to the discontinued operations, have been classified as part of the operating activities cash flows.

Accounts Receivable and Others

Accounts Receivable and Others (Tables)	12 Months Ended
	Dec. 31, 2021
Trade And Other Receivables [Abstract]
Summary of Trade and Other Receivables	December 31, December 31, 2021 2020 Trade receivables $ 229 $ 943 Tax credits and government grants — 1,808 Sales taxes receivable 280 431 Restricted cash — 178 Other receivables 559 721 $ 1,068 $ 4,081

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Classes Of Inventories [Abstract]
Summary of Inventories	December 31, December 31, 2021 2020 Raw materials $ — $ 9,138 Finished goods — 239 $ — $ 9,377

Other Long-term Assets (Tables)

Other Long-term Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Other Non Current Assets [Abstract]
Summary of Other Long-term Assets	December 31, December 31, 2021 2020 Long-term deposits $ 30 $ 137 Tax credits receivable 332 1,216 $ 362 $ 1,353

Capital Assets (Tables)

Capital Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Property Plant And Equipment [Abstract]
Summary of Capital Assets	Production Furniture and Land and Leasehold and laboratory computer Buildings improvements equipment equipment Total Cost Balance at January 1, 2020 $ 4,567 $ 8,558 $ 32,417 $ 3,223 $ 48,765 Additions — 214 295 550 1,059 Disposals — ( 1,380 ) ( 2,791 ) ( 404 ) ( 4,575 ) Effect of foreign exchange differences — ( 43 ) ( 17 ) ( 4 ) ( 64 ) Balance at December 31, 2020 $ 4,567 $ 7,349 $ 29,904 $ 3,365 $ 45,185 Additions — — 99 13 112 Disposals — ( 399 ) ( 1,516 ) ( 306 ) ( 2,221 ) Sold - discontinued operations (note 6) — ( 6,324 ) ( 21,525 ) ( 2,256 ) ( 30,105 ) Effect of foreign exchange differences — ( 107 ) ( 45 ) ( 9 ) ( 161 ) Balance at December 31, 2021 $ 4,567 $ 519 $ 6,917 $ 807 $ 12,810 Accumulated depreciation Balance at January 1, 2020 $ 609 $ 3,429 $ 20,796 $ 2,460 $ 27,294 Depreciation expense 195 710 1,450 424 2,779 Disposals — ( 1,380 ) ( 2,527 ) ( 404 ) ( 4,311 ) Impairments (note 25) — 167 498 — 665 Effect of foreign exchange differences — ( 25 ) ( 9 ) 1 ( 33 ) Balance at December 31, 2020 $ 804 $ 2,901 $ 20,208 $ 2,481 $ 26,394 Depreciation expense 195 268 662 243 1,368 Impairments (note 6) — — 22 — 22 Disposals — ( 400 ) ( 1,301 ) ( 306 ) ( 2,007 ) Sold - discontinued operations (note 6) — ( 2,400 ) ( 14,281 ) ( 1,744 ) ( 18,425 ) Effect of foreign exchange differences — ( 12 ) ( 7 ) ( 6 ) ( 25 ) Balance at December 31, 2021 $ 999 $ 357 $ 5,303 $ 668 $ 7,327 Carrying amounts At December 31, 2021 $ 3,568 $ 162 $ 1,614 $ 139 $ 5,483 At December 31, 2020 3,763 4,448 9,696 884 18,791

Right-of-use Assets (Tables)

Right-of-use Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]
Summary of Quantitative Information About Right-Of-Use Assets	Production and laboratory Buildings equipment Other Total Balance at January 1, 2020 $ 32,246 $ 912 $ 96 $ 33,254 Additions 378 151 15 544 Lease modifications and other remeasurements ( 1,998 ) — — ( 1,998 ) Depreciation expense ( 3,956 ) ( 561 ) ( 61 ) ( 4,578 ) Impairments (note 6) ( 18,553 ) ( 70 ) ( 4 ) ( 18,627 ) Effect of foreign exchange differences ( 31 ) ( 6 ) ( 1 ) ( 38 ) Net book value at December 31, 2020 $ 8,086 $ 426 $ 45 $ 8,557 Lease modifications and other remeasurements 3 ( 53 ) ( 2 ) ( 52 ) Sold - discontinued operations (note 6) ( 5,497 ) ( 272 ) ( 26 ) ( 5,795 ) Depreciation expense ( 906 ) ( 95 ) ( 12 ) ( 1,013 ) Effect of foreign exchange differences ( 77 ) ( 6 ) ( 5 ) ( 88 ) Net book value at December 31, 2021 $ 1,609 $ — $ — $ 1,609

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Intangible Assets [Abstract]
Summary of Intangible Assets	Licenses and Patents Software Total Cost Balance at January 1, 2020 $ 158,268 $ 6,309 $ 3,648 $ 168,225 Additions (note 5) 3,796 668 29 4,493 Disposals — ( 179 ) ( 362 ) ( 541 ) Effect of foreign exchange differences — ( 15 ) ( 9 ) ( 24 ) Balance at December 31, 2020 $ 162,064 $ 6,783 $ 3,306 $ 172,153 Additions — 114 ( 1 ) 113 Disposals ( 1,300 ) ( 61 ) ( 33 ) ( 1,394 ) Sold - discontinued operations (note 6) ( 15,006 ) ( 1,403 ) ( 2,963 ) ( 19,372 ) Effect of foreign exchange differences 1 ( 2 ) ( 19 ) ( 20 ) Balance at December 31, 2021 $ 145,759 $ 5,431 $ 290 $ 151,480 Accumulated amortization Balance at January 1, 2020 $ 149,870 $ 3,039 $ 1,470 $ 154,379 Amortization expense 242 289 559 1,090 Disposals — ( 23 ) ( 333 ) ( 356 ) Impairments (notes 6, 25) 480 1,072 15 1,567 Effect of foreign exchange differences — ( 12 ) ( 7 ) ( 19 ) Balance at December 31, 2020 $ 150,592 $ 4,365 $ 1,704 $ 156,661 Amortization expense 316 1,248 399 1,963 Disposals ( 1,298 ) ( 51 ) ( 34 ) ( 1,383 ) Sold - discontinued operations (note 6) ( 8,698 ) ( 533 ) ( 1,772 ) ( 11,003 ) Impairments (notes 6, 25) 1,389 341 — 1,730 Effect of foreign exchange differences 16 ( 13 ) ( 7 ) ( 4 ) Balance at December 31, 2021 $ 142,317 $ 5,357 $ 290 $ 147,964 Carrying amounts At December 31, 2021 $ 3,442 $ 74 $ — $ 3,516 At December 31, 2020 11,472 2,418 1,602 15,492

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Trade And Other Current Payables [Abstract]
Summary of Accounts Payable and Accrued Liabilities	December 31, December 31, Trade payables $ 5,762 $ 9,153 Wages and benefits payable 1,297 3,083 Refundable tax credits 113 — Current portion of royalty payment obligations 25 3,248 Current portion of other employee benefit 146 1,351 $ 7,343 $ 16,835

Lease Liabilities (Tables)

Lease Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Lease Liabilities [Abstract]
Summary of Lease Liabilities	The transactions affecting the lease liabilities during the years ended December 31, 2021 and 2020 were as follows: 2021 2020 Balance at January 1 $ 33,452 $ 38,237 Additions — 544 Interest expense 3,754 6,030 Payments ( 4,321 ) ( 9,167 ) Derecognized - discontinued ( 7,549 ) — Lease modification and other remeasurements ( 2,588 ) ( 1,934 ) Effect of foreign exchange differences ( 277 ) ( 258 ) Balance at December 31 $ 22,471 $ 33,452 Less current portion of lease liabilities ( 7,194 ) ( 6,946 ) Long-term portion of lease liabilities $ 15,277 $ 26,506

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Dec. 31, 2021
Restructuring provision [abstract]
Summary of Provisions	Initial recognition of provisions at June 30, 2021 $ 21,928 Increase to provisions during the period 439 Effect of foreign exchange difference ( 262 ) Interest expense 90 Balance at December 31, 2021 $ 22,195 Less current portion of provisions ( 3,957 ) Long-term portion of provisions $ 18,238

Warrant Liability (Tables)

Warrant Liability (Tables)	12 Months Ended
	Dec. 31, 2021
Warrant Liability [Abstract]
Schedule of Fair Value of Warrants	The fair value of the November 2020 warrants on the various dates discussed above was calculated using a Black-Scholes option pricing model in a Monte Carlo simulation in order to evaluate the downward adjustment mechanism to the exercise price. The assumptions used at the different valuation dates are provided in the table below: December 31, December 31, 2021 2020 Underlying common share fair value (in USD) $ 1.09 $ 4.20 Remaining life until expiry 3.8 4.8 Volatility 56.0 % 49.0 % Risk-free interest rate 1.13 % 0.34 % Expected dividend rate — — Fair value of a warrant calculated using a $ 0.08 $ 1.41 Fair value of exercise price adjustment mechanism $ 0.16 $ 0.22 Illiquidity discount 28.0 % 29.0 % Fair value of a warrant (in USD) $ 0.18 $ 1.16 Fair value of a warrant (in CAD) $ 0.22 $ 1.47

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Detailed Information About Borrowings [Abstract]
Summary of Transactions and Carrying Value of Long-term Debt	2021 2020 Balance at January 1 $ 40,532 $ 8,834 Stated and accreted interest 4,388 2,209 Drawdown on non-revolving line of credit — 29,123 Issuance of secured convertible debentures — 2,410 Conversion of secured convertible debt into shares ( 2,664 ) — Repayment of principal — ( 165 ) Repayment of stated interest ( 3,945 ) ( 1,879 ) Balance at December 31 $ 38,311 $ 40,532
Summary of Carrying Value of Long-term Debt	At December 31, 2021 and 2020, the carrying amount of the debt comprised the following loans: December 31, December 31, 2021 2020 First term loan having a principal of $ 10,000 maturing April 23, 2024 bearing stated interest of 10 % per annum 15.05 %) 1) $ 9,188 $ 8,910 Second term loan having a principal of $ 29,123 maturing on April 23, 2024 bearing stated interest of 10 % per annum 10.47 %) 1) 29,123 29,123 Secured convertible debentures having an aggregate principal 2,410 maturing on March 31, 2022 bearing stated 8 % per annum (effective interest rate of 8.24 %) 2) — 2,499 $ 38,311 $ 40,532 Less current portion of long-term debt — — Long-term portion of long-term debt $ 38,311 $ 40,532 1) The first and second term loans issued under the consolidated loan agreement with SALP are secured by all the assets of the Company and require that certain covenants be respected including maintaining an adjusted working capital ratio. In February 2022, these loans were repaid in full (note 33). 2) The secured convertible debentures were secured by all the assets of Fairhaven. The Company’s security interest granted in connection with its consolidated loan agreement with SALP, its parent, was subordinated to the security interest on the Fairhaven assets granted in favor of the holder of the secured convertible debentures.
Summary of Loss on Extinguishment of Liabilities	Loss on extinguishment of liabilities due to April 23, 2019 loan modification Comprising the following elements: Debt to equity conversion $ 87,379 Expensing of financing fees on loan extinguishment 653 Extinguishment of previous loan ( 4,667 ) Recognition of modified loan 8,521 Expensing of increase in the fair value of the warrants (note 19c) 408 Loss on extinguishment of liabilities due to April 23, 2019 loan modification $ 92,294 Loss on extinguishment of liabilities to suppliers (note 19a) 80 Loss on extinguishments of liabilities $ 92,374

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Miscellaneous Noncurrent Liabilities [Abstract]
Summary of Other Long-Term Liabilities	December 31, December 31, 2021 2020 Royalty payment obligations (a) $ 123 $ 3,355 Other employee benefit liabilities 146 1,557 $ 269 $ 4,912 Less: Current portion of royalty payment obligations (note 13) ( 25 ) ( 3,248 ) Current portion of other employee benefit liabilities (note 13) ( 146 ) ( 1,351 ) $ 98 $ 313

Share Capital and Other Equit_2

Share Capital and Other Equity Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	Changes in the issued and outstanding common shares during the year ended December 31, 2021 and 2020 were as follows: 2021 2020 Number Amount Number Amount Balance - beginning of year 29,943,839 $ 977,261 23,313,164 $ 932,951 Issued to acquire assets — — 299,141 4,681 Exercise of stock options (note 19b) — — 5,391 167 Exercise of pre-funded warrants (note 19c) — — 557,894 2,624 Shares issued pursuant to a restricted share 144 — 10,355 9,764 Shares issued for cash — — 5,757,894 27,074 Shares issued upon conversion of debt 1,098,577 2,588 — — Balance - end of year 31,042,560 $ 979,849 29,943,839 $ 977,261
Schedule of Changes in Number of Stock Options Outstanding and Weighted Average Exercise Price	For stock options having a CAD exercise price, the changes in the number of stock options outstanding during the years ended December 31, 2021 and 2020 were as follows: 2021 2020 2019 Weighted Weighted Weighted average average average exercise price exercise price exercise price Number ($) Number ($) Number ($) Balance - beginning of year 2,485,555 $ 18.70 2,209,864 $ 38.72 21,625 $ 1,464.49 Granted — — 436,570 14.06 2,218,810 33.13 Forfeited ( 1,321,651 ) 14.34 ( 153,982 ) 19.33 ( 16,774 ) 159.61 Exercised — — ( 5,391 ) 15.21 — — Cancelled — — — — ( 11,713 ) 1,237.94 Expired ( 136,126 ) 40.70 ( 1,506 ) 2,462.46 ( 2,084 ) 1,176.20 Repriced - options before repricing — — ( 1,929,685 ) 35.14 — — Repriced - options after repricing — — 1,929,685 15.21 — — Balance - end of year 1,027,778 $ 21.39 2,485,555 $ 18.70 2,209,864 $ 38.72 For options having a USD exercise price, the changes in the number of stock options outstanding during the years ended December 31, 2021 and 2020 were as follows: 2021 2020 Weighted Weighted average average exercise price exercise price Number (USD) Number (USD) Balance - beginning of year 305,000 $ 4.70 — $ — Granted 492,000 2.80 305,000 4.70 Forfeited ( 38,000 ) 4.10 — — Expired ( 10,000 ) 4.27 — — Balance - end of year 749,000 $ 3.49 305,000 $ 4.70
Summary of Weighted Average Inputs into Model and Resulting Grant Date Fair Values	The following Black-Scholes assumption were used: Expected dividend rate — Expected volatility of share price 93.2 % Risk-free interest rate 0.4 % Expected life in years 6.3 Weighted average grant date incremental fair value $ 1.55 The weighted average inputs into the model and the resulting grant date fair values during the years ended December 31, 2021, 2020 and 2019 were as follows: 2021 2020 2019 Expected dividend rate — — — Expected volatility of share price 115.0 % 100.5 % 45.0 % Risk-free interest rate 1.21 % 0.5 % 1.4 % Expected life in years 6.7 6.7 7.2 Weighted average grant date fair value $ 2.85 $ 8.66 $ 12.74
Schedule of Stock Options Issued and Outstanding by Range of Exercise Price	At December 31, 2021, stock options issued and outstanding denominated in CAD and USD by range of exercise price are as follows: Weighted Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in CAD outstanding (in years) ($) exercisable ($) $ 7.86 -$ 11.99 30,000 7.7 $ 11.99 16,875 $ 11.99 $ 14.06 141,650 8.4 14.06 78,112 14.06 $ 15.21 800,778 7.4 15.21 522,862 15.21 $ 27.00 -$ 2,220.00 55,350 7.3 134.61 54,985 130.88 1,027,778 7.6 $ 21.39 672,834 $ 24.45 Weighted Weighted Weighted Range of exercise remaining average average price for stock option Number contractual life exercise price Number exercise price issued in USD outstanding (in years) (USD) exercisable (USD) $ 2.17 349,000 9.8 $ 2.17 — $ — $ 3.93 -$ 5.34 380,000 9.1 4.31 192,500 4.34 $ 10.80 20,000 8.8 10.80 6,666 10.80 749,000 9.4 $ 3.49 199,166 $ 4.55
Schedule of Total Share-Based Payments Expense	The total share-based payments compensation expense, comprising the above-mentioned expenses for stock options and RSU, has been included in the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019 as indicated in the following table: 2021 2020 2019 Administration expenses $ 3,760 $ 3,248 $ 14,315 Research and development expenses 936 2,430 2,836 Loss from discontinued operations ( 444 ) 556 4,879 $ 4,252 $ 6,234 $ 22,030
Restricted Stock Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	Changes in the number of RSU outstanding during the years ended December 31, 2021, 2020 and 2019 were as follows: 2021 2020 2019 Balance - beginning of year 4,216 17,565 18,299 Granted — — 12,564 Forfeited ( 48 ) ( 46 ) ( 409 ) Released ( 144 ) ( 10,355 ) — Paid in cash ( 4,024 ) ( 2,948 ) ( 8,396 ) Cancelled — — ( 4,493 ) Balance - end of year — 4,216 17,565
Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Changes in Issued and Outstanding Common Share or RSU or Warrants	The following table presents the number of warrants outstanding with an exercise price in CAD during the years ended December 31, 2021 and 2020: 2021 2020 Weighted Weighted average average exercise price exercise price Number ($) Number ($) Balance of warrants - end of year 172,735 $ 84.33 172,735 $ 84.33 The following table presents the changes in the number of warrants outstanding with an exercise price in USD during the years ended December 31, 2021 and 2020: 2021 2020 Weighted Weighted average average exercise price exercise price Number (USD) Number (USD) Balance of warrants - beginning of year 7,894,734 $ 5.50 — $ — Issued for cash — — 6,873,682 5.05 Issued for no consideration — — 1,578,946 5.50 Exercised — — ( 557,894 ) — Balance of warrants - end of year 7,894,734 $ 5.50 7,894,734 $ 5.50
Schedule of Warrants Outstanding, Exercise Price, Expiry Rate and Overall Weighted Average Exercise Price	The warrants outstanding as at December 31, 2021, their exercise price in CAD or in USD, expiry rate and the overall weighted average exercise price in both currency are as follows: Number Expiry Exercise 4,000 January 2023 $ 3,000.00 168,735 April 2027 15.21 Warrants outstanding with an exercise price in CAD 172,735 $ 84.33 Number Expiry Exercise Warrants outstanding with an exercise price in USD 7,894,734 November 2025 $ 5.50

Non-controlling Interests (Tabl

Non-controlling Interests (Tables)	12 Months Ended
	Dec. 31, 2021
Non Controlling Interests [Abstract]
Summary of Company's Subsidiaries	The consolidated financial statements include the accounts of Liminal BioSciences Inc., and those of its subsidiaries. The Company’s subsidiaries at December 31, 2021, 2020 and 2019 are as follows: Name of subsidiary Segment activity Place of incorporation and Proportion of ownership interest held 2021 2020 2019 Fairhaven Pharmaceuticals Inc. Small molecule therapeutics Quebec, Canada 100 % 100 % nil Liminal R&D BioSciences Inc. Small molecule therapeutics Quebec, Canada 100 % 100 % 100 % Liminal BioSciences Holdings Limited Small molecule therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Liminal BioSciences Limited Small molecule therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Prometic Pharma SMT B.V Small molecule therapeutics Amsterdam, Netherlands 100 % 100 % N/A Prometic Bioproduction Inc. Plasma-derived therapeutics Quebec, Canada nil * 100 % 100 % Prometic Plasma Resources Inc. Plasma-derived therapeutics Winnipeg, Canada nil * 100 % 100 % Telesta Therapeutics Inc. Plasma-derived therapeutics Quebec, Canada 100 % 100 % 100 % NantPro Biosciences, LLC Plasma-derived therapeutics Delaware, U.S. 73 % 73 % 73 % Prometic Biotherapeutics Inc. Plasma-derived therapeutics Delaware, U.S. nil * 100 % 100 % Prometic Plasma Resources USA Inc. Plasma-derived therapeutics Delaware, U.S. nil * 100 % 100 % Prometic Biotherapeutics Ltd Plasma-derived therapeutics Cambridge, United Kingdom 100 % 100 % 100 % Prometic Biotherapeutics B.V. Plasma-derived therapeutics Amsterdam, Netherlands 100 % 100 % N/A Pathogen Removal and Diagnostic Corporate Delaware, U.S. 77 % 77 % 77 % The Company held less than 100 % interest in the following two entities during the last three fiscal years. The Company's interest in these subsidiaries at December 31, 2021 and 2020 was as follows: Name of subsidiary Segment activity Place of incorporation and operation Proportion of ownership interest held by group Pathogen Removal and Diagnostic Corporate Delaware, U.S. 77 % NantPro Biosciences, LLC Plasma-derived therapeutics Delaware, U.S. 73 %
Summary of Financial Information for Entities Non-controlling Interest	Summarized statements of financial position for PRDT: December 31, December 31, 2021 2020 Receivables (current) $ 227 $ 233 Capital and intangible assets (long-term) 74 113 Trade and other payables (current) ( 987 ) ( 877 ) Intercompany loan ( 17,329 ) ( 16,846 ) Total equity (negative equity) $ ( 18,015 ) $ ( 17,377 ) Attributable to non-controlling interests $ ( 8,756 ) $ ( 8,087 ) Summarized statement of operations of PRDT: Year ended December 31 2021 2020 2019 Royalty revenues $ 565 $ 572 $ 585 Royalty expenses ( 88 ) ( 128 ) ( 132 ) Research and development expenses ( 244 ) ( 196 ) ( 215 ) Administration expenses ( 946 ) ( 1,506 ) ( 896 ) Impairment loss — — ( 129 ) Net loss and comprehensive loss $ ( 713 ) $ ( 1,258 ) $ ( 787 ) Attributable to non-controlling interests $ ( 669 ) $ ( 832 ) $ ( 713 )

Capital Management (Tables)

Capital Management (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Capital Management [Abstract]
Summary of Capital Management	The Company defines its capital as shareholders’ equity including warrants presented as a liability and financial instruments of a long-term nature (including the current portion) less cash. December 31, December 31, 2021 2020 Warrant liability $ 1,754 $ 11,640 Lease liabilities 22,471 33,452 Provisions 22,195 — Long-term debt 38,311 40,532 Total equity 33,881 15,012 Cash ( 108,490 ) ( 45,075 ) Total capital $ 10,122 $ 55,561

Revenues from Continuing Oper_2

Revenues from Continuing Operations (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue [Abstract]
Summary of Revenues from Continuing Operations	2021 2020 2019 Royalty revenues $ 565 $ 572 $ 575 Rental revenue 78 152 170 $ 643 $ 724 $ 745

Supplemental Information (Table

Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Supplemental Information Regarding Consolidated Statements Of Operations [Abstract]
Summary of Supplemental Information Regarding the Consolidated Statements of Operations	The Company also recognized research and development tax credits during the years ended December 31, 2021 and 2020. These grants were recorded as a reduction of salary expenses and other related charges and are recognized as follows in the consolidated statement of operations: Year ended December 31 2021 2020 2019 Government grants recognized in research Salary subsidy $ 372 $ 1,017 $ — Rent subsidy 140 108 — Research and development tax credits 124 426 572 $ 636 $ 1,551 $ 572 Government grants recognized in Salary subsidy $ 325 $ 1,457 $ — Rent subsidy 86 63 — $ 411 $ 1,520 $ — Government grants recognized in loss from Salary subsidy $ 2,502 $ 4,758 $ — Rent subsidy 682 426 — Research and development tax credits 116 1,332 — $ 3,300 $ 6,516 $ — ii) Finance costs Year ended December 31 2021 2020 2019 Interest accretion on long-term debt $ 4,388 $ 2,209 $ 7,874 Amortization of fees for credit facility — — 10 Financing fees on warrant liability — 709 — Interest expense on provisions 90 — — Other interest expense, transaction and bank fees 413 485 594 Interest expense on lease liabilities 3,754 6,030 7,068 Interest income ( 73 ) ( 451 ) ( 753 ) $ 8,572 $ 8,982 $ 14,793 The table above includes financing costs from continuing and discontinued operations. Financing costs from discontinued operations for the years ended December 31, 2021, 2020 and 2019 were $ 2,242 , $ 6,083 and $ 7,926 , respectively, and mainly represented interest expense on lease liabilities (note 6 ). iii) Employee compensation expense Year ended December 31 2021 2020 2019 Wages and salaries $ 19,731 $ 32,410 $ 48,846 Employer's benefits 3,201 5,443 8,263 Share-based payments expense 4,252 6,234 22,030 $ 27,184 $ 44,087 $ 79,139
Summary of Information by Geographic Area	i) Capital, intangible and right-of-use assets by geographic area 2021 2020 Canada $ 10,041 $ 28,231 United Kingdom 567 2,092 United States — 12,517 $ 10,608 $ 42,840 ii) Revenues by location from continuing operations 2021 2020 2019 Canada 78 152 170 United Kingdom 565 572 575 $ 643 $ 724 $ 745

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Major Components Of Tax Expense Income [Abstract]
Summary of Income Tax Recovery in Consolidated Statement of Operations	The income tax expense (recovery) reported in the consolidated statement of operations for the years ended December 31, 2021, 2020 and 2019 are as follows: 2021 2020 2019 Current income tax expense (recovery) $ — $ ( 144 ) $ ( 336 ) Deferred income tax expense (recovery) 118 ( 65 ) 111 Income tax expense (recovery) from continuing operations 118 ( 209 ) ( 225 ) Current income tax expense (recovery) 1 8 53 Deferred income tax expense (recovery) — — ( 24 ) Total income tax expense (recovery) $ 119 $ ( 201 ) $ ( 196 )
Summary of Reconciliation of Income Tax Expense (Recovery) for Continuing and Discontinued Operations Recognized in Consolidated Statement of Operations	The following table provides a reconciliation of the income tax expense (recovery) calculated at the combined statutory income tax rate to the income tax expense (recovery) for both continuing and discontinued operations, recognized in the consolidated statements of operations. 2021 2020 2019 Net loss before tax from continuing operations $ ( 44,945 ) $ ( 49,230 ) $ ( 150,897 ) Net income before tax from discontinued operations 57,277 ( 69,728 ) ( 56,052 ) Combined Canadian statutory income tax rate 26.5 % 26.5 % 26.6 % Income tax expense (recovery) at combined income tax rate 3,268 ( 31,524 ) ( 55,048 ) Increase (decrease) in income taxes resulting from: Unrecorded potential tax benefit arising from 1,658 33,238 31,962 Effect of tax rate differences in foreign subsidiaries 9,756 1,101 4,989 Non-deductible or taxable items ( 6,149 ) ( 157 ) ( 696 ) Change in tax rate ( 5,354 ) ( 1,455 ) 1,609 Non-deductible loss (taxable gain) on debt renegotiation — — 24,572 Research and development tax credit ( 3,012 ) ( 494 ) ( 740 ) Non-taxable gain on disposition of subsidiary (note 6) — ( 896 ) ( 6,903 ) Other ( 48 ) ( 14 ) 59 Income tax expense (recovery) $ 119 $ ( 201 ) $ ( 196 )
Summary of Deferred Tax Assets (Recoveries)	The following table presents the deferred tax assets (recoveries) related to R&D expenditures at December 31, 2021 and 2020. 2021 2020 Balance - beginning of year $ ( 572 ) $ ( 507 ) Credited to profit and loss 118 ( 65 ) Balance - end of year $ ( 454 ) $ ( 572 )
Summary of Available Temporary Differences Not Recognized	Available temporary differences not recognized at December 31, 2021 and 2020 are as follows: 2021 2020 Tax losses (non-capital) $ 371,146 $ 569,542 Tax losses (capital) 185,085 305 Unused research and development expenses 25,170 84,556 Undeducted financing expenses 16,914 27,053 Interest expenses carried forward 22,616 32,475 Trade and other payable 22,592 1,640 Capital assets 4,575 3,392 Intangible assets 2,578 68,329 Start-up expense 1,908 5,358 Unrealized loss on exchange rate — 5,430 Lease obligations 21,583 15,494 Other 51 1,071 $ 674,218 $ 814,645
Summary of Unused Non-capital Losses Expire	The unused non-capital losses expire as indicated in the table below: Canada Foreign At December 31, 2021 Federal Provincial Countries Losses carried forward expiring in: 2027 $ 3,510 $ 3,495 $ — 2028 — — $ — 2029 — — — 2030 — — — 2031 — — — 2032 1,001 995 — 2033 4,610 4,606 — 2034 7,760 9,807 — 2035 12,565 12,563 — 2036 14,468 22,678 — 2037 7,393 7,394 — 2038 7,003 6,595 — 2039 26,441 26,305 — 2040 37,884 37,751 — 2041 39,933 39,904 — $ 162,568 $ 172,093 $ — Not expiring - UK — — 270,144 Not expiring - US (post 2017) 1) — — 2,821 $ 162,568 $ 172,093 $ 272,965 1) US tax rules impose restrictions that will impact how $ 114,107 of losses are available to shelter income in future taxation years. As a result, approximately $ 111,286 of losses will no longer be available to the company and are not presented in the available tax loss table presented above.

Compensation of Key Managemen_2

Compensation of Key Management Personnel (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Of Key Management Personnel [Abstract]
Summary of the Remuneration of the Key Management Personnel	The remuneration of the key management personnel during the years ended December 31, 2021 and 2020 was as follows: 2021 2020 2019 Current employee benefits 1) $ 5,466 $ 6,153 $ 10,083 Pension costs 78 115 267 Share-based payments 4,351 4,917 16,842 Termination benefits 406 319 2,919 $ 10,301 $ 11,504 $ 30,111 1) Current employee benefits include salaries, bonuses, other employee benefits other than those listed in the table and director fees paid in cash.

Financial Instruments and Fin_2

Financial Instruments and Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]
Schedule of Contractual Maturities of Financial Liabilities	The following table presents the contractual maturities of the financial liabilities as of December 31, 2021: Contractual Cash flows Carrying amount Less than 2-3 4 - 5 More than Total Accounts payable and accrued 1) $ 7,343 $ 7,343 $ — $ — $ — $ 7,343 Long-term portion of royalty 98 — 51 51 197 299 Lease liabilities 22,471 7,369 10,629 8,285 — 26,283 Provisions 22,195 3,961 9,094 9,544 — 22,599 Long-term debt 2) 38,311 3,945 44,297 — — 48,242 $ 90,418 $ 22,618 $ 64,071 $ 17,880 $ 197 $ 104,766 1) Short-term portions of the royalty payment obligations and of other employee benefit liabilities are included in the account payable and accrued liabilities. 2) The Company has fully repaid its long-term debt in February 2022 (note 33).
Schedule of Net Exposure to Currency Risk through Financial Assets and Financial Liabilities	As at December 31, 2021 and 2020, the Company’s net exposure to currency risk through financial assets and financial liabilities denominated respectively in USD and GBP was as follows: 2021 2020 Amount Equivalent in Amount Equivalent in Exposure in USD in USD full CAD in USD full CAD Cash 78,045,915 99,094,899 17,281,338 22,018,153 Accounts receivable 185,954 236,106 886,211 1,129,121 Other long-term assets — — 45,428 57,880 Accounts payable and accrued liabilities ( 951,284 ) ( 1,207,845 ) ( 6,023,877 ) ( 7,675,022 ) Lease liabilities — — ( 10,918,525 ) ( 13,911,293 ) Other long-term liabilities ( 77,075 ) ( 97,862 ) ( 162,000 ) ( 206,404 ) Long-term derivatives ( 1,381,603 ) ( 1,754,221 ) — — Net exposure 75,821,907 96,271,077 1,108,575 1,412,435 2021 2020 Amount Equivalent in Amount Equivalent in Exposure in GBP in GBP full CAD in GBP full CAD Cash 2,832,439 4,859,049 4,619,225 8,032,832 Accounts receivable 134,605 230,914 230,588 400,993 Accounts payable and accrued liabilities ( 1,026,984 ) ( 1,761,791 ) ( 983,697 ) ( 1,710,649 ) Lease liabilities ( 203,186 ) ( 348,566 ) ( 271,623 ) ( 472,352 ) Net exposure 1,736,873 2,979,606 3,594,493 6,250,824

Nature of Operations and Goin_2

Nature of Operations and Going Concern - Additional Information (Details) - CAD ($) $ in Thousands	Feb. 15, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Nature Of Operations And Going Concern [Abstract]
Net loss from continuing operations		$ (45,063)	$ (49,021)	$ (150,672)
Operating cash flows		99,603	75,917	$ 99,390
Accumulated deficit		1,074,167	1,087,049
Working capital		$ 96,100	$ 49,200
Repayment of long-term debt	$ 39,100

Material Accounting Policies -

Material Accounting Policies - Summary of Company's Subsidiaries (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of subsidiaries [line items]
Proportion of ownership interest held by group	100.00%	100.00%	100.00%
Fairhaven Pharmaceuticals Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Fairhaven Pharmaceuticals Inc.
Segment activity	Small molecule therapeutics
Place of incorporation and operation	Quebec, Canada
Proportion of ownership interest held by group	100.00%	100.00%	0.00%
Liminal R&D BioSciences Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Liminal R&D BioSciences Inc.
Segment activity	Small molecule therapeutics
Place of incorporation and operation	Quebec, Canada
Proportion of ownership interest held by group	100.00%	100.00%	100.00%
Liminal BioSciences Holdings Limited
Disclosure of subsidiaries [line items]
Name of subsidiary	Liminal BioSciences Holdings Limited
Segment activity	Small molecule therapeutics
Place of incorporation and operation	Cambridge, United Kingdom
Proportion of ownership interest held by group	100.00%	100.00%	100.00%
Liminal BioSciences Limited
Disclosure of subsidiaries [line items]
Name of subsidiary	Liminal BioSciences Limited
Segment activity	Small molecule therapeutics
Place of incorporation and operation	Cambridge, United Kingdom
Proportion of ownership interest held by group	100.00%	100.00%	100.00%
Prometic Pharma SMT B.V
Disclosure of subsidiaries [line items]
Name of subsidiary	Prometic Pharma SMT B.V
Segment activity	Small molecule therapeutics
Place of incorporation and operation	Amsterdam, Netherlands
Proportion of ownership interest held by group	100.00%	100.00%
Prometic Bioproduction Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Prometic Bioproduction Inc.
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Quebec, Canada
Proportion of ownership interest held by group	0.00%	100.00%	100.00%
Prometic Plasma Resources Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Prometic Plasma Resources Inc.
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Winnipeg, Canada
Proportion of ownership interest held by group	0.00%	100.00%	100.00%
Telesta Therapeutics Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Telesta Therapeutics Inc.
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Quebec, Canada
Proportion of ownership interest held by group	100.00%	100.00%	100.00%
NantPro Biosciences, LLC
Disclosure of subsidiaries [line items]
Name of subsidiary	NantPro Biosciences, LLC
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Delaware, U.S.
Proportion of ownership interest held by group	73.00%	73.00%	73.00%
Prometic Biotherapeutics Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Prometic Biotherapeutics Inc.
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Delaware, U.S.
Proportion of ownership interest held by group	0.00%	100.00%	100.00%
Prometic Plasma Resources USA Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Prometic Plasma Resources USA Inc.
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Delaware, U.S.
Proportion of ownership interest held by group	0.00%	100.00%	100.00%
Prometic Biotherapeutics Ltd
Disclosure of subsidiaries [line items]
Name of subsidiary	Prometic Biotherapeutics Ltd
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Cambridge, United Kingdom
Proportion of ownership interest held by group	100.00%	100.00%	100.00%
Prometic Biotherapeutics B.V.
Disclosure of subsidiaries [line items]
Name of subsidiary	Prometic Biotherapeutics B.V.
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Amsterdam, Netherlands
Proportion of ownership interest held by group	100.00%	100.00%
Pathogen Removal and Diagnostic Technologies Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Pathogen Removal and Diagnostic Technologies Inc.
Segment activity	Corporate
Place of incorporation and operation	Delaware, U.S.
Proportion of ownership interest held by group	77.00%	77.00%	77.00%

Material Accounting Policies _2

Material Accounting Policies - Additional Information - (Details)	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies [Line Items]
Description of leases of low value assets	The Company applies the short-term lease recognition exemption to leases of 12 months or less, as well as the lease of low-value assets recognition exemption.

Material Accounting Policies _3

Material Accounting Policies - Summary of Estimated Useful Lives of the Capital Assets (Details)	12 Months Ended
	Dec. 31, 2021
Buildings and Improvements
Summary Of Significant Accounting Policies Details Estimated Useful Lives Of Assets [Line Items]
Useful lives of capital asset	20 years
Leasehold Improvements
Summary Of Significant Accounting Policies Details Estimated Useful Lives Of Assets [Line Items]
Useful lives of capital asset	The lower of the lease term and the useful life
Production and Laboratory Equipment
Summary Of Significant Accounting Policies Details Estimated Useful Lives Of Assets [Line Items]
Useful lives of capital asset	5 - 20 years
Furniture
Summary Of Significant Accounting Policies Details Estimated Useful Lives Of Assets [Line Items]
Useful lives of capital asset	5 - 10 years
Computer Equipment
Summary Of Significant Accounting Policies Details Estimated Useful Lives Of Assets [Line Items]
Useful lives of capital asset	3 - 5 years

Material Accounting Policies _4

Material Accounting Policies - Summary of Estimated Useful Lives of the Intangible Asset (Details)	12 Months Ended
	Dec. 31, 2021
Licenses and Other Rights
Significant Accounting Policies [Line Items]
Useful lives of Intangible asset	30 years
Donor Lists
Significant Accounting Policies [Line Items]
Useful lives of Intangible asset	10 years
Patents
Significant Accounting Policies [Line Items]
Useful lives of Intangible asset	20 years
Software
Significant Accounting Policies [Line Items]
Useful lives of Intangible asset	5 years

Significant Accounting Judgem_2

Significant Accounting Judgements and Estimation Uncertainty - Additional Information - (Details) - CAD ($) $ / shares in Units, $ in Thousands	May 26, 2020	Dec. 31, 2021
Significant Accounting Judgements And Estimation Uncertainty [Line Items]
Revised exercise price of share options	$ 15.21
Ryplazim CGU
Significant Accounting Judgements And Estimation Uncertainty [Line Items]
Change in impairment recorded rate		10.00%
Impairment Loss		$ 3,638

Acquisition of Fairhaven Phar_3

Acquisition of Fairhaven Pharmaceuticals Inc - Additional Information (Details) - Fairhaven Pharmaceuticals Inc. $ in Thousands	Jul. 17, 2020CAD ($)shares
Disclosure Of Business Combinations [Line Items]
Fair value of common shares	$ 3,441
Transaction costs incurred were capitalized and allocated to net assets acquired	$ 308
Share Purchase Agreement
Disclosure Of Business Combinations [Line Items]
Date of business acquisition	Jul. 17, 2020
Common Shares | Share Purchase Agreement
Disclosure Of Business Combinations [Line Items]
Business acquisition, ownership percentage	100.00%
Shares issued for acquisition | shares	202,308
Aggregate value of additional payment in shares	$ 4,374
Number of days in average volume weighted trading price	5 days
Fair value of common shares	$ 3,441
Transaction costs incurred were capitalized and allocated to net assets acquired	$ 308

Acquisition of Fairhaven Phar_4

Acquisition of Fairhaven Pharmaceuticals Inc - Summary of Consideration Paid and Allocation to Net Assets Acquired (Details) $ in Thousands	Jul. 17, 2020CAD ($)
Fairhaven Pharmaceuticals Inc.
Cost of acquisition
Fair value of common shares issued	$ 3,441
Cash payment	50
Total consideration paid	3,491
Transaction fees	308
Total cost of acquisition	3,799
Net assets acquired
Current assets	217
Current liabilities	(214)
Total net assets acquired	3,799
Licenses and Other Rights
Net assets acquired
Licenses and other rights (note 12)	$ 3,796

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) $ in Millions		Sep. 28, 2021CAD ($)	Aug. 06, 2021USD ($)	Nov. 25, 2019OperatingsegmentOperatingSegment	Sep. 30, 2021CAD ($)	Jun. 30, 2021CAD ($)	Dec. 31, 2021CAD ($)SharepurchaseagreementSpas	Dec. 31, 2020CAD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2020GBP (£)
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Number of share purchase agreement | SharepurchaseagreementSpas							2
Impairment of ROU assets								$ 18,627,000
Intangible assets						$ 341,000
Plasma Derived Therapeutics
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Impairment of capital assets							$ 665,000		$ 7,070,000
Impairment of ROU assets							18,553,000
Intangible assets							480,000		4,535,000
Impairment loss							19,698,000
Other impairments of ROU asset							$ 74,000
Level 3
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
FVLCD valuation, description							The FVLCD was calculated using a discounted cash flow model for one year and a terminal value of $58.1 million using a post-tax discount rate of 7.75%. The fair value computed by management is considered as a level 3 computation in the fair value hierarchy under IFRS 13, Fair value measurement. As part of this valuation exercise, management needed to make several key assumptions which affected the cash inflows and outflows considered in the model.
Terminal value							$ 58,100,000
Post-tax discount rate							7.75%
Prometic Biotherapeutics Inc. | PRV
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Fair value of the consideration received			$ (105)
Prometic Biotherapeutics Inc. | Definitive Agreement for Sale | PRV
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Upfront payment received		$ 130,966
Upfront payment received, net of selling costs		$ 1,891
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Number of operations sold | OperatingsegmentOperatingSegment				2
Fair value of the consideration received									(50,752,000)
Fair value of the consideration receivable									1,175,000
Additional amount of fair value consideration received and receivable related to taxation								$ 3,380,000
Number of years the performance criteria transactions followed								4 years
Cash consideration receivable								$ 13,724,000		£ 8,000,000
Fair value of consideration determined at the time of sale								0
Impairment loss	[1]						$ 1,411,000	19,772,000	11,603,000
Discontinued Operations | Intangible Assets
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Impairments					$ 1,389,000		$ 1,389,000	$ 480,000	$ 4,533,000
[1]	During the year 2019, the Company, evaluated its intellectual property and the related market opportunities in the context of the Company’s financial situation and has made further decisions about the areas the Company will or will not pursue.

Discontinued Operations - Summa

Discontinued Operations - Summary of Sale of Subsidiaries (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Total income (loss) from discontinued operations	$ 140,403	$ 3,380	$ 26,346
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Proceeds received			50,752
Total income (loss) from discontinued operations	140,403	3,380	26,346
Discontinued Operations | Bioseparations Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Proceeds received		3,380	51,927
Carrying Amount of Net Assets Sold			22,015
Transaction costs			5,015
Reclassification of foreign currency translation reserve from other comprehensive income into the statement of operations			(1,449)
Total income (loss) from discontinued operations		$ 3,380	$ 26,346
Discontinued Operations | Plasma Collection Centers
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Proceeds received	13,570
Carrying Amount of Net Assets Sold	10,849
Transaction costs	204
Reclassification of foreign currency translation reserve from other comprehensive income into the statement of operations	(44)
Total income (loss) from discontinued operations	2,561
Discontinued Operations | Ryplazim Business
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Proceeds received	159,787
Carrying Amount of Net Assets Sold	19,541
Indemnification adjustments	116
Transaction costs	2,288
Total income (loss) from discontinued operations	$ 137,842

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Sale of Subsidiaries (Parenthetical) (Details) - Discontinued Operations - CAD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Income tax	$ 0	$ 0	$ 0
Bioseparations Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Income tax		$ 0	$ 0
Plasma Collection Centers
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Income tax	0
Ryplazim Business
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Income tax	$ 0

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Carrying Amounts of Assets and Liabilities Sold (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash	$ 108,490	$ 45,075	$ 41,761
Accounts receivable (note 7)	229	943
Inventories (note 8)		9,377
Prepaids	5,071	14,486
Other long-term assets (note 9)	362	1,353
Capital assets (note 10)	5,483	18,791
Right-of-use assets (note 11)	1,609	8,557	$ 33,254
Intangible assets (note 12)	3,516	15,492
Deferred tax assets (note 26)	454	572
Total assets	126,053	117,784
Accounts payable and accrued liabilities (note 13)	7,343	16,835
Current portion of lease liabilities (note 14)	7,194	6,946
Long-term portion of lease liabilities (note 14)	15,277	26,506
Total liabilities	92,172	$ 102,772
Discontinued Operations | Bioseparations Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash	6,794
Accounts receivable (note 7)	1,148
Inventories (note 8)	8,313
Prepaids	236
Other long-term assets (note 9)	48
Capital assets (note 10)	8,483
Right-of-use assets (note 11)	3,300
Intangible assets (note 12)	370
Deferred tax assets (note 26)	12
Total assets	28,704
Accounts payable and accrued liabilities (note 13)	2,163
Deferred revenue	370
Current portion of lease liabilities (note 14)	809
Long-term portion of deferred revenues	87
Long-term portion of lease liabilities (note 14)	3,260
Total liabilities	6,689
Net assets sold	22,015
Discontinued Operations | Plasma Collection Centers
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Accounts receivable (note 7)	137
Inventories (note 8)	8,441
Prepaids	21
Other long-term assets (note 9)	54
Capital assets (note 10)	2,376
Right-of-use assets (note 11)	2,000
Intangible assets (note 12)	1,092
Total assets	14,121
Accounts payable and accrued liabilities (note 13)	639
Current portion of lease liabilities (note 14)	665
Long-term portion of lease liabilities (note 14)	1,968
Total liabilities	3,272
Net assets sold	10,849
Discontinued Operations | Ryplazim Business
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Accounts receivable (note 7)	1,879
Inventories (note 8)	4,640
Prepaids	399
Other long-term assets (note 9)	50
Capital assets (note 10)	9,304
Right-of-use assets (note 11)	3,795
Intangible assets (note 12)	7,277
Total assets	27,344
Accounts payable and accrued liabilities (note 13)	2,887
Current portion of lease liabilities (note 14)	986
Long-term portion of lease liabilities (note 14)	3,930
Total liabilities	7,803
Net assets sold	$ 19,541

Discontinued Operations - Sum_4

Discontinued Operations - Summary of Net Loss From Discontinued Operations (Details) - CAD ($) $ in Thousands		Feb. 27, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Revenues			$ 643	$ 724	$ 745
Expenses
Research and development expenses			18,347	14,234	15,873
Administration expenses			31,928	32,619	37,661
Gain on extinguishment of liabilities		$ (80)		79
Finance costs			6,330	2,899	6,867
Total income (loss) from discontinued operations			57,276	(69,736)	(56,081)
Current income tax (note 26)				(144)	(336)
Deferred income tax (note 26)			118	(65)	111
Net loss from discontinued operations			57,276	(69,736)	(56,081)
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Revenues			949	2,593	27,233
Expenses
Cost of sales and other production expenses			1,465	1,868	14,012
Research and development expenses	[1],[2]		76,733	42,757	65,840
Administration expenses			2,360	5,933	11,009
Gain on foreign exchange			(136)	(633)	(759)
Impairment loss	[3]		1,411	19,772	11,603
Gain on extinguishment of liabilities				(79)
Finance costs			2,242	6,083	7,926
Total income (loss) from discontinued operations			(83,126)	(73,108)	(82,398)
Current income tax (note 26)			1	8	53
Deferred income tax (note 26)					(24)
Net loss from discontinued operations			$ (83,127)	$ (73,116)	$ (82,427)
[1]	On September 29, 2021 prior to the closing of the sale of PBT, PBT paid PBP, which ownership had already passed to Kedrion, $ 39,457 representing 30 % of the net proceeds it received from the sale of the PRV, as compensation for past research and development services. A second payment made by PBT to PBP of $ 6,357 in prepayment for future R&D services on the same date was recognized as R&D expense since this amount would not be recoverable upon the sale of PBT.
[2]	The expense relating to an agreement with a contract development and manufacturing organization, or CDMO, which is considered an onerous contract (note 15) is included in research and development expenses for the year ended December 31, 2021.
[3]	During the year 2019, the Company, evaluated its intellectual property and the related market opportunities in the context of the Company’s financial situation and has made further decisions about the areas the Company will or will not pursue.

Discontinued Operations - Sum_5

Discontinued Operations - Summary of Net Loss From Discontinued Operations (Parenthetical) (Details) - Discontinued Operations - Plasma-derived Therapeutic Activities $ in Thousands	Sep. 29, 2021CAD ($)
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Percentage Of Proceeds From Subsidiaries Net	30.00%
Proceeds from sale of subsidiary	$ 39,457
Prepayment made for R&D services	$ 6,357

Discontinued Operations - Sum_6

Discontinued Operations - Summary of Cash Flows from Discontinued Operations and the Gain on Sale of Subsidiaries (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Net effect of currency exchange rate on cash		$ 750	$ (3)	$ (729)
Discontinued Operations
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash flows from (used in) from operating activities	[1]	(43,089)	8,015	19,493
Cash flows from (used in) financing activities		(3,470)	(7,943)	(8,446)
Cash flows from (used in) investing activities		171,225	(729)	36,275
Net effect of currency exchange rate on cash		(30)	76	(3)
Cash flows generated during the year		124,636	(581)	47,319
Total cash generated (used) by discontinued operations		$ 124,636	$ (581)	$ 47,319
[1]	When compiling the cash flows from discontinued operations which include only certain entities from the Liminal group of companies, intra-group cash transfers between entities in the discontinued operations group and those part of continuing activities, for example the funding provided by Liminal to the discontinued operations, have been classified as part of the operating activities cash flows.

Accounts Receivable and Other_2

Accounts Receivable and Others - Summary of Trade and Other Receivables (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade And Other Receivables [Abstract]
Trade receivables	$ 229	$ 943
Tax credits and government grants receivable		1,808
Sales taxes receivable	280	431
Restricted cash		178
Other receivables	559	721
Trade and other receivables	$ 1,068	$ 4,081

Inventories - Summary of Invent

Inventories - Summary of Inventories (Details) $ in Thousands	Dec. 31, 2020CAD ($)
Classes Of Inventories [Abstract]
Raw materials	$ 9,138
Finished goods	239
Inventories	$ 9,377

Inventories - Additional Inform

Inventories - Additional Information (Details) - Discontinued Operations - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Classes Of Inventories [Line Items]
Cost of sales and other production expenses	$ 376	$ 1,102	$ 12,441
Inventory write-downs	$ 0	$ 0	$ 642

Other Long-term Assets - Summar

Other Long-term Assets - Summary of Other Long-Term Assets (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Other Non Current Assets [Abstract]
Long-term deposits	$ 30	$ 137
Tax credits receivable	332	1,216
Other non-current assets	$ 362	$ 1,353

Capital Assets - Summary of Cap

Capital Assets - Summary of Capital Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	$ 18,791
Depreciation expense			$ 3,734
Impairments	22	$ 665	7,070
Ending balance	5,483	18,791
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	45,185	48,765
Additions	112	1,059
Disposals	(2,221)	(4,575)
Sold - discontinued operations (note 6)	(30,105)
Effect of foreign exchange differences	(161)	(64)
Ending balance	12,810	45,185	48,765
Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	26,394	27,294
Depreciation expense	1,368	2,779
Disposals	(2,007)	(4,311)
Impairments	22	665
Sold - discontinued operations (note 6)	(18,425)
Effect of foreign exchange differences	(25)	(33)
Ending balance	7,327	26,394	27,294
Land and Buildings
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	3,763
Ending balance	3,568	3,763
Land and Buildings | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	4,567	4,567
Ending balance	4,567	4,567	4,567
Land and Buildings | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	804	609
Depreciation expense	195	195
Ending balance	999	804	609
Leasehold Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	4,448
Ending balance	162	4,448
Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	7,349	8,558
Additions		214
Disposals	(399)	(1,380)
Sold - discontinued operations (note 6)	(6,324)
Effect of foreign exchange differences	(107)	(43)
Ending balance	519	7,349	8,558
Leasehold Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	2,901	3,429
Depreciation expense	268	710
Disposals	(400)	(1,380)
Impairments		167
Sold - discontinued operations (note 6)	(2,400)
Effect of foreign exchange differences	(12)	(25)
Ending balance	357	2,901	3,429
Production and Laboratory Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	9,696
Ending balance	1,614	9,696
Production and Laboratory Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	29,904	32,417
Additions	99	295
Disposals	(1,516)	(2,791)
Sold - discontinued operations (note 6)	(21,525)
Effect of foreign exchange differences	(45)	(17)
Ending balance	6,917	29,904	32,417
Production and Laboratory Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	20,208	20,796
Depreciation expense	662	1,450
Disposals	(1,301)	(2,527)
Impairments	22	498
Sold - discontinued operations (note 6)	(14,281)
Effect of foreign exchange differences	(7)	(9)
Ending balance	5,303	20,208	20,796
Furniture and Computer Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	884
Ending balance	139	884
Furniture and Computer Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	3,365	3,223
Additions	13	550
Disposals	(306)	(404)
Sold - discontinued operations (note 6)	(2,256)
Effect of foreign exchange differences	(9)	(4)
Ending balance	807	3,365	3,223
Furniture and Computer Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	2,481	2,460
Depreciation expense	243	424
Disposals	(306)	(404)
Sold - discontinued operations (note 6)	(1,744)
Effect of foreign exchange differences	(6)	1
Ending balance	$ 668	$ 2,481	$ 2,460

Capital Assets - Additional Inf

Capital Assets - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Property Plant And Equipment [Abstract]
Impairment losses on capital assets	$ 22	$ 665	$ 7,070
Depreciation expense			$ 3,734

Right-of-use Assets - Summary o

Right-of-use Assets - Summary of Quantitative Information About Right-Of-Use Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value	$ 8,557	$ 33,254
Additions		544
Lease modifications and other remeasurements	(52)	(1,998)
Sold - discontinued operations (note 6)	(5,795)
Depreciation expense	(1,013)	(4,578)	$ (4,913)
Impairments (note 6)		(18,627)
Effect of foreign exchange differences	(88)	(38)
Net book value	1,609	8,557	33,254
Buildings
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value	8,086	32,246
Additions		378
Lease modifications and other remeasurements	3	(1,998)
Sold - discontinued operations (note 6)	(5,497)
Depreciation expense	(906)	(3,956)
Impairments (note 6)		(18,553)
Effect of foreign exchange differences	(77)	(31)
Net book value	1,609	8,086	32,246
Production and Laboratory Equipment
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value	426	912
Additions		151
Lease modifications and other remeasurements	(53)
Sold - discontinued operations (note 6)	(272)
Depreciation expense	(95)	(561)
Impairments (note 6)		(70)
Effect of foreign exchange differences	(6)	(6)
Net book value		426	912
Other
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Net book value	45	96
Additions		15
Lease modifications and other remeasurements	(2)
Sold - discontinued operations (note 6)	(26)
Depreciation expense	(12)	(61)
Impairments (note 6)		(4)
Effect of foreign exchange differences	$ (5)	(1)
Net book value		$ 45	$ 96

Right-of-use Assets - Additiona

Right-of-use Assets - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]
Depreciation expense	$ 1,013	$ 4,578	$ 4,913

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - CAD ($) $ in Thousands	Jul. 17, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Intangible Assets [Line Items]
Beginning balance		$ 15,492
Amortization expense		(1,963)	$ (1,090)	$ (1,259)
Ending balance		3,516	15,492
Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance		172,153	168,225
Additions		113	4,493
Disposals		(1,394)	(541)
Sold - discontinued operations (note 6)		(19,372)
Effect of foreign exchange differences		(20)	(24)
Ending balance		151,480	172,153	168,225
Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance		156,661	154,379
Amortization expense		1,963	1,090
Disposals		(1,383)	(356)
Sold - discontinued operations (note 6)		(11,003)
Impairments		1,730	1,567
Effect of foreign exchange differences		(4)	(19)
Ending balance		147,964	156,661	154,379
Licenses and Other Rights
Disclosure Of Intangible Assets [Line Items]
Beginning balance		11,472
Additions	$ 3,796
Ending balance		3,442	11,472
Licenses and Other Rights | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance		162,064	158,268
Additions			3,796
Disposals		(1,300)
Sold - discontinued operations (note 6)		(15,006)
Effect of foreign exchange differences		1
Ending balance		145,759	162,064	158,268
Licenses and Other Rights | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance		150,592	149,870
Amortization expense		316	242
Disposals		(1,298)
Sold - discontinued operations (note 6)		(8,698)
Impairments		1,389	480
Effect of foreign exchange differences		16
Ending balance		142,317	150,592	149,870
Patents
Disclosure Of Intangible Assets [Line Items]
Beginning balance		2,418
Ending balance		74	2,418
Patents | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance		6,783	6,309
Additions		114	668
Disposals		(61)	(179)
Sold - discontinued operations (note 6)		(1,403)
Effect of foreign exchange differences		(2)	(15)
Ending balance		5,431	6,783	6,309
Patents | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance		4,365	3,039
Amortization expense		1,248	289
Disposals		(51)	(23)
Sold - discontinued operations (note 6)		(533)
Impairments		341	1,072
Effect of foreign exchange differences		(13)	(12)
Ending balance		5,357	4,365	3,039
Software
Disclosure Of Intangible Assets [Line Items]
Beginning balance		1,602
Impairments			(15)
Ending balance			1,602
Software | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance		3,306	3,648
Additions		1	29
Disposals		(33)	(362)
Sold - discontinued operations (note 6)		(2,963)
Effect of foreign exchange differences		(19)	(9)
Ending balance		290	3,306	3,648
Software | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance		1,704	1,470
Amortization expense		399	559
Disposals		(34)	(333)
Sold - discontinued operations (note 6)		(1,772)
Impairments			15
Effect of foreign exchange differences		(7)	(7)
Ending balance		$ 290	$ 1,704	$ 1,470

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Intangible Assets [Line Items]
Amortisation expense				$ 1,259
Licenses and Patents
Disclosure Of Intangible Assets [Line Items]
Impairments		$ 341	$ 1,087	763
Intangible Assets | Discontinued Operations
Disclosure Of Intangible Assets [Line Items]
Impairments	$ 1,389	$ 1,389	$ 480	$ 4,533

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade And Other Current Payables [Abstract]
Trade payables	$ 5,762	$ 9,153
Wages and benefits payable	1,297	3,083
Refundable tax credits	113
Current portion of royalty payment obligations (note 18)	25	3,248
Current portion of other employee benefit liabilities (note 18)	146	1,351
Trade and other current payables	$ 7,343	$ 16,835

Lease Liabilities - Summary of

Lease Liabilities - Summary of Lease Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Balance at January 1	$ 33,452
Interest expense			$ 7,068
Balance at December 31	22,471	$ 33,452
Less current portion of lease liabilities	(7,194)	(6,946)
Long-term portion of lease liabilities	15,277	26,506
Lease Liabilities
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Balance at January 1	33,452	38,237
Additions		544
Interest expense	3,754	6,030
Payments	(4,321)	(9,167)
Derecognized - discontinued operations (note 6)	(7,549)
Lease modification and other remeasurements	(2,588)	(1,934)
Effect of foreign exchange differences	(277)	(258)
Balance at December 31	22,471	33,452	$ 38,237
Less current portion of lease liabilities	(7,194)	(6,946)
Long-term portion of lease liabilities	$ 15,277	$ 26,506

Lease Liabilities - Additional

Lease Liabilities - Additional Information (Details) - CAD ($) $ in Thousands	Aug. 12, 2021	Dec. 31, 2019
Lease Liabilities [Abstract]
Interest expense on lease liabilities		$ 7,068
Early cancellation notification period under CDMO contract	5 years
Decrease in term of CDMO contract	3 years 9 months 18 days
Decrease in lease liabilities	$ 2,529

Provisions - Summary of Provisi

Provisions - Summary of Provisions (Details) $ in Thousands	6 Months Ended
	Dec. 31, 2021CAD ($)
Restructuring provision [abstract]
Initial recognition of provisions at June 30, 2021	$ 21,928
Increase to provisions during the period	439
Effect of foreign exchange difference	(262)
Interest expense	90
Balance at December 31, 2021	22,195
Less current portion of provisions	3,957
Long-term portion of provisions	$ 18,238

Provisions - Additional Informa

Provisions - Additional Information (Details) $ in Thousands	Dec. 31, 2021CAD ($)
Disclosure of provision matrix [abstract]
Future minimum lease payments	$ 9,000

Warrant Liability - Additional

Warrant Liability - Additional Information (Details) $ / shares in Units, $ in Thousands

Nov. 25, 2020CAD ($)shares

Nov. 03, 2020CAD ($)

Nov. 03, 2020$ / shares

Apr. 23, 2019CAD ($)$ / sharesshares

Mar. 31, 2019CAD ($)

Feb. 22, 2019CAD ($)CreditFacility$ / sharesshares

Apr. 23, 2019CAD ($)$ / sharesshares

Dec. 31, 2021CAD ($)shares

Dec. 31, 2020CAD ($)

Dec. 31, 2019CAD ($)

Feb. 15, 2022$ / sharesshares

Mar. 20, 2019

Dec. 31, 2018CAD ($)

Disclosure Of Detailed Information About Warrant Liability [Line Items]

Number of warrants issued | shares

7,894,734

7,894,734

Warrants expiration date

November 3, 2025

Warrants exercise price per share | $ / shares

$ 5.50

Warrant description

Each warrant can be exercised to acquire one common share at an exercise price initially set at USD 5.50 and that can be reduced if equity financings are completed at a lower price before its expiry.

Fair value of warrants issued

$ 2,227

$ 10,263

Transaction cost on warrant liability

$ 709

Fair value of warrant liability

$ 1,754

$ 11,640

$ 157

Change in fair value of warrant liability

$ 218

9,886

850

Date of warrants issued to long term debt

on or before March 20, 2019

Percentage of warrants issued to increase ownership of long-term debt on fully diluted basis

19.99%

Increase (decrease) in fair value of warrants

$ 11

$ 1,137

$ (1,369)

Number of tranches under credit facility | CreditFacility

2

Credit facility

38,311

40,532

$ 8,834

Estimated fair value of warrants

$ 153

Warrant liability classified as equity

$ 153

$ 153

Warrants Held by SALP

Disclosure Of Detailed Information About Warrant Liability [Line Items]

Number Of Warrants Cancelled | shares

168,735

168,735

168,735

Warrants cancelled exercise price per share | $ / shares

$ 15.21

$ 15.21

$ 15.21

Fourth Loan Agreement

Disclosure Of Detailed Information About Warrant Liability [Line Items]

Maximum exercise price of preferred share | $ / shares

$ 1,000

Minimum exercise price of preferred share | $ / shares

$ 156.36

Number of warrant shares issued | shares

19,402

Price of per preferred share | $ / shares

$ 156.36

Preferred share expiration date

Feb. 22, 2027

Fourth Loan Agreement | Tranche One

Disclosure Of Detailed Information About Warrant Liability [Line Items]

Date of credit facility drawn

Feb. 22, 2019

Credit facility

$ 10,000

Fourth Loan Agreement | Tranche Two

Disclosure Of Detailed Information About Warrant Liability [Line Items]

Date of credit facility drawn

Mar. 22, 2019

Credit facility

$ 5,000

S A L P

Disclosure Of Detailed Information About Warrant Liability [Line Items]

Fair value of warrant liability

$ 877

$ 5,820

Warrant Liability - Schedule of

Warrant Liability - Schedule of Fair Value of Warrants on Various Dates Calculated Using a Black-Scholes Option Pricing Model with Assumptions (Details) - Black Scholes Option Pricing Model	12 Months Ended
	Dec. 31, 2021yr$ / shares	Dec. 31, 2021yr$ / shares	Dec. 31, 2020yr$ / shares	Dec. 31, 2020yr$ / shares
Disclosure Of Detailed Information About Stock Option Assumption [Line Items]
Underlying common share fair value (in USD)	$ 1.09		$ 4.20
Remaining life until expiry | yr	3.8	3.8	4.8	4.8
Volatility	56.00%	56.00%	49.00%	49.00%
Risk-free interest rate	1.13%	1.13%	0.34%	0.34%
Fair value of a warrant calculated using a Black-Sholes pricing model (in USD)	$ 0.08		$ 1.41
Fair value of exercise price adjustment mechanism (in USD)	$ 0.16		$ 0.22
Illiquidity discount	28.00%	28.00%	29.00%	29.00%
Fair value of a warrant | (per share)	$ 0.18	$ 0.22	$ 1.16	$ 1.47

Long-term Debt - Summary of Tra

Long-term Debt - Summary of Transactions and Carrying Value of Long-term Debt (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Detailed Information About Borrowings [Abstract]
Balance at January 1	$ 40,532	$ 8,834
Stated and accreted interest	4,388	2,209
Drawdown on non-revolving line of credit (second term loan)		29,123
Issuance of secured convertible debentures		2,410
Conversion of secured convertible debt into shares	(2,664)
Repayment of principal		(165)
Repayment of stated interest	(3,945)	(1,879)
Balance at December 31	$ 38,311	$ 40,532

Long-term Debt - Summary of Car

Long-term Debt - Summary of Carrying Value of Long-term Debt (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings	$ 38,311	$ 40,532	$ 8,834
Long-term portion of long-term debt	38,311	40,532
First Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings	9,188	8,910
Second Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings	$ 29,123	29,123
Secured Convertible Debentures
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings		$ 2,499

Long-term Debt - Summary of C_2

Long-term Debt - Summary of Carrying Value of Long-term Debt (Parenthetical) (Details) - CAD ($) $ in Thousands	Sep. 14, 2020	Dec. 31, 2021	Dec. 31, 2020	Apr. 23, 2019
First Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount		$ 10,000
Maturity date		April 23, 2024
Interest rate				10.00%
First Term Loan | Fixed Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate		10.00%
First Term Loan | Effective Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate		15.05%
Second Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount		$ 29,123
Maturity date	April 23, 2024	April 23, 2024
Interest rate		10.00%
Second Term Loan | Fixed Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate		10.00%
Second Term Loan | Effective Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate		10.47%
Secured Convertible Debentures
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount			$ 2,410
Maturity date			March 31, 2022
Secured Convertible Debentures | Fixed Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate			8.00%
Secured Convertible Debentures | Effective Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate			8.24%

Long-term Debt - 2019 - Additio

Long-term Debt - 2019 - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Millions	Nov. 25, 2020	Apr. 23, 2019CAD ($)$ / sharesshares	Apr. 23, 2019USD ($)	Dec. 31, 2019CAD ($)	Feb. 15, 2022shares	Dec. 31, 2021CAD ($)	Dec. 31, 2020CAD ($)	Dec. 30, 2020shares	Jun. 30, 2019shares	Apr. 22, 2019CAD ($)
Disclosure Of Detailed Information About Borrowings [Line Items]
Common shares, issued | shares								557,894	2,592,628
Share capital				$ 932,951		$ 979,849	$ 977,261
Warrants maturity date	November 3, 2025
Loss (gain) on extinguishments of liabilities				(92,374)
Interest accretion on long-term debt				$ 7,874
Warrants Held by SALP
Disclosure Of Detailed Information About Borrowings [Line Items]
Number of warrants cancelled | shares		168,735			168,735
Third Original Issue Discount Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Conversion price per common share | $ / shares		$ 15.21
Interest due on credit facility		$ 663
Principal/face amount		$ 10,000
Exercise price of warrants per common share | $ / shares		$ 15.21
Warrants maturity date		April 23, 2027	April 23, 2027
Extinguishment of loans following a debt modification		$ 4,667
Incremental fair value of replacement warrants		$ 408
US Credit Facility Agreement
Disclosure Of Detailed Information About Borrowings [Line Items]
Drawdown on credit facility			$ 95
Original Issue Discount Loan Agreement
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount										$ 99,552
First Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Conversion price per common share | $ / shares		$ 15.21
Principal/face amount						$ 10,000
Reduction of long-term debt		$ 141,536
Common shares, issued | shares		15,050,312
Share capital		$ 228,915
Loss on extinguishment of loan		87,379
Interest due on credit facility paid in cash		663
Recognition of loans following a debt modification		8,521
Gain (loss) on debt extinguishment		$ 3,854
Credit facility, interest rate		10.00%
Deferred financing fees pertaining to extinguished loans		$ 653
First Term Loan | Discounted Cash Flow
Disclosure Of Detailed Information About Borrowings [Line Items]
Credit facility, interest rate		15.10%

Long-term Debt - Summary of Los

Long-term Debt - Summary of Loss on Extinguishment of Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019CAD ($)
Gain Loss On Extinguishment Of Liabilities [Abstract]
Loss on extinguishment of liabilities to suppliers	$ 80
Loss on extinguishment of liabilities	92,374
April 23, 2019 Loan Modification
Gain Loss On Extinguishment Of Liabilities [Abstract]
Debt to equity conversion	87,379
Expensing of financing fees on loan extinguishment	653
Extinguishment of previous loan	(4,667)
Recognition of modified loan	8,521
Expensing of increase in the fair value of the warrants (note 18c)	408
Loss on extinguishment of liabilities	$ 92,294

Long-term Debt - 2020 - Additio

Long-term Debt - 2020 - Additional Information (Details)	Sep. 14, 2020CAD ($)	Jul. 17, 2020CAD ($)TradingDay	Dec. 31, 2021CAD ($)	Dec. 31, 2020CAD ($)	Nov. 30, 2021CAD ($)
Top of Range | Convertible Common Shares
Disclosure Of Detailed Information About Borrowings [Line Items]
Option to purchase additional secured convertible debentures		$ 5,740,000			$ 5,740,000
Secured Convertible Debentures
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount				$ 2,410,000
Maturity date				March 31, 2022
Non-revolving Line of Credit
Disclosure Of Detailed Information About Borrowings [Line Items]
Date of credit facility drawn	Sep. 14, 2020
Drawdown on credit facility	$ 29,123,000
Second Term Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal/face amount			$ 29,123,000
Interest rate			10.00%
Maturity date	April 23, 2024		April 23, 2024
Fairhaven Acquisition | Secured Convertible Debentures
Disclosure Of Detailed Information About Borrowings [Line Items]
Acquisition closure date		Jul. 17, 2020
Principal/face amount		$ 2,410,000
Interest rate		8.00%
Maturity date		March 31, 2022
Conversion features			The conversion features were determined to have no value.
Fairhaven Acquisition | Secured Convertible Debentures | VWAP
Disclosure Of Detailed Information About Borrowings [Line Items]
Number of trading day | TradingDay		5

Long-term Debt - 2021 - Additio

Long-term Debt - 2021 - Additional Information (Details)	Oct. 20, 2021CAD ($)$ / sharesshares	Dec. 31, 2021CAD ($)	Nov. 30, 2021CAD ($)	Oct. 20, 2021$ / shares	Dec. 31, 2020CAD ($)	Jul. 17, 2020CAD ($)	Dec. 31, 2019CAD ($)
Disclosure Of Detailed Information About Borrowings [Line Items]
Conversion of secured convertible debt into shares		$ 2,664,000
Share capital		$ 979,849,000			$ 977,261,000		$ 932,951,000
Top of Range | Convertible Common Shares
Disclosure Of Detailed Information About Borrowings [Line Items]
Option to purchase additional secured convertible debentures			$ 5,740,000			$ 5,740,000
Secured Convertible Debentures
Disclosure Of Detailed Information About Borrowings [Line Items]
Conversion of secured convertible debt into shares	$ 2,664,000
Debt conversion converted instrument common shares issued | shares	1,098,577
Conversion price per common share | (per share)	$ 2.42			$ 1.96
Minimum cash balance required for conversion right became exercisable	$ 75,000,000
Share capital	2,589,000
Gain on extinguishment of liability	$ 75,000

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Miscellaneous Noncurrent Liabilities [Abstract]
Royalty payment obligations (a)	$ 123	$ 3,355
Other employee benefit liabilities	146	1,557
Other Liabilities	269	4,912
Current portion of royalty payment obligations (note 13)	(25)	(3,248)
Current portion of other employee benefit liabilities (note 13)	(146)	(1,351)
Other non-current liabilities	$ 98	$ 313

Other Long-Term Liabilities - A

Other Long-Term Liabilities - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021CAD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)
Other Long Term Liabilities [Line Items]
Royalty payment obligations			$ 123		$ 3,355
Reacquired Right | Plasminogen
Other Long Term Liabilities [Line Items]
Royalty payment obligations					3,223	$ 2,500,000
Royalty rate		5.00%
Percentage of reacquisition of rights		50.00%
Top of Range | Reacquired Right | Plasminogen
Other Long Term Liabilities [Line Items]
Royalty payments		$ 2,500,000
Tranche Two
Other Long Term Liabilities [Line Items]
Quarterly minimum royalty payment	$ 5,000,000	$ 5,000,000
Royalty payment obligations			$ 123		$ 132
Net sales royalty commitment for liabilities				$ 0

Share Capital and Other Equit_3

Share Capital and Other Equity Instruments - Share Capital - Additional Information (Details) $ / shares in Units, $ in Thousands

Oct. 20, 2021shares

Dec. 30, 2020CAD ($)shares

Nov. 25, 2020CAD ($)

Nov. 03, 2020CAD ($)Instrumentshares

Jan. 29, 2020CAD ($)shares

Feb. 27, 2019CAD ($)shares

Jun. 30, 2019CAD ($)shares

May 31, 2019CAD ($)$ / shares

Apr. 30, 2019CAD ($)

Dec. 31, 2021$ / sharesshares

Dec. 31, 2020CAD ($)shares

Jul. 17, 2020CAD ($)shares

May 21, 2019shares

Disclosure Of Classes Of Share Capital [Line Items]

Par value per share | $ / shares

$ 15.21

Shares issued upon conversion of debt, Number | shares

1,098,577

1,098,577

Shares issued in settlement of license acquisition payment obligation | shares

96,833

299,141

Carrying value liabilities

$ 1,319

Shares issued in payment to suppliers

1,240

$ 545

Gain (loss) on extinguishment of liabilities

$ (80)

$ 79

Common shares, issued | shares

557,894

2,592,628

Fair value of warrants issued

$ 2,227

$ 10,263

Common share value

27,074

Share issue transaction costs

$ 2,755

$ 271

Number of instruments issued | Instrument

3

Common shares and prefunded warrants recognized in deficit amount

$ 2,048

Prefunded warrants exercised | shares

557,894

Proceeds from issue of common shares

$ 1

39,434

Amount reclassified from warrants to common shares

$ 2,623

Net proceeds from issue of common shares

$ 39,163

Shares issued in payment to suppliers, Number | shares

1,472

Carrying value accounts payable to suppliers

$ 465

Shares issued in payment to suppliers

$ 1,240

$ 545

Share purchase loan outstanding

$ 400

Amount held in escrow used for payment on loan extinguishment

$ 137

Top of Range

Disclosure Of Classes Of Share Capital [Line Items]

Proceeds from issue of common shares

$ 75,000

Rights offering additional shares offered | shares

20

Private Placement

Disclosure Of Classes Of Share Capital [Line Items]

Gross proceeds from private placement

$ 39,960

Common shares, issued | shares

5,757,894

Prefunded warrants issued | shares

557,894

Warrants issued | shares

6,315,788

Private Placement | S A L P

Disclosure Of Classes Of Share Capital [Line Items]

Gross proceeds from private placement

$ 19,980

Acquisition of Fairhaven

Disclosure Of Classes Of Share Capital [Line Items]

Number of shares issued, partial payment | shares

202,308

Fair value of common shares issued

$ 3,441

Common Shares

Disclosure Of Classes Of Share Capital [Line Items]

Share capital description

unlimited number authorized, participating, carrying one vote per share, entitled to dividends.

Preferred Shares

Disclosure Of Classes Of Share Capital [Line Items]

Share capital description

unlimited number authorized, issuable in one or more series.

Series A Preferred Shares

Disclosure Of Classes Of Share Capital [Line Items]

Share capital description

unlimited number authorized, no par value, non-voting, ranking in priority to the common shares, entitled to the same dividends as the common shares, non-transferable, redeemable at the redemption amount offered for the common shares upon a change in control event.

Par value per share | $ / shares

$ 0

Share Capital and Other Equit_4

Share Capital and Other Equity Instruments - Schedule of Changes in Issued and Outstanding Common Shares (Details) - CAD ($) $ in Thousands	Oct. 20, 2021	Jan. 29, 2020	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Classes Of Share Capital [Abstract]
Balance - beginning of year, Number			29,943,839	23,313,164
Issued to acquire assets, Number		96,833		299,141
Exercise of stock options, Number				5,391
Exercise of pre-funded warrants, Number				557,894
Shares issued pursuant to a restricted share units plan, Number			144	10,355
Shares issued for cash, Number				5,757,894
Shares issued upon conversion of debt, Number	1,098,577		1,098,577
Balance - end of year, Number			31,042,560	29,943,839
Balance - beginning of year			$ 977,261	$ 932,951
Issued to acquire assets				4,681
Exercise of stock options				167
Exercise of pre-funded warrants				2,624
Shares issued pursuant to a restricted share units plan				9,764
Shares issued for cash				27,074
Shares issued upon conversion of debt			2,588
Balance - end of year			$ 979,849	$ 977,261

Share Capital and Other Equit_5

Share Capital and Other Equity Instruments - Contributed Surplus (Share-Based Payments) - Additional Information (Details) $ / shares in Units, $ in Thousands	Oct. 01, 2021shares	Jan. 31, 2021shares$ / shares	Jun. 08, 2020shares$ / shares	May 26, 2020CAD ($)$ / shares	Dec. 03, 2019$ / sharesshares	Sep. 03, 2019$ / sharesshares	Jun. 19, 2019shares$ / shares	Jun. 04, 2019shares$ / shares	May 30, 2019CAD ($)shares	May 07, 2019shares	Jan. 31, 2019shares$ / shares	Jan. 24, 2019shares$ / shares	Oct. 31, 2021shares$ / shares	Jul. 31, 2021shares$ / shares	Jun. 30, 2021shares$ / shares	Dec. 31, 2020shares$ / shares	Oct. 31, 2020shares$ / shares	Jun. 30, 2020shares$ / shares	Jun. 30, 2019shares$ / shares	Dec. 31, 2021CAD ($)shares$ / shares	Dec. 31, 2020CAD ($)shares$ / shares	Dec. 31, 2019CAD ($)shares$ / shares	Dec. 31, 2021shares
Disclosure Of Classes Of Share Capital [Line Items]
Contractual life of outstanding share options																				7 years 7 months 6 days
Weighted Average Exercise Price, Repriced - options after repricing | $ / shares				$ 15.21																	$ 15.21
Incremental fair value of the repricing options | $				$ 3,000
Number of stock options granted		40,000											352,000	50,000	50,000						436,570	2,218,810
Exercise price of options granted | $ / shares		$ 5.34											$ 2.17	$ 3.93	$ 4.09
Vesting period		1 year											4 years	1 year	1 year
Number of stock options vested	12,500	20,000													25,000
Number of stock options expired																				136,126	1,506	2,084
Weighted average price of options, cancelled | $ / shares																				$ 40.70	$ 2,462.46	$ 1,176.20
Number of stock options exercised																					5,391
Proceeds from exercise of options | $																					$ 82
Transfer from contributed surplus to share capital | $																					82
Share-based payment compensation expense | $																				$ 4,252	6,234	$ 22,030
Share-based payments expense (note 19b) | $																				$ 4,232	$ 6,194	$ 21,609
Weighted Average Exercise Price, Granted | $ / shares																					$ 14.06	$ 33.13
2017-2019
Disclosure Of Classes Of Share Capital [Line Items]
Performance based RSU										12,886
2018-2020
Disclosure Of Classes Of Share Capital [Line Items]
Performance based RSU										12,886
Stock Options
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares reserved for issue under options																				3,749,714			3,749,714
Stock Options Issued Exercise Period																				10 years
Contractual life of outstanding share options																				10 years
Share-based payment arrangement options vesting period																				4 years
Stock options exercise period, description																				The exercise price is based on the weighted average share price for the five business days prior to the grant.
Weighted average exercise price of repricing options | $ / shares			$ 27	$ 15.21
Number of repricing of options outstanding			1,929,685
Weighted Average Exercise Price, Repriced - options after repricing | $ / shares			$ 36	$ 15.21
Number of stock options granted												1,622					20,000	436,570
Exercise price of options granted | $ / shares												$ 300					$ 10.80	$ 14.06
Vesting period					4 years	4 years	4 years										3 years	4 years
Number of stock options vested							60,717
Number of stock options issued					100,000	71,250	251,714
Exercise price of options issued | $ / shares					$ 7.86	$ 11.99	$ 27
Weighted average grant date fair value of stock options issued | $ / shares																						$ 12.74
Number of stock options expired																			11,084
Weighted average price of options, cancelled | $ / shares																			$ 1,256.73
Number of stock options exercised																					5,391	0
Weighted average share price | $ / shares																					$ 18.47
Proceeds from exercise of options | $																					$ 82
Transfer from contributed surplus to share capital | $																					85
Share-based payment compensation expense | $																				$ 4,252	$ 6,169	$ 12,212
Stock Options | Key Management
Disclosure Of Classes Of Share Capital [Line Items]
Number of stock options granted								1,794,224								285,000
Exercise price of options granted | $ / shares								$ 36								$ 4.27
Vesting period								6 years								3 years
Number of stock options vested								248,825								95,000
Stock Options | Top of Range
Disclosure Of Classes Of Share Capital [Line Items]
Percentage of Common Shares Reserved for Issuance to Individual																				5.00%
Share-based payment arrangement options vesting period																				6 years
Restricted Share Units
Disclosure Of Classes Of Share Capital [Line Items]
Vesting period											1 year
Number RSU vested									12,564												4,216	13,262
Number RSU paid in cash									8,396											4,024	2,948	8,396
Reduction to contributed surplus | $									$ 421											$ 20	$ 40
Granted											12,564											12,564	0
Weighted Average Exercise Price, Granted | $ / shares											$ 300
Cancellation of units																						4,493
Number of unvested RSU outstanding																						4,303
Share-based payments
Disclosure Of Classes Of Share Capital [Line Items]
Share-based payments expense (note 19b) | $																				$ 0	$ 65	$ 9,818
Performance-based RSU
Disclosure Of Classes Of Share Capital [Line Items]
Time vesting units achievement range										100.00%
Cancellation of units										4,305
Performance-based RSU | Top of Range
Disclosure Of Classes Of Share Capital [Line Items]
Outcome of Performance Conditions										150.00%
Performance-based RSU | Bottom of Range
Disclosure Of Classes Of Share Capital [Line Items]
Outcome of Performance Conditions										0.00%

Share Capital and Other Equit_6

Share Capital and Other Equity Instruments - Schedule of Changes in Number of Stock Options Outstanding and Weighted Average Exercise Price (Details)	Jan. 31, 2021shares	May 26, 2020$ / shares	Oct. 31, 2021shares	Jul. 31, 2021shares	Jun. 30, 2021shares	Dec. 31, 2021shares$ / shares	Dec. 31, 2021shares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of Share Options, Beginning Balance | shares						2,485,555	2,485,555	2,209,864	2,209,864	21,625
Number of Share Options, Granted | shares	40,000		352,000	50,000	50,000			436,570	436,570	2,218,810
Number of Share Options, Forfeited | shares						(1,321,651)	(1,321,651)	(153,982)	(153,982)	(16,774)
Number of Share Options, Exercised | shares								(5,391)	(5,391)
Number of Share Options, Cancelled | shares										(11,713)
Number of Share Options, Expired | shares						(136,126)	(136,126)	(1,506)	(1,506)	(2,084)
Number of options, Repriced - options before repricing | shares								(1,929,685)	(1,929,685)
Number of options, Repriced - options after repricing | shares								1,929,685	1,929,685
Number of share Options, Ending Balance | shares						1,027,778	1,027,778	2,485,555	2,485,555	2,209,864
Weighted Average Exercise Price, Beginning Balance | $ / shares						$ 18.70		$ 38.72		$ 1,464.49
Weighted Average Exercise Price, Granted | $ / shares								14.06		33.13
Weighted Average Exercise Price, Forfeited | $ / shares						14.34		19.33		159.61
Weighted Average Exercise Price, Exercised | $ / shares								15.21
Weighted Average Exercise Price, Cancelled | $ / shares										1,237.94
Weighted Average Exercise Price, Expired | $ / shares						40.70		2,462.46		1,176.20
Weighted Average Exercise Price, Repriced - options before repricing | $ / shares								35.14
Weighted Average Exercise Price, Repriced - options after repricing | $ / shares		$ 15.21						15.21
Weighted Average Exercise Price, Ending Balance | $ / shares						$ 21.39		$ 18.70		$ 38.72
US$
Disclosure Of Classes Of Share Capital [Line Items]
Number of Share Options, Beginning Balance | shares						305,000	305,000
Number of Share Options, Granted | shares						492,000	492,000	305,000	305,000
Number of Share Options, Forfeited | shares						(38,000)	(38,000)
Number of Share Options, Expired | shares						(10,000)	(10,000)
Number of share Options, Ending Balance | shares						749,000	749,000	305,000	305,000
Weighted Average Exercise Price, Beginning Balance | $ / shares							$ 4.70
Weighted Average Exercise Price, Granted | $ / shares							2.80		$ 4.70
Weighted Average Exercise Price, Forfeited | $ / shares							4.10
Weighted Average Exercise Price, Expired | $ / shares							4.27
Weighted Average Exercise Price, Ending Balance | $ / shares							$ 3.49		$ 4.70

Share Capital and Other Equit_7

Share Capital and Other Equity Instruments - Summary of Weighted Average Inputs into Model and Resulting Grant Date Fair Values (Details)	May 26, 2020yr$ / shares	Dec. 31, 2021yr$ / shares	Dec. 31, 2020yr$ / shares	Dec. 31, 2019yr$ / shares
Disclosure Of Classes Of Share Capital [Abstract]
Expected volatility of share price	93.20%	115.00%	100.50%	45.00%
Risk-free interest rate	0.40%	1.21%	0.50%	1.40%
Expected life in years | yr	6.3	6.7	6.7	7.2
Weighted average grant date incremental fair value | $ / shares	$ 1.55	$ 2.85	$ 8.66	$ 12.74

Share Capital and Other Equit_8

Share Capital and Other Equity Instruments - Schedule of Stock Options Issued and Outstanding by Range of Exercise Price (Details)	12 Months Ended
	Dec. 31, 2021shares$ / shares	Dec. 31, 2021shares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares	Dec. 31, 2018shares$ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	1,027,778	1,027,778	2,485,555	2,485,555	2,209,864	21,625
Weighted average remaining contractual life (in years)	7 years 7 months 6 days
Options outstanding, weighted average exercise price | $ / shares	$ 21.39		$ 18.70		$ 38.72	$ 1,464.49
Number exercisable, options | shares	672,834	672,834
Options exercisable, weighted average exercise price | $ / shares	$ 24.45
US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	749,000	749,000	305,000	305,000
Weighted average remaining contractual life (in years)	9 years 4 months 24 days
Options outstanding, weighted average exercise price | $ / shares		$ 3.49		$ 4.70
Number exercisable, options | shares	199,166	199,166
Options exercisable, weighted average exercise price | $ / shares		$ 4.55
$7.86 - $11.99
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	30,000	30,000
Weighted average remaining contractual life (in years)	7 years 8 months 12 days
Options outstanding, weighted average exercise price | $ / shares	$ 11.99
Number exercisable, options | shares	16,875	16,875
Options exercisable, weighted average exercise price | $ / shares	$ 11.99
$14.06
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	141,650	141,650
Weighted average remaining contractual life (in years)	8 years 4 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 14.06
Number exercisable, options | shares	78,112	78,112
Options exercisable, weighted average exercise price | $ / shares	$ 14.06
$15.21
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	800,778	800,778
Weighted average remaining contractual life (in years)	7 years 4 months 24 days
Options outstanding, weighted average exercise price | $ / shares	$ 15.21
Number exercisable, options | shares	522,862	522,862
Options exercisable, weighted average exercise price | $ / shares	$ 15.21
$27.00 - $2,220.00
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	55,350	55,350
Weighted average remaining contractual life (in years)	7 years 3 months 18 days
Options outstanding, weighted average exercise price | $ / shares	$ 134.61
Number exercisable, options | shares	54,985	54,985
Options exercisable, weighted average exercise price | $ / shares	$ 130.88
$2.17 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	349,000	349,000
Weighted average remaining contractual life (in years)	9 years 9 months 18 days
Options outstanding, weighted average exercise price | $ / shares		$ 2.17
$3.93-$5.34 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	380,000	380,000
Weighted average remaining contractual life (in years)	9 years 1 month 6 days
Options outstanding, weighted average exercise price | $ / shares		$ 4.31
Number exercisable, options | shares	192,500	192,500
Options exercisable, weighted average exercise price | $ / shares		$ 4.34
$10.80 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number outstanding, options | shares	20,000	20,000
Weighted average remaining contractual life (in years)	8 years 9 months 18 days
Options outstanding, weighted average exercise price | $ / shares		$ 10.80
Number exercisable, options | shares	6,666	6,666
Options exercisable, weighted average exercise price | $ / shares		$ 10.80

Share Capital and Other Equit_9

Share Capital and Other Equity Instruments - Schedule of Stock Options Issued and Outstanding by Range of Exercise Price (Parenthetical) (Details)	Dec. 31, 2021$ / shares
$7.86 - $11.99 | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	$ 7.86
$7.86 - $11.99 | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	11.99
$14.06
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	14.06
$15.21
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	15.21
$27.00 - $2,220.00 | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	27
$27.00 - $2,220.00 | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	2,220
$2.17 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	2.17
$3.93-$5.34 | Bottom of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	3.93
$3.93-$5.34 | Top of Range | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	5.34
$10.80 | US$
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of exercise price	$ 10.80

Share Capital and Other Equi_10

Share Capital and Other Equity Instruments - Schedule of Changes in Number of RSU outstanding (Details) - Restricted Share Units	May 30, 2019shares	Jan. 31, 2019shares	Dec. 31, 2021shares	Dec. 31, 2020shares	Dec. 31, 2019shares	Dec. 31, 2021shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Balance - beginning of year			4,216	17,565	18,299
Granted		12,564			12,564	0
Forfeited			(48)	(46)	(409)
Released			(144)	(10,355)
Paid in cash	(8,396)		(4,024)	(2,948)	(8,396)
Cancelled					(4,493)
Balance - end of year				4,216	17,565

Share Capital and Other Equi_11

Share Capital and Other Equity Instruments - Schedule of Total Share-Based Payments Expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	$ 4,252	$ 6,234	$ 22,030
Administration Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	3,760	3,248	14,315
Research and Development Expenses
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	936	2,430	2,836
Loss From Discontinued Operations
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based payments expense	$ (444)	$ 556	$ 4,879

Share Capital and Other Equi_12

Share Capital and Other Equity Instruments - Summary of Changes in Number of Warrants Outstanding and Weighted Average Exercise Price (Details)	12 Months Ended
	Dec. 31, 2021$ / shares	Dec. 31, 2021shares	Dec. 31, 2021$ / shares	Dec. 31, 2021Warrant	Dec. 31, 2020shares$ / shares	Dec. 31, 2020shares$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants, beginning of year | shares		172,735
Number of warrants, ending of year		172,735		172,735	172,735	172,735
Weighted average exercise price, beginning of year | $ / shares	$ 84.33
Weighted average exercise price, end of year | $ / shares	$ 84.33				$ 84.33
US$
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants, beginning of year | shares		7,894,734
Number of warrants, Issued for cash | shares					6,873,682	6,873,682
Number of warrants, Issued for no consideration | shares		0			1,578,946	1,578,946
Number of warrants, Exercised | shares					557,894	557,894
Number of warrants, ending of year | shares		7,894,734			7,894,734	7,894,734
Weighted average exercise price, beginning of year | $ / shares			$ 5.50
Weighted average exercise price, Issued for cash | $ / shares						$ 5.05
Weighted average exercise price, Issued for no consideration | $ / shares						5.50
Weighted average exercise price, end of year | $ / shares			$ 5.50			$ 5.50

Share Capital and Other Equi_13

Share Capital and Other Equity Instruments - Warrants - Additional Information (Details) $ / shares in Units, $ in Thousands	Dec. 30, 2020shares	Nov. 25, 2020shares	Dec. 31, 2021shares	Dec. 31, 2020CAD ($)shares$ / shares	Feb. 15, 2022$ / sharesshares	Dec. 31, 2021Warrant
Disclosure Of Classes Of Share Capital [Line Items]
Number or warrants outstanding			172,735	172,735		172,735
Number of warrants issued		7,894,734	7,894,734
Warrant Transaction
Disclosure Of Classes Of Share Capital [Line Items]
Range of exercise price | $ / shares					$ 15.21
Number of warrants cancelled					168,735
Private Placement
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants issued				6,315,788
Range of exercise price | $ / shares				$ 0.001
Term of warrants				5 years
Amendment to Private Placement Agreement
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants issued		1,578,946
Pre-Funded Warrants | Private Placement
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants issued				557,894
Gross proceeds allocated | $				$ 2,623
Pre-Funded Warrants | Amendment to Private Placement Agreement
Disclosure Of Classes Of Share Capital [Line Items]
Common stock issued due to exercise of warrants	557,894

Share Capital and Other Equi_14

Share Capital and Other Equity Instruments - Schedule of Warrants Outstanding, Exercise Price, Expiry Rate and Overall Weighted Average Exercise Price (Details)	12 Months Ended
	Dec. 31, 2021$ / shares	Dec. 31, 2021shares	Dec. 31, 2021$ / shares	Dec. 31, 2021Warrant	Dec. 31, 2020shares$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Number		172,735		172,735	172,735
Exercise price (CA$)	$ 84.33				$ 84.33
Warrant Expires on January 2023
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant				4,000
Expiry date	Jan. 31, 2023
Exercise price (CA$)	$ 3,000
Warrant Expires on April 2027
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant				168,735
Expiry date	Apr. 30, 2027
Exercise price (CA$)	$ 15.21
Warrant Expires on November 2025
Disclosure Of Classes Of Share Capital [Line Items]
Number | Warrant				7,894,734
Expiry date	Nov. 30, 2025
Exercise price (CA$)			$ 5.50

Non-controlling Interests - Add

Non-controlling Interests - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of subsidiaries [line items]
Proportion of ownership interest held by group	100.00%	100.00%	100.00%
Share of NCI	$ (8,756)	$ (8,087)
NantPro Biosciences, LLC
Disclosure of subsidiaries [line items]
Proportion of ownership interest held by group	73.00%	73.00%	73.00%

Non-controlling Interests - Sum

Non-controlling Interests - Summary of Interests in Subsidiaries for which Company Holds or Held Less Than 100% Interest (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of subsidiaries [line items]
Proportion of ownership interest held by group	100.00%	100.00%	100.00%
Pathogen Removal and Diagnostic Technologies Inc.
Disclosure of subsidiaries [line items]
Name of subsidiary	Pathogen Removal and Diagnostic Technologies Inc.
Segment activity	Corporate
Place of incorporation and operation	Delaware, U.S.
Proportion of ownership interest held by group	77.00%	77.00%	77.00%
NantPro Biosciences, LLC
Disclosure of subsidiaries [line items]
Name of subsidiary	NantPro Biosciences, LLC
Segment activity	Plasma-derived therapeutics
Place of incorporation and operation	Delaware, U.S.
Proportion of ownership interest held by group	73.00%	73.00%	73.00%

Non-controlling Interests - S_2

Non-controlling Interests - Summary of Statement of Financial Position (Details) - CAD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Information About Consolidated Structured Entities [Line Items]
Receivables (current)	$ 229,000	$ 943,000
Total equity (negative equity)	(33,881,000)	(15,012,000)	$ (94,934,000)	$ 63,146,000
Attributable to non-controlling interests	8,756,000	8,087,000
PRDT
Disclosure Of Information About Consolidated Structured Entities [Line Items]
Receivables (current)	227	233
Capital and intangible assets (long-term)	74	113
Trade and other payables (current)	(987)	(877)
Intercompany loan	(17,329)	(16,846)
Total equity (negative equity)	(18,015)	(17,377)
Attributable to non-controlling interests	$ (8,756)	$ (8,087)

Non-controlling Interests - S_3

Non-controlling Interests - Summary of Statement of Operations (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Information About Consolidated Structured Entities [Line Items]
Royalty revenues	$ 565	$ 572	$ 575
Research and development expenses	(18,347)	(14,234)	(15,873)
Administration expenses	(31,928)	(32,619)	(37,661)
Net income (loss)	12,213	(118,757)	(206,753)
PRDT
Disclosure Of Information About Consolidated Structured Entities [Line Items]
Royalty revenues	565	572	585
Royalty expenses	(88)	(128)	(132)
Research and development expenses	(244)	(196)	(215)
Administration expenses	(946)	(1,506)	(896)
Impairment loss			(129)
Net income (loss)	(713)	(1,258)	(787)
Total non-controlling interests	$ (669)	$ (832)	$ (713)

Capital Management - Summary of

Capital Management - Summary of Capital Management (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Capital Management [Abstract]
Warrant Liability	$ 1,754	$ 11,640
Lease liabilities	22,471	33,452
Provisions	22,195
Long-term debt	38,311	40,532	$ 8,834
Total equity	33,881	15,012	$ 94,934	$ (63,146)
Cash	(108,490)	(45,075)
Total capital	$ 10,122	$ 55,561

Revenues from Continuing Oper_3

Revenues from Continuing Operations - Summary of Revenues from Continuing Operations (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue [Abstract]
Royalty revenues	$ 565	$ 572	$ 575
Rental revenue	78	152	170
Revenues from continuing operations	$ 643	$ 724	$ 745

Supplemental Information - Addi

Supplemental Information - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021CAD ($)Program	Dec. 31, 2020CAD ($)Program	Dec. 31, 2019CAD ($)
Supplemental Information Of Statements Of Operations [Line Items]
Number of subsidies program | Program	2	2
Interest expense on lease liabilities			$ 7,068
Discontinued Operations
Supplemental Information Of Statements Of Operations [Line Items]
Employee compensation expense	$ 9,958	$ 23,146	40,536
Lease Liabilities
Supplemental Information Of Statements Of Operations [Line Items]
Interest expense on lease liabilities	3,754	6,030
Finance Costs | Lease Liabilities | Discontinued Operations
Supplemental Information Of Statements Of Operations [Line Items]
Interest expense on lease liabilities	$ 2,242	$ 6,083	$ 7,926

Supplemental Information - Summ

Supplemental Information - Summary of Consolidated Statements of Operations (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Supplemental Information Of Statements Of Operations [Line Items]
Total income (loss) from discontinued operations	$ 57,276	$ (69,736)	$ (56,081)
Research and development expense	18,347	14,234	15,873
Administration expenses	31,928	32,619	37,661
Interest accretion on long-term debt			7,874
Finance costs	6,330	2,899	6,867
Employer's benefits	598	1,055	1,495
Share-based payments expense	4,232	6,194	21,609
Research And Development
Supplemental Information Of Statements Of Operations [Line Items]
Research and development tax credits	124	426	572
Salary subsidy	372	1,017
Rent subsidy	140	108
Research and development expense	636	1,551	572
Administration Expenses
Supplemental Information Of Statements Of Operations [Line Items]
Salary subsidy	325	1,457
Rent subsidy	86	63
Administration expenses	411	1,520
Loss From Discontinued Operations
Supplemental Information Of Statements Of Operations [Line Items]
Salary subsidy	2,502	4,758
Rent subsidy	682	426
Research and development tax credits	116	1,332
Total income (loss) from discontinued operations	3,300	6,516
Finance Costs
Supplemental Information Of Statements Of Operations [Line Items]
Interest accretion on long-term debt	4,388	2,209	7,874
Amortization of fees for credit facility			10
Financing fees on warrant liability		709
Interest Expense On Provisions	90
Other interest expense, transaction and bank fees	413	485	594
Interest expense on lease liabilities	3,754	6,030	7,068
Interest income	(73)	(451)	(753)
Finance costs	8,572	8,982	14,793
Employee Compensation Expense
Supplemental Information Of Statements Of Operations [Line Items]
Wages and salaries	19,731	32,410	48,846
Employer's benefits	3,201	5,443	8,263
Share-based payments expense	4,252	6,234	22,030
Employee compensation expense	$ 27,184	$ 44,087	$ 79,139

Supplemental Information - Su_2

Supplemental Information - Summary of Information by Geographic Area (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Geographical Areas [Line Items]
Capital, intangible and right of use assets	$ 10,608	$ 42,840
Revenue	643	724	$ 745
Canada
Disclosure Of Geographical Areas [Line Items]
Capital, intangible and right of use assets	10,041	28,231
Revenue	78	152	170
United Kingdom
Disclosure Of Geographical Areas [Line Items]
Capital, intangible and right of use assets	567	2,092
Revenue	$ 565	572	$ 575
United States
Disclosure Of Geographical Areas [Line Items]
Capital, intangible and right of use assets		$ 12,517

Pension Plan - Additional Infor

Pension Plan - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Defined Benefit Plans [Abstract]
Employer's benefits	$ 598	$ 1,055	$ 1,495

Impairment Losses - Additional

Impairment Losses - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Impairment Loss And Reversal Of Impairment Loss [Line Items]
Fair value of asset	$ 0
Intangible assets	$ 341
Software
Disclosure Of Impairment Loss And Reversal Of Impairment Loss [Line Items]
Impairments		$ 15
Small Molecule Therapeutics
Disclosure Of Impairment Loss And Reversal Of Impairment Loss [Line Items]
Fair value of asset		0	$ 0
Intangible assets		$ 1,072	634
Bioseparations Operations
Disclosure Of Impairment Loss And Reversal Of Impairment Loss [Line Items]
Fair value of asset			0
Intangible assets			$ 127

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Recovery in Consolidated Statement of Operations (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Current income tax expense (recovery)		$ (144)	$ (336)
Deferred income tax expense (recovery)	$ 118	(65)	111
Income tax expense (recovery) from continuing operations	118	(209)	(225)
Total income tax expense (recovery)	119	(201)	(196)
Income Tax Recovery
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Income tax expense (recovery) from continuing operations	118	(209)	(225)
Current income tax expense (recovery) from discontinued operations (note 6)	1	8	53
Deferred income tax expense (recovery) from discontinued Operations (note 6)			(24)
Total income tax expense (recovery)	$ 119	$ (201)	$ (196)

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Income Tax Expense (Recovery) for Continuing and Discontinued Operations Recognized in Consolidated Statement of Operations (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major Components Of Tax Expense Income [Abstract]
Net loss before tax from continuing operations	$ (44,945)	$ (49,230)	$ (150,897)
Net income before tax from discontinued operations	$ 57,277	$ (69,728)	$ (56,052)
Combined Canadian statutory income tax rate	26.50%	26.50%	26.60%
Income tax expense (recovery) at combined income tax rate	$ 3,268	$ (31,524)	$ (55,048)
Increase (decrease) in income taxes resulting from:
Unrecorded potential tax benefit arising from current-period losses and other deductible temporary differences	1,658	33,238	31,962
Effect of tax rate differences in foreign subsidiaries	9,756	1,101	4,989
Non-deductible or taxable items	(6,149)	(157)	(696)
Change in tax rate	(5,354)	(1,455)	1,609
Non-deductible loss (taxable gain) on debt renegotiation			24,572
Research and development tax credit	(3,012)	(494)	(740)
Non-taxable gain on disposition of subsidiary (note 6)		(896)	(6,903)
Other	(48)	(14)	59
Total income tax expense (recovery)	$ 119	$ (201)	$ (196)

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Tax Assets (Recoveries) (Details) - R&D Expenses - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Balance - beginning of year	$ (572)	$ (507)
Credited to profit and loss	118	(65)
Balance - end of year	$ (454)	$ (572)

Income Taxes - Summary of Avail

Income Taxes - Summary of Available Temporary Differences Not Recognized (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	$ 674,218	$ 814,645
Tax Losses (Non-capital)
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	371,146	569,542
Tax Losses (Capital)
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	185,085	305
Unused Research and Development Expenses
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	25,170	84,556
Undeducted Financing Expenses
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	16,914	27,053
Interest Expenses Carried Forward
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	22,616	32,475
Trade and Other Payable
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	22,592	1,640
Capital Assets
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	4,575	3,392
Intangible Assets
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	2,578	68,329
Start-up Expense
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	1,908	5,358
Unrealized Loss on Exchange Rate
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized		5,430
Lease Obligations
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	21,583	15,494
Other
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	$ 51	$ 1,071

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Losses/credit expire date	2024 and 2041
Available temporary differences not recognized	$ 674,218	$ 814,645
Unused federal tax credits available to reduce future income tax	8,980
Unused Non-capital Losses
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Non-capital losses	439,706
Available to reduce future taxable income for which the benefits have not been recognized	371,146
Available temporary differences not recognized	371,146	569,542
Unused Non-capital Losses | Canada Provincial
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available to reduce future taxable income for which the benefits have not been recognized	$ 172,093
Unused Research and Development Expenses
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Losses/credit expire date	2022 to 2041
Available temporary differences not recognized	$ 25,170	$ 84,556
Total amount available of unused R&D expenses	33,283
Unused Research and Development Expenses | Canada Provincial
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Total amount available of unused R&D expenses	17,552
Unused Research and Development Expenses | Available to Reduce Future Taxable Income
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Available temporary differences not recognized	$ 31,570

Income Taxes - Summary of Unuse

Income Taxes - Summary of Unused Non-capital Losses Expire (Details) - Unused Non-capital Losses $ in Thousands	Dec. 31, 2021CAD ($)
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	$ 371,146
Canada Federal
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	162,568
Canada Federal | 2027
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	3,510
Canada Federal | 2032
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	1,001
Canada Federal | 2033
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	4,610
Canada Federal | 2034
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	7,760
Canada Federal | 2035
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	12,565
Canada Federal | 2036
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	14,468
Canada Federal | 2037
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	7,393
Canada Federal | 2038
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	7,003
Canada Federal | 2039
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	26,441
Canada Federal | 2040
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	37,884
Canada Federal | 2041
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	39,933
Canada Federal | Expiration
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	162,568
Canada Provincial
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	172,093
Canada Provincial | 2027
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	3,495
Canada Provincial | 2032
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	995
Canada Provincial | 2033
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	4,606
Canada Provincial | 2034
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	9,807
Canada Provincial | 2035
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	12,563
Canada Provincial | 2036
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	22,678
Canada Provincial | 2037
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	7,394
Canada Provincial | 2038
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	6,595
Canada Provincial | 2039
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	26,305
Canada Provincial | 2040
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	37,751
Canada Provincial | 2041
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	39,904
Canada Provincial | Expiration
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	172,093
Foreign Countries
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	272,965
Foreign Countries | United Kingdom | Not Expiration
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	270,144
Foreign Countries | United States | Not Expiration
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused non-capital losses expire	$ 2,821	[1]
[1]	US tax rules impose restrictions that will impact how $ 114,107 of losses are available to shelter income in future taxation years. As a result, approximately $ 111,286 of losses will no longer be available to the company and are not presented in the available tax loss table presented above.

Income Taxes - Summary of Unu_2

Income Taxes - Summary of Unused Non-capital Losses Expire (Parenthetical) (Details) - UNITED STATES $ in Thousands	12 Months Ended
	Dec. 31, 2021CAD ($)
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax losses available to shelter income in future taxation	$ 114,107
Unused Tax Losses Not Available For Tax Loss Carryforwards	$ 111,286

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related Party Transactions [Line Items]
Interest paid on loan	$ 3,945	$ 1,879	$ 3,540
Former CEO
Related Party Transactions [Line Items]
Owing amount under tax equalization program	283	170
S A L P
Related Party Transactions [Line Items]
Interest expense	4,222	2,121
Interest paid on loan	3,945	1,879
Legal expenses	326	0
Legal expenses paid	$ 181	$ 0

Compensation of Key Managemen_3

Compensation of Key Management Personnel - Additional Information (Details) - Individual	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Of Key Management Personnel [Abstract]
Number of key management personnel	16	20	28

Compensation of Key Managemen_4

Compensation of Key Management Personnel - Summary of the Remuneration of the Key Management Personnel (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Of Key Management Personnel [Abstract]
Current employee benefits	[1]	$ 5,466	$ 6,153	$ 10,083
Pension costs		78	115	267
Share-based payments		4,351	4,917	16,842
Termination benefits		406	319	2,919
Remuneration of key management personnel		$ 10,301	$ 11,504	$ 30,111
[1]	Current employee benefits include salaries, bonuses, other employee benefits other than those listed in the table and director fees paid in cash.

Commitments - Additional Inform

Commitments - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Jan. 31, 2022
Commitments [Line Items]
Royalty percentage on future revenues relating to patents	2.00%
Royalty Stream Agreement | Entering into License Agreements
Commitments [Line Items]
Minimum upfront payment		$ 400

Legal proceedings - Additional

Legal proceedings - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2021
Legal proceedings provision [abstract]
Plaintiff's request in damages, initial amount		$ 700,000
Amount based on loss of future value of shares	$ 905,000
Plaintiff's request in damages	$ 950,000
Provisions		$ 22,195

Financial Instruments and Fin_3

Financial Instruments and Financial Risk Management - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Instruments [Line Items]
Long-term debt, fair value	$ 39,132	$ 41,922
Long-term debt, carrying amount	$ 38,311	$ 40,532
Consolidated Net Loss | U.S. Dollar
Disclosure Of Financial Instruments [Line Items]
Percentage of depreciation or appreciation of currency against foreign currencies which would result in increase decrease of consolidated net loss and other comprehensive loss	10.00%
Decrease or increase of loss due to depreciation or appreciation of currency against foreign currency	$ 9,627
Consolidated Net Loss | U.S. Dollar | Excluding Cash Denominated in USD From Net Exposure
Disclosure Of Financial Instruments [Line Items]
Percentage of depreciation or appreciation of currency against foreign currencies which would result in increase decrease of consolidated net loss and other comprehensive loss	10.00%
Decrease or increase of loss due to depreciation or appreciation of currency against foreign currency	$ 282
Total Comprehensive Loss | Great Britain Pound
Disclosure Of Financial Instruments [Line Items]
Percentage of depreciation or appreciation of currency against foreign currencies which would result in increase decrease of consolidated net loss and other comprehensive loss	10.00%
Decrease or increase of loss due to depreciation or appreciation of currency against foreign currency	$ 298
Discounted Cash Flow
Disclosure Of Financial Instruments [Line Items]
Market interest rates specific to term of debt instrument	10.47%	10.00%

Financial Instruments and Fin_4

Financial Instruments and Financial Risk Management - Schedule of Contractual Maturities of Financial Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Accounts payable and accrued liabilities	$ 7,343	$ 16,835
Long-term portion of royalty payment obligations	98
Lease liabilities	22,471	33,452
Provisions	22,195
Long-term debt	38,311	$ 40,532	$ 8,834
Contractual maturities of financial liabilities	90,418
Accounts payable and accrued liabilities, Contractual cash flows	7,343
Long-term portion of royalty payment obligations, Contractual cash flows	299
Lease liabilities, Contractual cash flows	26,283
Provisions, Contractual cash flows	22,599
Long-term debt, Contractual cash flows	48,242
Contractual cash flow maturities of financial liabilities	104,766
Within 1-year
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Accounts payable and accrued liabilities, Contractual cash flows	7,343
Lease liabilities, Contractual cash flows	7,369
Provisions, Contractual cash flows	3,961
Long-term debt, Contractual cash flows	3,945
Contractual cash flow maturities of financial liabilities	22,618
2-3 Years
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Long-term portion of royalty payment obligations, Contractual cash flows	51
Lease liabilities, Contractual cash flows	10,629
Provisions, Contractual cash flows	9,094
Long-term debt, Contractual cash flows	44,297
Contractual cash flow maturities of financial liabilities	64,071
4-5 Years
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Long-term portion of royalty payment obligations, Contractual cash flows	51
Lease liabilities, Contractual cash flows	8,285
Provisions, Contractual cash flows	9,544
Contractual cash flow maturities of financial liabilities	17,880
More than 5 years
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Long-term portion of royalty payment obligations, Contractual cash flows	197
Contractual cash flow maturities of financial liabilities	$ 197

Financial Instruments and Fin_5

Financial Instruments and Financial Risk Management - Schedule of Net Exposure to Currency Risk through Financial Assets and Financial Liabilities (Details)	Dec. 31, 2021CAD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2021GBP (£)	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020GBP (£)	Dec. 31, 2019CAD ($)
Disclosure Of Risk Management Strategy Related To Hedge Accounting [Line Items]
Cash	$ 108,490,000			$ 45,075,000			$ 41,761,000
Other long-term assets	362,000			1,353,000
Accounts payable and accrued liabilities	(7,343,000)			(16,835,000)
Lease liabilities	(22,471,000)			(33,452,000)
Other long-term liabilities	(98,000)			(313,000)
Currency Risk | Exposure in US Dollars
Disclosure Of Risk Management Strategy Related To Hedge Accounting [Line Items]
Cash	99,094,899	$ 78,045,915		22,018,153	$ 17,281,338
Accounts receivable	236,106	185,954		1,129,121	886,211
Other long-term assets				57,880	45,428
Accounts payable and accrued liabilities	(1,207,845)	(951,284)		(7,675,022)	(6,023,877)
Lease liabilities				(13,911,293)	(10,918,525)
Other long-term liabilities	(97,862)	(77,075)		(206,404)	(162,000)
Long-term derivatives	(1,754,221)	(1,381,603)
Net exposure	96,271,077	$ 75,821,907		1,412,435	$ 1,108,575
Currency Risk | Exposure in GBP
Disclosure Of Risk Management Strategy Related To Hedge Accounting [Line Items]
Cash	4,859,049		£ 2,832,439	8,032,832		£ 4,619,225
Accounts receivable	230,914		134,605	400,993		230,588
Accounts payable and accrued liabilities	(1,761,791)		(1,026,984)	(1,710,649)		(983,697)
Lease liabilities	(348,566)		(203,186)	(472,352)		(271,623)
Net exposure	$ 2,979,606		£ 1,736,873	$ 6,250,824		£ 3,594,493

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands	Feb. 15, 2022	Dec. 31, 2020	Dec. 31, 2019	Apr. 23, 2019
Disclosure of non-adjusting events after reporting period [line items]
Repayment of loans		$ 165	$ 988
Warrants Held by SALP
Disclosure of non-adjusting events after reporting period [line items]
Number of warrants cancelled	168,735			168,735
Warrants cancelled exercise price per share	$ 15.21			$ 15.21
First and Second Term Loan | Repayment of Long-term Debt
Disclosure of non-adjusting events after reporting period [line items]
Repayment of loans	$ 39,123